

**Novel approaches to the management of non-eosinophilic asthma**

Journal:	<i>Therapeutic Advances in Respiratory Disease</i>
Manuscript ID	TAR-15-077.R1
Manuscript Type:	Review
Date Submitted by the Author:	02-Jan-2016
Complete List of Authors:	Thomson, Neil; University of Glasgow, Institute of Infection Immunity and Inflammation
Abstract:	<p>Non-eosinophilic airway inflammation occurs in approximately 50% of patients with asthma. It is subdivided into neutrophilic or paucigranulocytic inflammation, although the proportion of each subtype is uncertain because of variable cut-off points used to define neutrophilia. This article reviews the evidence for non-eosinophilic inflammation being a target for therapy in asthma and assesses clinical trials of licensed drugs, novel small molecules and biologics agents in non-eosinophilic inflammation. Current symptoms, rate of exacerbations and decline in lung function are generally less in non-eosinophilic asthma than eosinophilic asthma. Non-eosinophilic inflammation is associated with corticosteroid insensitivity. Neutrophil activation in the airways and systemic inflammation is reported in neutrophilic asthma. Neutrophilia in asthma may be due to corticosteroids, associated chronic pulmonary infection, altered airway microbiome and/or delay neutrophil apoptosis. The cause of poorly controlled non-eosinophilic asthma may differ between patients and involve several mechanism including neutrophilic inflammation, Th2-low or other subtypes of airway inflammation and/or corticosteroid insensitivity as well as non-inflammatory pathways such as airway hyperreactivity and remodelling. Smoking cessation in asthmatic smokers and removal from exposure to occupational agents reduces neutrophilic inflammation. Preliminary studies of 'off-label' use of licensed drugs suggest that macrolides show efficacy in non-smokers with non-eosinophilic severe asthma and statins, low-dose theophylline and PPAR<math>\gamma</math> agonists may benefit asthmatic smokers with non-eosinophilic inflammation. Novel small molecules targeting neutrophilic inflammation, such as CXCR2 antagonists reduce neutrophils, but do not improve clinical outcomes in studies to date. Inhaled PDE4 inhibitors, dual PDE3 and PDE4 inhibitors, p38MAPK inhibitors, tyrosine kinase inhibitors and PI3kinase inhibitors are under development and these compounds may be of benefit in non-eosinophilic inflammation. The results of clinical trials of biological agents targeting mediators associated with non-eosinophilic inflammation, such as IL-17 and TNF-<math>\alpha</math> are disappointing. Greater understanding of the mechanisms of non-eosinophilic inflammation in asthma should lead to improved therapies.</p>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



SCHOLARONE™  
Manuscripts

For Peer Review

## Novel approaches to the management of non-eosinophilic asthma

Neil C Thomson MD, FRCP, FERS

Institute of Infection, Immunity & Inflammation,  
University of Glasgow, Glasgow, UK

### Corresponding author

Professor Neil C Thomson, Institute of Infection, Immunity & Inflammation, University of  
Glasgow, Glasgow, G12 OYN, UK Telephone: 44-141-211-1673. Fax: 44-141-211-3464

E- mail: [neil.thomson@glasgow.ac.uk](mailto:neil.thomson@glasgow.ac.uk)

**Word count:** 8024 words

**ABSTRACT**

Non-eosinophilic airway inflammation occurs in approximately 50% of patients with asthma. It is subdivided into neutrophilic or paucigranulocytic inflammation, although the proportion of each subtype is uncertain because of variable cut-off points used to define neutrophilia. This article reviews the evidence for non-eosinophilic inflammation being a target for therapy in asthma and assesses clinical trials of licensed drugs, novel small molecules and biologics agents in non-eosinophilic inflammation. Current symptoms, rate of exacerbations and decline in lung function are generally less in non-eosinophilic asthma than eosinophilic asthma. Non-eosinophilic inflammation is associated with corticosteroid insensitivity. Neutrophil activation in the airways and systemic inflammation is reported in neutrophilic asthma. Neutrophilia in asthma may be due to corticosteroids, associated chronic pulmonary infection, altered airway microbiome and/or delay neutrophil apoptosis. The cause of poorly controlled non-eosinophilic asthma may differ between patients and involve several mechanism including neutrophilic inflammation, Th2-low or other subtypes of airway inflammation and/or corticosteroid insensitivity as well as non-inflammatory pathways such as airway hyperreactivity and remodelling. Smoking cessation in asthmatic smokers and removal from exposure to occupational agents reduces neutrophilic inflammation. Preliminary studies of 'off-label' use of licensed drugs suggest that macrolides show efficacy in non-smokers with non-eosinophilic severe asthma and statins, low-dose theophylline and PPAR $\gamma$  agonists may benefit asthmatic smokers with non-eosinophilic inflammation. Novel small molecules targeting neutrophilic inflammation, such as CXCR2 antagonists reduce neutrophils, but do not improve clinical outcomes in studies to date. Inhaled PDE $_4$  inhibitors, dual PDE $_3$  and PDE $_4$  inhibitors, p38MAPK inhibitors, tyrosine kinase inhibitors and PI3kinase inhibitors are under development and these

1  
2  
3 compounds may be of benefit in non-eosinophilic inflammation. The results of clinical trials of  
4  
5 biological agents targeting mediators associated with non-eosinophilic inflammation, such as IL-  
6  
7 17 and TNF- $\alpha$  are disappointing. Greater understanding of the mechanisms of non-eosinophilic  
8  
9 inflammation in asthma should lead to improved therapies.  
10  
11  
12  
13

14  
15 Word count: 299  
16  
17

18  
19 **Key words:** Airway inflammation; asthma; biological agents; biomarkers; cigarette smoking;  
20  
21 corticosteroid insensitivity; eosinophils; neutrophils; small molecules.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

Personalised medicine in asthma aims to individualise treatment using non-invasive biomarkers that predict a beneficial response and/or that identify individuals who are at risk of adverse effects [Agustí *et al.*, 2015]. Several airway inflammatory phenotypes are recognised that help identify a therapeutic response to specific treatments in asthma. For example, eosinophilic airway inflammation, which is usually identified on the bases of sputum or blood eosinophilia, predicts patients with asthma that are likely to obtain a favourable therapeutic response to corticosteroids [Pavord *et al.*, 1999, Little *et al.*, 2000, Green *et al.*, 2002, Bacci *et al.*, 2006, Berry *et al.*, 2007] and to monoclonal antibodies targeting interleukin (IL)-5 [Pavord *et al.*, 2012, Katz *et al.*, 2014, Thomson, 2014]. Type 2 helper T-cell (Th2)-high subtype of asthma is associated with increased epithelial expression of interleukin IL-4, IL-5 and IL-13 [Woodruff *et al.*, 2009, Arron *et al.*, 2013] and is considered to overlap with eosinophilic airway inflammation [Arron *et al.*, 2013]. Evidence from clinical trials suggests that the presence of Type-2 eosinophilic inflammation predicts a therapeutic response not only to corticosteroids [Woodruff *et al.*, 2009], but to monoclonal antibodies targeting specific cytokines such as IL-5 [Bel *et al.*, 2014, Ortega *et al.*, 2014] and IL-13 [Corren *et al.*, 2011]. Many patients with asthma have non-eosinophilic asthma, sometimes associated with neutrophilic inflammation and/or have a Th2-low type of inflammation. Compared to type-2 eosinophilic inflammation there are relatively few interventions available for non-type 2 inflammatory sub-groups. This article aims to discuss the evidence that non-eosinophilic airway inflammation, with or without neutrophilic inflammation, is an appropriate target for therapy in asthma and also aims to assess the results of recent clinical trials of licensed drugs, novel small molecules and biologics agents in the treatment of non-eosinophilic asthma.

## IS NON-EOSINOPHILIC AIRWAY INFLAMMATION AN APPROPRIATE TARGET FOR THERAPY IN ASTHMA?

A number of factors need to be considered when attempting to answer the question of whether non-eosinophilic inflammation is an appropriate target for treatment in asthma including the criteria used to define neutrophilic and eosinophilic inflammation, the stability of non-eosinophil inflammation over time, the prevalence of non-eosinophilic inflammation, the strength of evidence for the involvement of non-eosinophilic inflammation in clinical features of asthma and the cause(s) of non-eosinophilic airway inflammation.

### Definition of eosinophilic and neutrophilic airway inflammation

Non-eosinophilic airway inflammation is a term used to describe a subtype of asthma associated with normal numbers of sputum eosinophils. The non-eosinophilic phenotype is subdivided into neutrophilic inflammation, when neutrophil numbers are raised above a defined cut-off level or paucigranulocytic inflammation, when both eosinophil and neutrophil numbers are normal. In addition, some individuals have a mixed type of inflammation, when there is sputum neutrophilia and eosinophilia. Cut-off levels used to define sputum eosinophilia most commonly used are  $\geq 2\%$  [Mcgrath *et al.*, 2012, Hastie *et al.*, 2013],  $> 2\%$  [Peters *et al.*, 2014] or  $\geq 3\%$  [Schleich *et al.*, 2013, Zhang *et al.*, 2014, Wagener *et al.*, 2015]. A  $\geq 3\%$  cut-off is reported to be the most precise value to identify eosinophilic airway inflammation [Simpson *et al.*, 2010]. Sputum eosinophil counts are associated with bronchial tissue eosinophil numbers suggesting that they provide a good indicator of airway eosinophilic pathology [Arron *et al.*, 2014]. The cut-off for a raised sputum neutrophil count is not clearly established with a wide

1  
2  
3 range of values reported in the literature: >40% (Nair, Gaga et al. 2012; Moore, Hastie et al.  
4  
5 2014),  $\geq$ 50% (Chaudhuri, Norris et al. 2014), >61% (Simpson, Milne et al. 2009), >65% (Nair et al  
6  
7 2015) and  $\geq$ 76% (Schleich, Manise et al. 2013). The most appropriate cut-off value that  
8  
9 identifies individuals in whom neutrophils are activated and contributing to the pathogenic  
10  
11 processes in asthma is not certain. In addition, sputum neutrophils do not correlate with  
12  
13 bronchial tissue numbers bringing into doubt their predictive value for identifying neutrophil-  
14  
15 induced airway pathology [Arron *et al.*, 2014]. In addition to the presence of non-eosinophilic  
16  
17 inflammation, Haldar and Pavord [Haldar *et al.*, 2007] proposed that the criteria for a diagnosis  
18  
19 of non-eosinophilic asthma should include objective evidence of airflow obstruction or airway  
20  
21 hyperreactivity, a raised asthma control questionnaire (ACQ) score (>1.5) and the absence of a  
22  
23 significant smoking history, fixed airflow obstruction or associated bronchiectasis. In the  
24  
25 current article, the criteria for non-eosinophilic asthma include the presence of non-  
26  
27 eosinophilic inflammation as defined above plus objective evidence of asthma, but the review  
28  
29 also includes data from patients with both normal and raised ACQ scores, who have a  
30  
31 significant smoking history or who have fixed airflow obstruction.  
32  
33  
34  
35  
36  
37  
38  
39  
40

#### 41 **Stability of sputum cell counts**

42  
43  
44  
45 Published data on the long term stability of sputum neutrophil and eosinophil counts is  
46  
47 conflicting. Some studies report stable sputum cell counts in patients with mild to severe  
48  
49 asthma follow-up over 6 months [Berry *et al.*, 2007], 12 months [Green *et al.*, 2002], 2 years  
50  
51 [Jayaram *et al.*, 2006] and 5 years [Simpson *et al.*, 2006, Van Veen *et al.*, 2009]. In contrast,  
52  
53 sputum inflammatory cell phenotype changed in 48.6% of patients with severe asthma over  
54  
55 1 year among patients recruited to the BIOmarkers in Severe Chronic AIRway Disease  
56  
57  
58  
59  
60



(BIOAIR) study [Kupczyk *et al.*, 2014]. Similar variability in sputum cell counts has been reported by others [Hancox *et al.*, 2012] and in one study a stable inflammatory phenotype was found in only one third of patients [Al-Samri *et al.*, 2010]. Transient sputum eosinophilia is reported in up to 40% patients with non-eosinophilic inflammation [Bacci *et al.*, 2012, Mcgrath *et al.*, 2012]. The potential for the lack of stability in non-eosinophilic inflammation over time needs to be accounted for in intervention studies targeting sputum inflammatory cell biomarkers.

### **Prevalence of non-eosinophilic airway inflammation**

The different cut-off values used to define elevated sputum cell counts, particularly sputum neutrophils, may explain the variation in prevalence figures for non-eosinophilic inflammation between studies. Nevertheless, overall up to 50% of adults and adolescents with stable mild to severe asthma, and in some studies higher proportions, have non-eosinophilic inflammation [Gibson *et al.*, 2001, Green *et al.*, 2002, Simpson *et al.*, 2006, Wang *et al.*, 2011, Mcgrath *et al.*, 2012, Schleich *et al.*, 2013, Moore *et al.*, 2014, Brooks *et al.*, 2016]. For example, a review of sputum cytology data from 995 subjects with mild to moderate asthma enrolled in clinical trials undertaken by the Asthma Clinical Research Network (ACRN) reported that non-eosinophilic inflammation (sputum eosinophils <2%) was present in 64% of patients not taking inhaled corticosteroid and 83% of patients taking inhaled corticosteroids. In a sub-group of patients followed up for 6 months, 47% of the inhaled corticosteroid free patients and 72% of those taking inhaled corticosteroids had persistent non-eosinophilic inflammation [Mcgrath *et al.*, 2012]. In a cluster analysis performed on 423 patients recruited to the Severe Asthma Research Program (SARP)

1  
2  
3 cohort, four asthma inflammatory sub-phenotypes were identified (sputum eosinophilia  
4  
5  $\geq 2\%$ ; sputum neutrophilia  $>40\%$ ) [Moore *et al.*, 2014]. Two groups had mild-to-moderate  
6  
7 allergic asthma with minimal or eosinophil-predominant sputum inflammation whereas the  
8  
9 other two sub-phenotypes had moderate-to-severe asthma with neutrophil-predominant or  
10  
11 mixed granulocytic inflammation [Moore *et al.*, 2014]. A study in a small group of adults  
12  
13 with stable asthma found 51.7% of subjects had a paucigranulocytic phenotype, 27.6%  
14  
15 neutrophilic inflammation and 17.2% eosinophilic inflammation [Wang *et al.*, 2011].  
16  
17  
18  
19  
20  
21

### 22 **Involvement of neutrophilic and non-eosinophilic airway inflammation in asthma**

23  
24  
25  
26 Evidence for the involvement of non-eosinophilic inflammation in asthma is based mainly on  
27  
28 studies examining the association between sputum inflammatory phenotypes and clinical  
29  
30 outcomes in asthma including current symptom control, exacerbations, airflow obstruction and  
31  
32 therapeutic response to corticosteroids. Further evidence is provided by reports of local  
33  
34 activation of neutrophils and systemic inflammation in neutrophilic asthma.  
35  
36  
37  
38  
39

### 40 ***Current symptom control***

41  
42  
43  
44  
45 The severity of current symptoms is in general similar or slightly lower in non-eosinophilic or  
46  
47 neutrophilic subgroups of asthma compared to eosinophilic subgroups [Cowan *et al.*, 2010,  
48  
49 Hastie *et al.*, 2010, Wood *et al.*, 2012, Schleich *et al.*, 2013, Baines *et al.*, 2014, Newby *et al.*,  
50  
51 2014, Schleich *et al.*, 2014].  
52  
53  
54  
55

### 56 ***Exacerbations***

57  
58  
59  
60

1  
2  
3  
4  
5 Sputum neutrophilia is found in up to 80% of exacerbations in adults with asthma [Turner *et al.*,  
6  
7  
8 1995, Fahy *et al.*, 1995, Lamblin *et al.*, 1998, Green *et al.*, 2002, Jayaram *et al.*, 2006,  
9  
10 Maneechotesuwan *et al.*, 2007, Wang *et al.*, 2011], although the predominant sputum cell type  
11  
12 can alter during successive exacerbations [D'silva *et al.*, 2007]. Sputum eosinophilia is a better  
13  
14 predictor of future exacerbations than sputum neutrophilia [Jatakanon *et al.*, 2000, Leuppi *et*  
15  
16 *al.*, 2001, Kupczyk *et al.*, 2014, Schleich *et al.*, 2014]. For example, a cluster analysis performed  
17  
18 on patients recruited to the BIOAIR study identified two clusters with raised sputum eosinophil  
19  
20 counts that accounted for 83% of subjects who had 2 or more severe exacerbations during  
21  
22 follow-up for 1 year [Kupczyk *et al.*, 2014]. One of these clusters had a mixed inflammatory  
23  
24 profile with raised sputum neutrophils (43% percent of patients). A further cluster had a raised  
25  
26 neutrophil count and a normal eosinophil count (11% of patients) and a non-eosinophilic  
27  
28 paucigranulocytic inflammation was found in only 6% of cases. Patients with severe asthma  
29  
30 associated with eosinophil inflammation have more intubations than non-eosinophilic patients  
31  
32 [Wenzel *et al.*, 1999].  
33  
34  
35  
36  
37  
38  
39  
40

#### 41 **Airflow obstruction**

42  
43  
44  
45 Sputum neutrophilia is association with reduced lung function and based on this finding it has  
46  
47 been speculated that airway neutrophils may contribute to the development of persistent  
48  
49 airflow obstruction in asthma [Little *et al.*, 2002, Shaw *et al.*, 2007]. Against this hypothesis, a  
50  
51 recent cluster analysis of lung function decline and sputum eosinophil count performed in 97  
52  
53 patients with severe asthma identified a non-eosinophilic group in whom the decline in FEV<sub>1</sub>  
54  
55 was -14 ml per year compared to an eosinophilic group with highly variable eosinophil counts  
56  
57  
58  
59  
60

1  
2  
3 that had a greater rate of decline in FEV<sub>1</sub> of -41 ml per year [Newby *et al.*, 2014]. These findings  
4  
5 suggest that eosinophilic inflammation, particularly when there is high variability in eosinophil  
6  
7 count, is a greater risk factor for the development of persistent airflow obstruction than non-  
8  
9 eosinophilic inflammation. Bronchodilator reversibility and airway hyperresponsiveness are  
10  
11 similar in eosinophilic and non-eosinophilic asthma [Berry *et al.*, 2007, Mcgrath *et al.*, 2012],  
12  
13 although one study noted greater airway hyperresponsiveness in persistent or intermittent  
14  
15 eosinophilic groups [Mcgrath *et al.*, 2012].  
16  
17  
18  
19  
20  
21

### 22 ***Impaired response to inhaled corticosteroids***

23  
24  
25  
26 Non-eosinophilic inflammation is associated with an impaired therapeutic response to  
27  
28 inhaled corticosteroids [Pavord *et al.*, 1999, Green *et al.*, 2002, Bacci *et al.*, 2006, Berry *et*  
29  
30 *al.*, 2007, Thomson *et al.*, 2009, Mcgrath *et al.*, 2012], although the lack of efficacy may not  
31  
32 be complete. Several clinical studies performed in small numbers of patients with non-  
33  
34 eosinophilic asthma suggest that this group may obtain some benefit from inhaled  
35  
36 corticosteroids although less than that found in eosinophilic patients [Godon *et al.*, 2002,  
37  
38 Cowan *et al.*, 2010, Lemièrre *et al.*, 2011]. Intermittent eosinophilia might be a factor  
39  
40 accounting for corticosteroid sensitivity in some of these patients [Bacci *et al.*, 2012,  
41  
42 Mcgrath *et al.*, 2012, Suárez-Cuartín *et al.*, 2015].  
43  
44  
45  
46  
47  
48  
49

### 50 ***Evidence for neutrophil activation in asthma***

51  
52  
53  
54  
55 There is evidence to suggest that the innate immune system is activated in chronic asthma.  
56  
57 Firstly, sputum IL-8 and neutrophil elastase concentrations and innate immune receptors  
58  
59  
60

1  
2  
3 TLR2, TLR4 and CD14 as well as pro-inflammatory IL-8 and IL1- $\beta$  gene expression levels are  
4  
5 increased in neutrophilic asthma compared to non-neutrophilic asthma [Simpson *et al.*,  
6  
7 2007, Wood *et al.*, 2012]. Secondly, neutrophil activation, as measured by sputum  
8  
9 myeloperoxidase (MPO) levels, is positively associated with sputum neutrophil numbers in  
10  
11 asthma [Little *et al.*, 2002]. Thirdly, specific sputum gene expression signatures are  
12  
13 reported to discriminate eosinophilic asthma from non-eosinophilic asthma as well as to  
14  
15 predict a beneficial response to inhaled corticosteroids [Baines *et al.*, 2014]. In this study,  
16  
17 non-eosinophilic asthma was identified by increased sputum cell expression of IL1 $\beta$  ,  
18  
19 alkaline phosphatase, tissue nonspecific isozyme (ALPL ) and CXCR2, whereas eosinophilic  
20  
21 asthma was characterised by increased expression of Charcot-Leydon crystal protein or  
22  
23 galectin-10 (CLC), carboxypeptidase A3 (CPA3) and deoxyribonuclease I-like 3 (DNASE1L3).  
24  
25 The NLRP3 inflammasome is upregulated in neutrophilic asthma and may increase the  
26  
27 production of IL-1 $\beta$  [Simpson *et al.*, 2014, Kim *et al.*, 2015]. Anti-inflammatory responses  
28  
29 may be impaired in non-eosinophilic asthma based on reduced sputum galectin-3  
30  
31 concentrations, which increases uptake of apoptotic neutrophils and reduced IL-1RA/IL-1 $\beta$   
32  
33 ratio, and which might increase pro-inflammatory actions of IL-1 $\beta$  [Gao *et al.*, 2015]. In  
34  
35 addition, soluble receptor for advanced glycation end-products (RAGE), which is a pattern-  
36  
37 recognition receptor is deficient in BAL samples in neutrophilic asthma [Sukkar *et al.*,  
38  
39 2012]. The T-cell granzyme B pathway, which is thought to mediate apoptosis of epithelial  
40  
41 cells, might be defective in non-eosinophilic asthma, based on the finding of a higher ratio  
42  
43 of the expression of granzyme B to its inhibitor in T cells in this group compared to  
44  
45 eosinophilic asthma [Simpson *et al.*, 2014].  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Systemic inflammation is increased in patients with neutrophilic airway inflammation. The  
4  
5 proportion of patients with elevated CRP, IL-6 and neutrophil elastase concentrations is higher  
6  
7 in neutrophilic asthma compared to a non-neutrophic group [Baines *et al.*, 2011, Wood *et al.*,  
8  
9 2012]. Neutrophilic inflammation is associated with increased  $\alpha$ -defensin and neutrophil  
10  
11 protease gene expression in blood [Baines *et al.*, 2011]. In non-eosinophilic asthma, blood  
12  
13 neutrophils released significantly higher levels of IL-8 at rest [Baines *et al.*, 2010]. In a small  
14  
15 study, gene expression markers of systemic inflammation were associated with higher BMI,  
16  
17 greater history of cigarette smoking, lower FVC% predicted, and increased sputum neutrophils  
18  
19 [Fu *et al.*, 2013].  
20  
21  
22  
23  
24  
25  
26

### 27 **Potential inflammatory processes leading to non-eosinophilic airway inflammation**

28  
29  
30  
31 Several inflammatory processes could lead to non-eosinophilic inflammation and airway  
32  
33 damage in asthma although the exact immunological mechanisms are unclear (Figure 1)  
34  
35 [Trejo Bittar *et al.*, 2015]. Uncertainty in the clinical relevance of experimental animal  
36  
37 models of non-eosinophilic inflammation has hampered progress in understanding the  
38  
39 involvement of neutrophils and non-eosinophilic inflammation in the pathogenesis of  
40  
41 asthma. Stimuli such as viruses, cigarette smoke and pollutants could induce the release of  
42  
43 chemoattractants including IL-8 to recruit neutrophils to the airways. In experimental  
44  
45 asthma models, the release of IL-17A and IL-17F from activated Th17 cells stimulates the  
46  
47 synthesis of neutrophil chemoattractants including CXCL1 and IL-8 from the airway  
48  
49 epithelium. [Newcomb *et al.*, 2013].  $\text{INF-}\gamma$  may also be involved in the pathogenesis of  
50  
51 severe asthma associated with neutrophilic and eosinophilic inflammation, possibly in part  
52  
53 through the release of  $\text{INF-}\gamma$  from Th1 cells [Raundhal *et al.*, 2015]. Data from patients with  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 severe asthma and an experimental murine asthma model implicate high INF- $\gamma$  immune  
4 responses and low secretory leukocyte protease inhibitor expression (SLPI) in airway  
5 epithelial cells with airway hyperresponsiveness [Raundhal *et al.*, 2015 ]. Neutrophils are a  
6 potential source of oxygen free radicals and enzymes and their ability to activate other  
7 airway cell types [Futosi *et al.*, 2013]. Neutrophils in asthma are implicated in causing  
8 mucus gland hyperplasia and hypersecretion, airway hyperreactivity and remodelling as  
9 well as corticosteroid insensitivity. Interestingly, Th<sub>1</sub> and Th<sub>17</sub> cells may induce airway  
10 hyperreactivity and/or remodelling independently of neutrophil activation.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23

24 Limited information has been published on the immunopathological characteristics of non-  
25 eosinophilic inflammation in asthma compared with other inflammatory airway phenotypes  
26 including Th2-low inflammation, Th17-high inflammation or combination of Th2/Th17 profiles.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Bronchial biopsy studies of patients with non-eosinophilic asthma and with Th2-low  
inflammation report reduced sub-mucosal eosinophil numbers and normal sub-epithelial  
basement membrane thickness in both groups [Wenzel *et al.*, 1999, Berry *et al.*, 2007,  
Woodruff *et al.*, 2009]. In contrast, bronchial eosinophils numbers and sub-epithelial basement  
membrane thickness are both increased in eosinophilic asthma and in Th2-high asthma [Wenzel  
*et al.*, 1999, Berry *et al.*, 2007, Woodruff *et al.*, 2009]. Mast cell numbers are increased in  
eosinophilic asthma [Wenzel *et al.*, 1999] and Th2-high asthma [Dougherty *et al.*, 2010],  
whereas mast cells numbers are normal in the sub-mucosal of patients with severe non-  
eosinophilic asthma [Wenzel *et al.*, 1999] and in the epithelium of non-smoker with Th2-low  
asthma [Dougherty *et al.*, 2010]. Mast cell numbers in airway smooth muscle are increased in  
both non-eosinophilic and eosinophilic asthma [Berry *et al.*, 2007]. Bronchial biopsy neutrophil  
numbers are increased to a similar degree in non-eosinophilic severe asthma and eosinophilic

1  
2  
3 severe asthma [Wenzel *et al.*, 1999]. Neutrophil numbers in Th2-low asthma have not been  
4  
5 reported. A lower proportion of subjects with non-eosinophilic asthma are atopic compared to  
6  
7 eosinophilic asthma (18% versus 66%) [Berry *et al.*, 2007] and (58% versus 83%) [Gibson *et al.*,  
8  
9 2001]. Severe asthma associated with neutrophilia has significantly higher sputum levels of  
10  
11 Th17-related cytokines (CXCL1, CXCL10, CCL2, IL-6, and IL-8) compared with severe asthmatics  
12  
13 with other inflammatory phenotypes [Manni *et al.*, 2014]. The proportion of Th17 lymphocytes  
14  
15 and the ratio of Th17 to regulatory T cells (Treg) in the peripheral blood is greater in patients  
16  
17 with non-eosinophilic asthma taking inhaled corticosteroids compared to an eosinophilic  
18  
19 asthma group [Furukawa *et al.*, 2015]. Approximately one third of patients with severe  
20  
21 eosinophilic asthma have a Th17-high signature that is associated with a Th2-low gene  
22  
23 expression profile [Choy *et al.*, 2015]. The number of subjects with non-eosinophilic severe  
24  
25 asthma in this study was not sufficient to determine their Th17 profile [Choy *et al.*, 2015].  
26  
27 Taken together, these findings suggest that non-eosinophilic inflammation and Th2-low  
28  
29 inflammation in non-smokers with asthma share some similar immunopathological features  
30  
31 including normal eosinophil numbers, submucosal mast cell numbers and sub-epithelial  
32  
33 basement membrane thickness. There is a need for further studies to establish the similarities  
34  
35 and differences in endotypes of non-eosinophilic, Th2-low and Th17 high inflammation to help  
36  
37 identify sub-groups of patients for targeted therapies.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

#### 48 **Factors accounting for neutrophilic airway inflammation in asthma**

49  
50  
51  
52

53 Several factors either alone or in combination could explain raised sputum neutrophil counts in  
54  
55 asthma (Table 1). Firstly, corticosteroids inhibit apoptosis of neutrophils [Cox, 1995] and their  
56  
57 use in asthma may contribute to sputum neutrophilia [Saffar *et al.*, 2011]. In addition, Th2-  
58  
59  
60



1  
2  
3 targeted therapies, including oral corticosteroids may contribute to the development of Th17-  
4  
5 high neutrophilic inflammation [Choy *et al.*, 2015, Shum, 2015]. In support of corticosteroids  
6  
7 causing neutrophilia in asthma, inhaled corticosteroid withdrawal from patients with moderate  
8  
9 asthma resulted in only one subject with neutrophilic inflammation although the reintroduction  
10  
11 of inhaled fluticasone for 4 weeks resulted in a raised neutrophil count in only 5% of subjects  
12  
13 [Cowan *et al.*, 2010]. In one study of patients with severe oral corticosteroid dependent asthma  
14  
15 associated with increased sputum neutrophil number, markers of neutrophil activation  
16  
17 including oxidative burst and surface granular receptor expression were similar to patients with  
18  
19 mild asthma [Nair *et al.*, 2015]. In the SARP cohort, however corticosteroid use was not  
20  
21 associated with sputum neutrophilia, suggesting that continuous corticosteroid exposure may  
22  
23 not be the only influence on sputum neutrophil numbers in severe asthma [Moore *et al.*, 2014].  
24  
25 Secondly, co-morbid conditions such bronchiectasis or severe airflow obstructions occurring in  
26  
27 association with asthma may result in neutrophilic inflammation. Thirdly, delayed human  
28  
29 neutrophil apoptosis has been reported in severe asthma [Uddin *et al.*, 2010], possibly due to  
30  
31 epithelial growth factor induced release of mediators with neutrophil chemotactic and anti-  
32  
33 apoptotic actions from bronchial epithelial cells [Uddin *et al.*, 2010, Uddin *et al.*, 2013].  
34  
35 Fourthly, macrophage efferocytosis is impaired in non-eosinophilic asthma, which may cause  
36  
37 airway neutrophilia [Simpson *et al.*, 2013]. Fifthly, altered airway microbiome has been  
38  
39 implicated in airway neutrophilia. Airway colonisation determined by terminal restriction  
40  
41 fragment length polymorphism (T-RFLP) analysis is associated with more severe airways  
42  
43 obstruction and longer duration of disease as well as neutrophilic airway inflammation and  
44  
45 raised sputum IL-8 levels [Simpson *et al.*, 2013, Green *et al.*, 2014]. Taken together, these  
46  
47 finding suggest that the cause of airway neutrophilia in asthma is likely to be complex, possibly  
48  
49 due to corticosteroid treatment inducing impaired apoptosis of neutrophils and Th17 mediated  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 neutrophilic inflammation, delayed apoptosis of neutrophils due to epithelial growth factor  
4  
5 release and ineffective macrophage efferocytosis of neutrophils as well as an altered airway  
6  
7 microbiome.  
8  
9

### 10 11 12 **Clinical phenotypes associated with non-eosinophilic inflammation** 13 14 15

16  
17 Non-eosinophilic inflammation, either paucigranulocytic or neutrophilic occurs in a range of  
18  
19 clinical phenotypes that account for approximately 50% of adults never or ex-smokers with mild  
20  
21 to severe asthma or that have controlled or uncontrolled asthma (Table 2). Non-eosinophilic  
22  
23 inflammation, with or without neutrophilic inflammation is commonly found in smokers with  
24  
25 asthma [Chalmers *et al.*, 2002, Boulet *et al.*, 2006, Thomson *et al.*, 2013]. A high BMI is  
26  
27 associated with non-eosinophilic asthma in some people [Haldar *et al.*, 2008], although others  
28  
29 have submucosal eosinophilia [Desai *et al.*, 2013]. Approximately two thirds of cases of  
30  
31 occupational asthma due to low molecular weight agents have non-eosinophilic inflammation  
32  
33 [Anees *et al.*, 2002], which is associated with a poor asthma prognosis [Lemiere *et al.*, 2014].  
34  
35 Non-occupational-induced asthma that is exacerbated by work exposures is associated with  
36  
37 non-eosinophilic phenotype [Lemière *et al.*, 2013]. Additional factors associated with higher  
38  
39 neutrophil counts include older age [Brooks *et al.*, 2013], exposure to environmental pollution  
40  
41 through living close to car pollution [Wallace *et al.*, 2011], exposure to occupational particulate  
42  
43 matter [Simpson *et al.*, 2015] and respiratory infections.  
44  
45  
46  
47  
48  
49  
50  
51

### 52 **Biomarkers that can identify non-eosinophilic airway inflammation** 53 54 55 56 57 58 59 60

1  
2  
3 Are there biomarkers that can identify patients with non-eosinophilic airway inflammation?  
4

5 Blood eosinophil numbers are moderately associated with sputum eosinophils [Schleich *et al.*,  
6  
7 2013, Zhang *et al.*, 2014, Wagener *et al.*, 2015]. Using a cut-off for a blood eosinophil count of  
8  
9  $>0.22 \times 10^9/L$  [Schleich *et al.*, 2013],  $>0.26 \times 10^9/L$  [Zhang *et al.*, 2014] or  $\geq 0.27 \times 10^9/L$   
10  
11 [Wagener *et al.*, 2015] accurately predicts sputum eosinophilia. In contrast, another study  
12  
13 reported that blood eosinophils had a poor predictive value of 47% for sputum eosinophilia  
14  
15 ( $\geq 3\%$  cut-off) although this was better in severe asthma (71%) [Hastie *et al.*, 2013]. In patients  
16  
17 with mild to severe asthma, blood eosinophils were reported to be better than serum periostin  
18  
19 and exhaled nitric oxide in identifying sputum eosinophilia [Wagener *et al.*, 2015]. Blood  
20  
21 neutrophil numbers has a weak relationship with sputum neutrophil count [Schleich *et al.*,  
22  
23 2013, Zhang *et al.*, 2014] and they have a poor predictive value for sputum neutrophilia (64% or  
24  
25 38% for a cut-off of  $\geq 40\%$  or  $\geq 61\%$  cut-off respectively) [Hastie *et al.*, 2013]. In one study  
26  
27 exhaled nitric oxide predicted inhaled corticosteroid response for airway hyperreactivity in non-  
28  
29 eosinophilic asthma (area under the curve 0.81), with an optimum cut-off point of 33 ppb  
30  
31 [Cowan *et al.*, 2010].  
32  
33  
34  
35  
36  
37  
38  
39  
40

#### 41 **Which inflammatory phenotype to target?**

42  
43  
44

45 In summary, non-eosinophilic airway inflammation is found in approximately 50% of patients  
46  
47 with mild to severe asthma. The proportion of this group with neutrophilic inflammation is less  
48  
49 certain because of variable cut-off points used in different studies to define neutrophilia.  
50  
51

52 Current symptoms, rate of exacerbations and rate of decline in lung function are generally less  
53  
54 severe in non-eosinophilic asthma compared to eosinophilic asthma. Non-eosinophilic  
55  
56 inflammation is associated with an impaired response to inhaled corticosteroids. There is some  
57  
58  
59  
60

1  
2  
3 evidence that neutrophils are activated in the airways of patients with neutrophilic asthma and  
4  
5 that biomarkers of systemic inflammation is increased in this group. Neutrophilia in asthma  
6  
7 may be due to corticosteroids, associated chronic pulmonary infection, altered airway  
8  
9 microbiome and/or delay neutrophil apoptosis, particularly in severe disease. Non-eosinophilic  
10  
11 asthma and Th2-low asthma may share some common immunopathological features, but  
12  
13 further investigation is required. Due to the lack of effective specific therapies targeting non-  
14  
15 eosinophilic inflammation including neutrophilic inflammation there is currently no definitive  
16  
17 evidence for the involvement of these inflammatory phenotypes in chronic asthma. Additional  
18  
19 pathways may account for poor asthma control in patients with non-eosinophilic asthma  
20  
21 including Th1 inflammation, Th17 inflammation, or a combination of Th2 and Th17  
22  
23 inflammation as well as corticosteroid insensitivity (Figure 1). Recent work suggests a  
24  
25 reciprocal relationship between Th2 and Th17 pathways in severe disease and that  
26  
27 corticosteroid treatment may contribute to the emergence of a Th17-high profile [Choy *et al.*,  
28  
29 2015]. Non-inflammatory mechanisms may also be important in some individuals including  
30  
31 airway hyperreactivity and airway remodelling.  
32  
33  
34  
35  
36  
37  
38  
39

#### 40 **TREATMENTS TARGETING NON-EOSINOPHILIC AIRWAY INFLAMMATION**

41  
42  
43  
44  
45 Many patients with asthma continue to have poorly controlled disease despite treatment with  
46  
47 currently available therapies. There is an unmet need for novel treatments that will impact  
48  
49 favourably on clinical outcomes in patients with non-eosinophilic inflammation. Non-  
50  
51 pharmacological interventions, 'off-label' use of licensed drugs, novel small molecules and  
52  
53 biologics agents are being investigated as possible treatments of non-eosinophilic inflammation  
54  
55 in asthma (Table 3 and Figure 2).  
56  
57  
58  
59  
60

## Non-pharmacological interventions

Avoidance from exposure to environmental and occupational pollutants may reduce neutrophilic inflammation in asthma. In a study of smokers with asthma of whom a subgroup quit smoking for 6 weeks the proportion of sputum neutrophils reduced, corticosteroid sensitivity improved and the FEV<sub>1</sub> increased compared to those who continued to smoke [Chaudhuri *et al.*, 2006]. After cessation of exposure to occupational agents, neutrophilic inflammation reduced in people in whom their asthma was cured or improved compared to those in whom there was no improvement [Maghni *et al.*, 2004].

Several clinical trials have examined the effect of dietary supplement of vitamin D in asthma, based on the anti-inflammatory and corticosteroid-enhancing actions of vitamin D [Nanzer *et al.*, 2013, Zhang *et al.*, 2014] [Xystrakis *et al.*, 2006]. Two large randomized clinical trials of vitamin D3 supplementation in patients with asthma and vitamin D insufficiency [VIDA and ViDiAs trials], although not selected for specific airway inflammatory cell profiles or corticosteroid insensitivity, reported no improvements in clinical outcomes [Castro *et al.*, 2014, Martineau *et al.*, 2015, Denlinger *et al.*, 2015]. Interestingly, vitamin D supplementation reduces eosinophilic inflammation in patients with non-atopic asthma, suggesting that certain inflammatory phenotypes might benefit from vitamin D3 supplementation [De Groot *et al.*, 2015].

## 'Off-label' use of licensed drugs

Several drugs licensed for the treatment of medical conditions other than asthma have been investigated for their efficacy in asthma, including patients with non-eosinophilic inflammation.

1  
2  
3 Candidate drugs have been chosen usually because of pre-clinical evidence of anti-  
4  
5 inflammatory effects that might be relevant to treatment of asthma. Some examples are  
6  
7 reviewed below.  
8  
9

### 10 11 12 **Macrolides** 13

14  
15  
16  
17 Macrolides may be of benefit in the treatment of chronic asthma [Reiter *et al.*, 2013], including  
18  
19 non-eosinophilic asthma [Simpson *et al.*, 2008], although prescribing macrolides as a long-term  
20  
21 treatment increases the risk of adverse drug effects and the development of microbial  
22  
23 resistance [Cameron *et al.*, 2012]. The mechanism(s) of action of macrolides in the treatment of  
24  
25 airway diseases is not known, but could be due to antibacterial and/or anti-inflammatory  
26  
27 actions, which include inhibition of NF- $\kappa$ B and other transcription factors as well as reduction in  
28  
29 neutrophil migration and/or function [Culic *et al.*, 2001, Fujitani *et al.*, 2003, Simpson *et al.*,  
30  
31 2008, Cameron *et al.*, 2012, Kobayashi *et al.*, 2013]. Macrolides have additional potentially  
32  
33 beneficial properties including anti-viral actions [Gielen *et al.*, 2010, Schögler *et al.*, 2015] and  
34  
35 an ability to restore corticosteroid sensitivity by inhibiting the phosphoinositide 3-kinase (PI3K)  
36  
37 pathway and restoring histone deacetylase (HDAC)2 activity [Spahn *et al.*, 2001, Kobayashi *et*  
38  
39 *al.*, 2013, Hao *et al.*, 2015] and by attenuating TNF $\alpha$  and IL-17 immune responses [Essilfie *et al.*,  
40  
41 2015]. Two recent exploratory clinical trials have investigated the effects of macrolides in non-  
42  
43 eosinophilic asthma. In one trial, smokers with mild to moderate asthma associated with non-  
44  
45 eosinophilic inflammation were randomized to azithromycin 250 mg per day or placebo  
46  
47 [Cameron *et al.*, 2013]. After 12 weeks, treatment with azithromycin was not associated with  
48  
49 improvements in morning PEF, ACQ score, AQLQ score and methacholine PC<sub>20</sub> compared to  
50  
51 placebo and did not alter induced sputum differential counts, bacterial load, *C. pneumonia*, *M.*  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 *pneumoniae* seropositivity or upper airways respiratory virus prevalence. In an other  
4  
5 randomized controlled trial patients with exacerbation-prone severe asthma received low-dose  
6  
7 azithromycin or placebo as add-on treatment to combination therapy of inhaled corticosteroids  
8  
9 and long-acting  $\beta_2$  agonists for 6 months [Brusselle *et al.*, 2013]. The rate of severe  
10  
11 exacerbations and lower respiratory tract infections requiring treatment with antibiotics was  
12  
13 not reduced by azithromycin. In a predefined subgroup with non-eosinophilic severe asthma  
14  
15 (blood eosinophilia  $\leq 200/\mu\text{l}$ ) there was a reduction in the rate of primary endpoints in  
16  
17 azithromycin-treated patients [Brusselle *et al.*, 2013]. Azithromycin improved AQLQ scores, but  
18  
19 did change ACQ scores or lung function. Based on these findings, further clinical trials of  
20  
21 macrolides in non-eosinophilic severe asthma are indicated. Novel analogues of macrolides  
22  
23 have been developed that have enhanced anti-inflammatory properties than current  
24  
25 macrolides, such as solithromycin (CEM-101) [Kobayashi *et al.*, 2013, Kobayashi *et al.*, 2013] or  
26  
27 that lack anti-bacterial properties, such as the non-antibiotic azithromycin derivative CSY0073  
28  
29 [Balloy *et al.*, 2014].  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

### Statins

43  
44 Statins have pleiotropic immunomodulatory actions [Greenwood *et al.*, 2006] that may of  
45  
46 value in the treatment of chronic inflammatory diseases [Greenwood *et al.*, 2006, Hothersall  
47  
48 *et al.*, 2006, Yeganeh *et al.*, 2014]. In experimental models of allergic asthma [Mckay *et al.*,  
49  
50 2004, Zeki *et al.*, 2009] and tobacco-smoke-induced lung inflammation [Lee *et al.*, 2005,  
51  
52 Davis *et al.*, 2013] statins reduce inflammatory pathways potentially relevant to the  
53  
54 pathogenesis of asthma and smoke-induced airway diseases. Statins might also restore  
55  
56 corticosteroid sensitivity in asthma [Samson *et al.*, 2006, Maneechotesuwan *et al.*, 2010].  
57  
58  
59  
60

1  
2  
3 Taken together, these findings suggest that statin treatment may have anti-inflammatory  
4 effects in people with asthma including smokers with asthma. A randomized double-blind  
5  
6 effects in people with asthma including smokers with asthma. A randomized double-blind  
7  
8 parallel group trial undertaken in seventy one smokers with mild to moderate asthma  
9  
10 associated with non-eosinophilic inflammation compared treatment with atorvastatin 40 mg  
11  
12 per day with placebo. After 4 weeks treatment inhaled beclometasone 400 µg per day was  
13  
14 added to both treatment arms for a further 4 weeks [Braganza *et al.*, 2011]. At 4 weeks,  
15  
16 there was an improvement in ACQ and AQLQ scores with atorvastatin, but not in lung  
17  
18 function. There was no significant improvement with atorvastatin and inhaled  
19  
20 beclometasone compared to inhaled beclometasone alone in clinical outcome measures at  
21  
22 8 weeks. In a follow-up study the effects of atorvastatin alone and in combination with  
23  
24 inhaled corticosteroid was investigated on their ability to suppress the concentration of a  
25  
26 range of cytokines, chemokines and growth factors in sputum samples collected during the  
27  
28 previous clinical trial [Braganza *et al.*, 2011, Thomson *et al.*, 2015 ]. Sputum mediator  
29  
30 concentrations were not reduced by inhaled beclometasone alone. Atorvastatin significantly  
31  
32 reduced sputum concentrations of CCL7, IL-12p70, sCD40L, FGF-2, CCL4, TGF- $\alpha$  and MMP-8  
33  
34 compared with placebo and, when combined with inhaled beclometasone, reduced sputum  
35  
36 concentrations of MMP-8, IL-1 $\beta$ , IL-10, MMP-9, sCD40L, FGF-2, IL-7, G-CSF and CCL7  
37  
38 compared to ICS alone. Improvements in ACQ and/or AQLQ scores with atorvastatin and  
39  
40 inhaled beclometasone were associated with decreases in G-CSF, IL-7, CCL2 and CXCL8.  
41  
42 Interestingly, simvastatin suppresses airway IL-17 and upregulated IL-10 in patients with  
43  
44 stable COPD [Maneechotesuwan *et al.*, 2013]. Taken together, these findings suggest that  
45  
46 short-term treatment with atorvastatin alone or in combination with inhaled  
47  
48 beclometasone reduces several sputum cytokines, chemokines and growth factors  
49  
50 concentrations unresponsive to inhaled corticosteroids alone in asthmatic smokers with  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 non-eosinophilic inflammation. There is a need for long-term clinical studies examining  
4  
5 effect of statins on exacerbations and airway remodelling in chronic non-eosinophilic  
6  
7 asthma.  
8  
9

### 10 11 **Low-dose theophylline**

12  
13  
14  
15  
16  
17 Low dose theophylline has been shown to restore corticosteroid sensitivity *in-vitro* possibly  
18  
19 by increasing HDAC-2 activity, which is suppressed in severe asthma and in smokers with  
20  
21 asthma and a similar clinical effect might occur in people with severe disease or who are  
22  
23 smokers [Barnes, 2009, To *et al.*, 2010]. Theophylline inhibits oxidative stress dependent  
24  
25 PI3K- $\delta$  activation and restores corticosteroid sensitivity in PBMCs from patients with COPD  
26  
27 [To *et al.*, 2010]. An exploratory clinical trial examined the effects of low dose theophylline  
28  
29 added to inhaled beclometasone compared to inhaled beclometasone alone in smokers  
30  
31 with asthma associated with non-eosinophilic inflammation [Spears *et al.*, 2009]. The  
32  
33 addition of low dose theophylline to inhaled beclometasone, at a dose titrated to provide a  
34  
35 'sub-therapeutic' concentration, resulted in increased efficacy as measured by lung function  
36  
37 and suggested the restoration of corticosteroid sensitivity in those treated with the  
38  
39 combination. Clinical trials to date have not investigated the therapeutic effects of adding  
40  
41 low dose theophylline to patients with severe asthma. A fixed combination of ultra-low dose  
42  
43 of theophylline with fluticasone, SKP-2075 (Skepharma), in a dry powder inhaler is under  
44  
45 development for the treatment COPD. This combination would potentially be of benefit in  
46  
47 the treatment of severe asthma and smokers with asthma, possibly in those people with  
48  
49 non-eosinophilic inflammation.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### **PPAR $\gamma$ agonist**

In pre-clinical studies peroxisome proliferator-activated receptor- $\gamma$  (PPAR $\gamma$ ) agonists exert anti-inflammatory effects potentially relevant to the treatment of inflammatory airway diseases including asthma and COPD [Spears *et al.*, 2006, Belvisi *et al.*, 2008, Seidel *et al.*, 2012, Stephen *et al.*, 2013, Bourke *et al.*, 2014, Lakshmi *et al.*, 2014, Lea *et al.*, 2014, Donovan *et al.*, 2015 ].

For example, PPAR $\gamma$  agonists reduce eosinophilic and neutrophilic lung infiltration in experimental animal models exposed to allergen or tobacco smoke [Bauer *et al.*, 2010, Lea *et al.*, 2014, Zhao *et al.*, 2014, Morissette *et al.*, 2015]. The oral PPAR $\gamma$  agonist rosiglitazone had a modest effect in attenuating the allergen-induced late asthmatic response [Richards *et al.*, 2010]. A further proof of concept study reported that rosiglitazone compared with inhaled beclometasone dipropionate resulted in improvement in lung function and a borderline reduction in sputum IL-8 concentration in smokers with mild to moderate asthma that was associated with non-eosinophilic inflammation [Spears *et al.*, 2009]. The oral PPAR $\gamma$  agonist pioglitazone is not effective in obese asthmatics [Dixon *et al.*, 2015]. Inhaled PPAR $\gamma$  agonist analogues, such as AD3277 (Pulmagen) are under development for the treatment of chronic inflammatory airway diseases and potentially might be of benefit in non-eosinophilic asthma.

### **Novel small molecule drugs**

Novel small molecule inhibitors have been developed for treating neutrophilic/non-eosinophilic asthma including CXCR2 antagonists, FLAP inhibitors, PDE<sub>4</sub> inhibitors, dual PDE<sub>3</sub> and PDE<sub>4</sub> inhibitor and various protein kinase inhibitors.

**CXCR2 antagonist**

CXCR2 receptors are expressed on neutrophils as well as on airway goblet cells, fibroblasts and airway smooth muscle [Chapman *et al.*, 2009]. Ligands for the CXCR2 receptor include the chemokines CXCL8 (IL-8), growth-related protein (Gro)- $\alpha$ , - $\beta$ , and - $\gamma$  (CXCL1–3), epithelial-derived neutrophil attractant-78 (ENA-78; CXCL5), granulocyte chemotactic protein-2 (GCP-2; CXCL6) and neutrophil-activating peptide-2 (NAP-2; CXCL7) [Chapman *et al.*, 2009, Campbell *et al.*, 2013]. Activation of CXCR2 receptors result in neutrophil chemotaxis, proteases production, airway goblet cell hyperplasia, pulmonary blood vessel angiogenesis, collagen deposition and airway smooth muscle contraction and migration [Chapman *et al.*, 2009]. The effects of CXCR2 antagonists have been studied on airway challenges that induce sputum neutrophilia. The CXCR2 antagonist, AZD8309 inhibits LPS-induced airway neutrophilic inflammation in healthy volunteers [Leaker *et al.*, 2013] and the CXCR2 antagonist, SB656933 inhibited *ex vivo* neutrophil activation and ozone-induced airway inflammation in humans [Lazaar *et al.*, 2011]. The CXCR2 antagonist, SCH527123 inhibits ozone-induced neutrophilia in healthy subjects [Holz *et al.*, 2010]. A randomized, placebo-controlled clinical trial of the CXCR2 antagonist SCH527123 administered for 4 weeks to patients with severe asthma and sputum neutrophils > 40% resulted in a reduction of 36.3% in sputum neutrophil percentage, fewer mild exacerbations and a trend towards improvement in ACQ score [Nair *et al.*, 2012]. A clinical trial of the efficacy and safety of a CXCR2 antagonist AZD5069 in severe, uncontrolled persistent asthma reported that the addition of AZD5069 to combination ICS/LABA treatment did not improve clinical outcomes despite a dose-dependent reduction in blood neutrophil counts [O'byrne *et al.*, 2015]. A lack

1  
2  
3 of improvement in clinical outcome despite a reduction in sputum neutrophil counts was  
4 reported with the CXCR2 antagonist AZD5069 in bronchiectasis [De Soyza *et al.*, 2015]. A  
5 recent trial of the CXCR2 antagonist Navarixin (SCH527123) in COPD led to significant  
6 improvements in FEV<sub>1</sub> and reduction in sputum neutrophil count, particularly in current  
7 smokers with COPD [Rennard *et al.*, 2015]. The CXCR2 antagonist AZD8309 administered  
8 for 4 weeks to patients with moderate to severe COPD was well tolerated with no increase  
9 in the rate of infections [Kirsten *et al.*, 2015]. A small-molecule oral CXCR2 antagonists  
10 Danirixin (GSK1325756) is undergoing a clinical trial in patients with COPD at risk of  
11 exacerbations (ClinicalTrials.gov Identifier: NCT02130193). Oral CXCR2 antagonists could  
12 potentially cause neutropenia, and the therapeutic index of these compounds requires  
13 careful assessment.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

### 31 **FLAP inhibitors**

32  
33  
34  
35 Pro-inflammatory cysteinyl leukotrienes (LTs) are synthesised from arachidonic acid in  
36 inflammatory cells by 5-lipoxygenase (LO) and 5-lipoxygenase activating protein (FLAP).  
37 FLAP inhibitors such as GSK-2190915 [Evans *et al.*, 2008] prevent the formation of LTB<sub>4</sub>,  
38 which may be of value in the treatment of neutrophilic asthma. GSK2190915 markedly  
39 inhibited *ex vivo* calcium ionophore stimulated blood LTB<sub>4</sub> formation and urinary  
40 leukotriene E<sub>4</sub> (LTE<sub>4</sub>) formation [Bain *et al.*, 2013]. Pre-treatment with GSK2190915 reduces  
41 the early and late phase response to allergen challenge and results in a significant reduction  
42 of sputum LTB<sub>4</sub> levels [Kent *et al.*, 2013]. Despite suppressing the target mediator LTB<sub>4</sub>, the  
43 FLAP inhibitor GSK2190915 has no short-term effect on sputum cell counts or clinical  
44 endpoints in smokers and non-smokers with asthma associated with neutrophilic  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 inflammation (sputum neutrophilia  $\geq 50\%$  for one sample and  $>45\%$  for the other),  
4  
5 suggesting that  $LTB_4$  suppression alone is inadequate in controlling airway neutrophils in  
6  
7 asthma [Chaudhuri *et al.*, 2014]. No active clinical trials of FLAP inhibitors in asthma are  
8  
9 currently registered on ClinicalTrials.gov.  
10  
11

### 12 13 14 ***PDE<sub>4</sub> inhibitors and dual PDE<sub>3</sub> and PDE<sub>4</sub> inhibitors*** 15

16  
17  
18  
19 Phosphodiesterase (PDE)<sub>4</sub> inhibitors have immunomodulatory effects on inflammatory cells  
20  
21 potentially relevant to the treatment of asthma [Lipworth, 2005, Page *et al.*, 2012, Kim *et*  
22  
23 *al.*, 2015 ]. In an allergen challenge study the oral PDE<sub>4</sub> inhibitor roflumilast attenuated the  
24  
25 rise in sputum eosinophils and neutrophils numbers after the late asthmatic response  
26  
27 [Gauvreau *et al.*, 2011]. High doses of PDE<sub>4</sub> inhibitors may be necessary to treat severe  
28  
29 asthma, and gastro-intestinal side effects limit their use [Lipworth, 2005, Bateman *et al.*,  
30  
31 2006, Bousquet *et al.*, 2006]. The inhaled administration of PDE<sub>4</sub> inhibitors may improve the  
32  
33 therapeutic index of PDE<sub>4</sub> inhibitors [Chapman *et al.*, 2010, Singh *et al.*, 2010, Nials *et al.*,  
34  
35 2011, De Savi *et al.*, 2014, Moretto *et al.*, 2015]. Inhaled PDE<sub>4</sub> inhibitors GSK256066 and  
36  
37 CHF6001 both inhibit allergen-induced late asthmatic responses [Singh *et al.*, 2010, Dave *et*  
38  
39 *al.*, 2014] and in patients with moderate COPD inhaled GSK256066 for 4 weeks was well  
40  
41 tolerated although there was no inhibitory effect on sputum and blood inflammatory  
42  
43 biomarkers [Watz *et al.*, 2013]. The inhaled dual PDE<sub>3</sub> and PDE<sub>4</sub> inhibitor RPL554 (Verona  
44  
45 Pharma) has bronchodilator effects and is well tolerated in patients with asthma and COPD  
46  
47 [Franciosi *et al.*, 2013]. In healthy subjects inhaled RPL554 attenuates the neutrophilic  
48  
49 response to LPS challenge [Franciosi *et al.*, 2013]. RPL554 is under development for the  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 treatment of asthma and COPD (ClinicalTrials.gov Identifier: NCT02427165 and  
4  
5 NCT02542254 respectively).  
6  
7  
8  
9

### 10 **Protein kinase inhibitors**

11  
12  
13  
14  
15 Protein kinases are involved in cellular signalling of pro-inflammatory cytokines in asthma  
16  
17 and the inhibition of these kinases may have a role in the treatment of severe asthma  
18  
19 associated with non-eosinophilic asthma [Bhavsar *et al.*, 2010, Cohen *et al.*, 2010,  
20  
21 Hammaker *et al.*, 2010, Chung, 2011, Guntur *et al.*, 2012]. Several p38MAPK inhibitors  
22  
23 restore corticosteroid sensitivity in PBMCs from patients with severe asthma [Bhavsar *et al.*,  
24  
25 2010, Mercado *et al.*, 2012] and COPD [Khorasani *et al.*, 2015]. Clinical trials of p38MAPK  
26  
27 inhibitors oral losmapimod (GW856553) and inhaled AZD7624 are register for the treatment  
28  
29 COPD (ClinicalTrials.gov Identifier: NCT02299375 and NCT02238483 respectively), although  
30  
31 neither are registered for the treatment of asthma. Interestingly, a *post-hoc* analysis of a 6  
32  
33 month clinical trial of oral losmapimod (GW856553) in COPD reported a reduction in  
34  
35 exacerbations in a sub-group of patients with a blood eosinophil count  $\leq 2\%$  [Marks-  
36  
37 Konczalik *et al.*, 2015], which may suggest a preferentially beneficial effect of p38MAPK  
38  
39 inhibitors in non-eosinophilic inflammation. A imatinib, a specific ckit tyrosine kinase  
40  
41 inhibitor that attenuates airway hyperresponsiveness, inflammation and remodelling in  
42  
43 murine model of asthma [Berlin *et al.*, 2005, Rhee *et al.*, 2011] is under development for  
44  
45 patients with severe refractory asthma (ClinicalTrials.gov Identifier: NCT01097694). A  
46  
47 tyrosine kinase inhibitor masitinib targets c-kit and platelet-derived growth factor (PDGF)  
48  
49 receptor improved asthma control in patients with severe corticosteroid-dependent asthma  
50  
51 [Humbert *et al.*, 2009] and a further clinical trial underway in patients with severe asthma  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 treated with oral corticosteroids (ClinicalTrials.gov Identifier: NCT01449162). An alternative  
4  
5 therapeutic strategy to silencing c-kit with small interference RNA has been shown to  
6  
7 attenuate inflammation in a murine model of allergic asthma [Wu *et al.*, 2012, Wu *et al.*,  
8  
9 2014]. Clinical trials of protein kinase inhibitors have not been studied in patients with  
10  
11 sputum inflammatory subtypes such as non-eosinophilic asthma.  
12  
13

### 14 15 16 17 **PI3kinase inhibitors**

18  
19  
20  
21 Low dose theophylline is thought to act, at least in part, through the inhibition of PI3K [Ito *et*  
22  
23 *al.*, 2007, To *et al.*, 2010]. Pre-clinical studies suggest that PI3K- $\delta$  inhibitors could potentially  
24  
25 reverse corticosteroid insensitivity by increasing HDAC2 activity [Marwick *et al.*, 2009, Marwick  
26  
27 *et al.*, 2010] and by reversing fungal-induced steroid resistant airway inflammation through  
28  
29 modulation of endoplasmic reticulum stress [Lee *et al.*, 2016]. Selective PI3K inhibitors are  
30  
31 being developed as novel therapies for the treatment of chronic inflammatory airway diseases.  
32  
33 An inhaled PI3K $\delta$  inhibitor GSK2269557 is undergoing several clinical trials in asthma and COPD.  
34  
35 PI3K  $\delta$  and  $\gamma$  isoforms are involved in inflammatory cell recruitment and activation and dual  
36  
37 PI3K $\delta/\gamma$  inhibitors, such as TG100-115 and IPI-145 reduces airway inflammation induced by  
38  
39 allergen or cigarette smoke in murine models [Doukas *et al.*, 2009, Winkler *et al.*, 2013] and  
40  
41 restored corticosteroid sensitivity in the smoke model [Doukas *et al.*, 2009]. RV1729, a PI3K $\delta/\gamma$   
42  
43 Inhibitor has undergone early stage clinical evaluation in asthma and COPD. SH2-containing  
44  
45 inositol-50-phosphatase 1 (SHIP1) is an endogenous inhibitor of the PI3K pathway. A SHIP1  
46  
47 activator AQX-1125 reduced the allergen-induced late asthmatic response with a non-  
48  
49 significant trend for a reduction in sputum eosinophils and neutrophils [Leaker *et al.*, 2014].  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Further development of AQX-1125 is underway for the treatment of COPD (ClinicalTrials.gov  
4  
5 Identifier: NCT01954628).  
6  
7  
8  
9

## 10 **Biological agents**

11  
12  
13  
14  
15 Monoclonal antibody blockers of inflammatory cytokines such as IL-17 and TNF- $\alpha$  that activate  
16  
17 receptors on the surface of neutrophils have been investigated as treatments for asthma.  
18  
19

### 20 ***IL-17 blockers***

21  
22  
23  
24  
25  
26 In pre-clinical studies Th<sub>17</sub> cells and IL-17 are implicated in causing neutrophilic inflammation  
27  
28 and corticosteroid insensitivity [Shen *et al.*, 2011, Newcomb *et al.*, 2013, Chesné *et al.*,  
29  
30 2014]. IL-17 concentrations and expression are increased in BAL, sputum and bronchial  
31  
32 biopsy samples in severe patients asthma that correlate with sputum neutrophils.  
33  
34

35  
36 Monoclonal inhibitors of IL-17 are in clinical development [Miossec *et al.*, 2012].  
37

38  
39 Brodalumab is a human monoclonal antibody that binds with high affinity to human IL-  
40  
41 17RA, blocking the biologic activity of IL-17A, -17F, -17A/F heterodimer, and IL-25. A  
42  
43 randomized clinical trial of brodalumab in adults with inadequately controlled moderate to  
44  
45 severe asthma receiving regular inhaled corticosteroids, but not selected for neutrophilic  
46  
47 inflammation, reported no improvement in the primary outcome ACQ score or in lung  
48  
49 function and symptom-free days [Busse *et al.*, 2013]. A subgroup with high bronchodilator  
50  
51 reversibility demonstrated a borderline improvement an ACQ score. A further clinical trial of  
52  
53 brodalumab in inadequately controlled asthma subjects with high bronchodilator  
54  
55 reversibility was recently terminated due to a lack of observed efficacy in a pre-specified  
56  
57  
58  
59  
60



1  
2  
3 interim analysis (ClinicalTrials.gov Identifier: NCT01902290). The results of a preliminary  
4  
5 proof of efficacy study of the IL-17A monoclonal antibody blocker secukinumab (AIN457) in  
6  
7 patients with uncontrolled asthma was also recently terminated. The investigators report  
8  
9 that further investigations would require changes in study design, the use of different  
10  
11 endpoints, a different IL-17 antibody or a different patient population (ClinicalTrials.gov  
12  
13 Identifier: NCT01478360).  
14  
15

### 16 17 18 19 **TNF- $\alpha$ blockers**

20  
21  
22  
23  
24 Neutralizing TNF $\alpha$  restores corticosteroid sensitivity in a mouse model of neutrophilic airway  
25  
26 inflammation [Dejager *et al.*, 2015]. Several small clinical studies in severe asthma of the  
27  
28 soluble TNF- $\alpha$  receptor blocker etanercept reported beneficial effects on clinical outcomes  
29  
30 [Howarth *et al.*, 2005, Berry *et al.*, 2006], whereas larger studies with etanercept [Holgate *et al.*,  
31  
32 2011] and the TNF- $\alpha$  receptor blocker golimumab [Wenzel *et al.*, 2009] did not confirm a  
33  
34 consistent beneficial clinical effect. When combined with concerns over increased risk of severe  
35  
36 infections and malignancies with TNF- $\alpha$  receptor blocker treatment [Wenzel *et al.*, 2009] it is  
37  
38 unlikely that this target will be developed further for the treatment of asthma.  
39  
40  
41  
42  
43  
44

### 45 46 **Other monoclonal antibodies**

47  
48  
49  
50 Monoclonal antibodies that block IL-1 $\beta$ , for example, canakinumab or block the soluble IL-1  
51  
52 receptor, for example, anakinra [Hernandez *et al.*, 2015] might be of benefit in neutrophilic  
53  
54 asthma, although no clinical studies are currently registered. An IL-6 monoclonal antibody  
55  
56 blocker tocilizumab is licensed for the treatment of rheumatoid arthritis. Tocilizumab could  
57  
58  
59  
60

1  
2  
3 potentially be of benefit in neutrophilic asthma although no clinical studies are registered in  
4  
5 asthma.  
6  
7  
8  
9

## 10 **Conclusions and future developments**

11  
12  
13  
14  
15 Non-eosinophilic airway inflammation is a term used to describe a subtype of asthma  
16 associated with normal numbers of sputum eosinophils. Up to 50% of patients with stable mild  
17 to severe never or ex-smokers with asthma have non-eosinophilic inflammation and this  
18 inflammatory phenotype is also found in smokers with asthma, some patient with a high BMI or  
19 occupational asthma. The non-eosinophilic phenotype is subdivided into neutrophilic  
20 inflammation, when neutrophil numbers are raised above a defined cut-off level or  
21 paucigranulocytic inflammation, when both eosinophil and neutrophil numbers are normal. The  
22 relative proportions of each subtype is uncertain because of variable cut-off points used to  
23 define neutrophilia. The most appropriate value that indicates that neutrophils are activated  
24 and contributing to the pathogenic processes in asthma is not certain. The severity of current  
25 symptoms are in general similar or slightly better in non-eosinophilic or neutrophilic subgroups  
26 of asthma compare to eosinophilic subgroups. Sputum eosinophilia is a better predictor of  
27 future exacerbations and a greater risk factor for more rapid decline in lung function than  
28 sputum neutrophilia. Non-eosinophilic inflammation is associated with an impaired therapeutic  
29 response to inhaled corticosteroids. Neutrophilic inflammation is associated with activation of  
30 the innate immune system in asthma and systemic inflammation. Several mechanisms either  
31 alone or in combination could explain raised sputum neutrophil counts in asthma including  
32 corticosteroids, associated chronic sinopulmonary infection, delay human neutrophil apoptosis  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 due to epithelial growth factor, impaired macrophage phagocytosis and altered airway  
4  
5 microbiome. Limited information has been published on the immunopathological  
6  
7 characteristics of non-eosinophilic inflammation compared with other inflammatory airway  
8  
9 phenotypes including Th2-low inflammation, Th17-high inflammation or combination of  
10  
11 Th2/Th17 profiles in asthma. Taken together, the finding suggest that non-eosinophilic  
12  
13 inflammation and Th2-low inflammation in non-smokers with asthma share some similar  
14  
15 immunopathological features including normal eosinophil numbers, submucosal mast cell  
16  
17 numbers and sub-epithelial basement membrane thickness. Due to the lack of effective specific  
18  
19 therapies targeting non-eosinophilic inflammation including neutrophilic inflammation there is  
20  
21 currently no definitive evidence for the involvement of these inflammatory phenotypes in  
22  
23 chronic asthma. Additional pathways may account for poor asthma control in patients with  
24  
25 non-eosinophilic asthma including Th1 inflammation, Th17 inflammation, or a combination of  
26  
27 Th2 and Th17 inflammation as well as corticosteroid insensitivity (Figure 2). The role of  
28  
29 corticosteroid treatment in causing neutrophilic and Th17 inflammation in severe asthma  
30  
31 requires further investigation. Non-inflammatory mechanisms may also be important in some  
32  
33 individuals including airway hyperreactivity and airway remodelling.  
34  
35  
36  
37  
38  
39  
40  
41  
42

43 There is an unmet need for novel treatments that will impact favourably on clinical outcomes in  
44  
45 patients with non-eosinophilic inflammation. Non-pharmacological interventions, 'off-label'  
46  
47 use of licensed drugs, novel small molecules and biologics agents are being investigated as  
48  
49 possible treatments of non-eosinophilic inflammation in asthma. Smoking cessation in smokers  
50  
51 with asthma and cessation of exposure to occupational agents are associated with a reduction  
52  
53 in neutrophilic inflammation. Preliminary data of studies of 'off-label' use of licensed drugs  
54  
55 suggest that macrolides show efficacy in non-smokers with non-eosinophilic asthma and  
56  
57  
58  
59  
60

1  
2  
3 statins, low-dose theophylline and PPAR $\gamma$  agonist may be beneficial in asthmatic smokers with  
4  
5 non-eosinophilic inflammation and corticosteroid insensitivity. Further clinical studies are  
6  
7 indicated to confirm these findings and to determine the role of these therapies in the  
8  
9 management of severe asthma. Novel small molecules targeting neutrophilic inflammation in  
10  
11 asthma such as CXCR2 antagonists reduce neutrophil counts, but do not improve clinical  
12  
13 outcomes. A FLAP inhibitor did not reduce neutrophils or improve symptoms. Inhaled PDE4  
14  
15 inhibitors and dual PDE3 and PDE4 inhibitors are potential therapies for neutrophilic asthma  
16  
17 and a dual PDE3 and PDE4 inhibitors is under development for the treatment of asthma and  
18  
19 COPD. Additional small molecule drugs including p38MAPK inhibitors, tyrosine kinase inhibitors  
20  
21 and PI3kinase inhibitors are under development for asthma. The development of biological  
22  
23 agents to target non-eosinophilic inflammation in asthma has been disappointing to date with  
24  
25 the termination of clinical programmes of monoclonal antibodies targeting IL-17 and TNF- $\alpha$ . In  
26  
27 the future, the selection of patients with severe asthma and evidence of Th17-high  
28  
29 inflammation may be more likely to identify a subpopulation that respond to IL-17 blockers.  
30  
31 Long-acting bronchodilators and/or bronchial thermoplasty are possible treatment options for  
32  
33 symptomatic patients with paucigranulocytic inflammation in whom there is no evidence of  
34  
35 activated inflammatory pathways or corticosteroid insensitivity that could be targeted by  
36  
37 specific therapies.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

48 Greater understanding of the mechanisms of non-eosinophilic inflammation in asthma should  
49  
50 lead to improved therapies. International collaborative programmes of research investigating  
51  
52 pathogenic mechanism of severe asthma have focused mainly on type 2 eosinophilic  
53  
54 inflammation. The Unbiased Biomarkers for the Prediction of Respiratory Disease Outcome (U-  
55  
56 BOPRED) study [Gaga *et al.*, 2015, Shaw *et al.*, 2015] and the UK Refractory Asthma  
57  
58  
59  
60

1  
2  
3 Stratification Programme (RASP-UK) [Heaney *et al.*, 2015 ] are designed to identify new  
4  
5 phenotypes/endotypes and treatment targets and will hopefully identify new approaches to  
6  
7 the treatment of patients with non-eosinophilic asthma.  
8  
9

### 10 11 **Declaration of Conflicting Interests** 12

13  
14  
15  
16 In the last three years Professor Thomson has participated in advisory boards and/or  
17  
18 received consultancy/lecture fees from Boston Scientific, Genentech, GlaxoSmithKline,  
19  
20 Novartis, Respivert, Roche and Takeda and industry-sponsored grant funding to the  
21  
22 University of Glasgow from Boston Scientific, Glaxo SmithKline and Novartis for participating  
23  
24 in clinical trials.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

Agustí, A., Antó, J.M., Auffray, C., Barbé, F., Barreiro, E., Dorca, J. *et al.* (2015) Personalized Respiratory Medicine: Exploring the Horizon, Addressing the Issues. Summary of a Brn-Ajrccm Workshop Held in Barcelona on June 12, 2014. *Am J Resp Crit Care Med* 191: 391-401.

Al-Samri, M.T., Benedetti, A., Préfontaine, D., Olivenstein, R., Lemièrre, C., Nair, P. *et al.* (2010) Variability of Sputum Inflammatory Cells in Asthmatic Patients Receiving Corticosteroid Therapy: A Prospective Study Using Multiple Samples. *J Allergy Clin Immunol* 125: 1161-1163.e1164.

Anees, W., Huggins, V., Pavord, I.D., Robertson, A.S., and Burge, P.S. (2002) Occupational Asthma Due to Low Molecular Weight Agents: Eosinophilic and Non-Eosinophilic Variants. *Thorax* 57: 231-236.

Arron, J.R., Choy, D.F., Laviolette, M., Kelsen, S.G., Hatab, A., Leigh, R. *et al.* (2014) Disconnect between Sputum Neutrophils and Other Measures of Airway Inflammation in Asthma. *Eur Respir J* 43: 627-629.

Arron, J.R., Scheerens, H., Matthews, J.G., and David, R.W. (2013) Redefining Approaches to Asthma: Developing Targeted Biologic Therapies. In: Editors: Webb, D., Enna, S., and Lecount, L., (eds), *Adv Pharmacol - Immunopharmacol*, Vol. Volume 66. Academic Press: Amsterdam.

Bacci, E., Cianchetti, S., Bartoli, M., Dente, F.L., Di Franco, A., Vagaggini, B. *et al.* (2006) Low Sputum Eosinophils Predict the Lack of Response to Beclomethasone in Symptomatic Asthmatic Patients. *Chest* 129: 565-572.

Bacci, E., Latorre, M., Cianchetti, S., Bartoli, M., Costa, F., Di Franco, A. *et al.* (2012) Transient Sputum Eosinophilia May Occur over Time in Non-Eosinophilic Asthma and This Is Not Prevented by Salmeterol. *Respirology* 17: 1199-1206.

Bain, G., King, C.D., Schaab, K., Rewolinski, M., Norris, V., Ambery, C. *et al.* (2013) Pharmacodynamics, Pharmacokinetics and Safety of Gsk2190915, a Novel Oral Anti-Inflammatory 5-Lipoxygenase-Activating Protein Inhibitor. *Br J Clin Pharmacol* 75: 779-790.

Baines, K.J., Simpson, J.L., Bowden, N.A., Scott, R.J., and Gibson, P.G. (2010) Differential Gene Expression and Cytokine Production from Neutrophils in Asthma Phenotypes. *Eur Respir J* 35: 522-531.

Baines, K.J., Simpson, J.L., Wood, L.G., Scott, R.J., Fibbens, N.L., Powell, H. *et al.* (2014) Sputum Gene Expression Signature of 6 Biomarkers Discriminates Asthma Inflammatory Phenotypes. *J Allergy Clin Immunol* 133: 997-1007.

- 1  
2  
3 Baines, K.J., Simpson, J.L., Wood, L.G., Scott, R.J., and Gibson, P.G. (2011) Systemic  
4 Upregulation of Neutrophil Alpha--Defensins and Serine Proteases in Neutrophilic Asthma.  
5 *Thorax* 66: 942-947.  
6  
7  
8 Balloy, V., Deveaux, A., Lebeaux, D., Tabary, O., Le Rouzic, P., Ghigo, J.M. *et al.* (2014)  
9 Azithromycin Analogue Csy0073 Attenuates Lung Inflammation Induced by Lps Challenge. *Br*  
10 *J Pharmacol* 171: 1783-1794.  
11  
12 Barnes, P.J. (2009) Role of Hdac2 in the Pathophysiology of Copd. *Annu Rev Physiol* 71: 451-  
13 464.  
14  
15  
16 Bateman, E., D., Izquierdo, J., L., Harnest, U., Hofbauer, P., Magyar, P., Schmid-Wirlitsch, C.  
17 *et al.* (2006) Efficacy and Safety of Roflumilast in the Treatment of Asthma. *Ann Allergy*  
18 *Asthma & Immunol* 96: 679-686.  
19  
20  
21 Bauer, C.M.T., Zavitz, C.C.J., Botelho, F.M., Lambert, K.N., Brown, E.G., Mossman, K.L. *et al.*  
22 (2010) Treating Viral Exacerbations of Chronic Obstructive Pulmonary Disease: Insights from  
23 a Mouse Model of Cigarette Smoke and H1n1 Influenza Infection. *PLoS ONE* 5: e13251.  
24  
25  
26 Bel, E.H., Wenzel, S.E., Thompson, P.J., Prazma, C.M., Keene, O.N., Yancey, S.W. *et al.* (2014)  
27 Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma. *N Eng J Med* 371:  
28 1189-1197.  
29  
30  
31 Belvisi, M.G. and Hele, D.J. (2008) Peroxisome Proliferator-Activated Receptors as Novel  
32 Targets in Lung Disease. *Chest* 134: 152-157.  
33  
34  
35 Berlin, A.A. and Lukacs, N.W. (2005) Treatment of Cockroach Allergen Asthma Model with  
36 Imatinib Attenuates Airway Responses. *Am J Respir Crit Care Med* 171: 35-39.  
37  
38  
39 Berry, M., Hargadon, B., Shelley, M., Parker, D., Shaw, D., Green, R. *et al.* (2006) Inhibition of  
40 Tumor Necrosis Factor A for Refractory Asthma. *N Eng J Med* 354: 754-758.  
41  
42  
43 Berry, M., Morgan, A., Shaw, D.E., Parker, D., Green, R., Brightling, C. *et al.* (2007)  
44 Pathological Features and Inhaled Corticosteroid Response of Eosinophilic and Non-  
45 Eosinophilic Asthma. *Thorax* 62: 1043-1049.  
46  
47  
48 Bhavsar, P., Khorasani, N., Hew, M., Johnson, M., and Chung, K.F. (2010) Effect of P38 Mapk  
49 Inhibition on Corticosteroid Suppression of Cytokine Release in Severe Asthma. *Eur Respir J*  
50 35: 750-756.  
51  
52  
53 Boulet, L.-P., Lemiere, C., Archambault, F., Carrier, G., Descary, M.C., and Deschesnes, F.  
54 (2006) Smoking and Asthma: Clinical and Radiologic Features, Lung Function, and Airway  
55 Inflammation. *Chest* 129: 661-668.  
56  
57  
58 Bourke, J.E., Bai, Y., Donovan, C., Esposito, J.G., Tan, X., and Sanderson, M.J. (2014) Novel  
59 Small Airway Bronchodilator Responses to Rosiglitazone in Mouse Lung Slices. *Am J Respir*  
60 *Cell Mol Biol* 50: 748-756.

1  
2  
3  
4 Bousquet, J., Aubier, M., Sastre, J., Izquierdo, J.L., Adler, L.M., Hofbauer, P. *et al.* (2006)  
5 Comparison of Roflumilast, an Oral Anti-Inflammatory, with Beclomethasone Dipropionate  
6 in the Treatment of Persistent Asthma. *Allergy* 61: 72-78.  
7

8  
9 Braganza, G., Chaudhuri, R., Mcsharry, C., Weir, C.J., Donnelly, I., Jolly, L. *et al.* (2011) Effects  
10 of Short-Term Treatment with Atorvastatin in Smokers with Asthma - a Randomized  
11 Controlled Trial. *BMC Pulm Med* 11: 16  
12

13  
14 Brooks, C.R., Gibson, P.G., Douwes, J., Van Dalen, C.J., and Simpson, J.L. (2013) Relationship  
15 between Airway Neutrophilia and Ageing in Asthmatics and Non-Asthmatics. *Respirology* 18:  
16 857-865.  
17

18  
19 Brooks, C.R., Van Dalen, C.J., Zacharasiewicz, A., Simpson, J.L., Harper, J.L., Le Gros, G. *et al.*  
20 (2016 ) Absence of Airway Inflammation in a Large Proportion of Adolescents with Asthma.  
21 *Respirology* Dec 22. doi: 10.1111/resp.12701. [Epub ahead of print]: n/a-n/a.  
22

23  
24 Brusselle, G.G., Vanderstichele, C., Jordens, P., Deman, R., Slabbynck, H., Ringoet, V. *et al.*  
25 (2013) Azithromycin for Prevention of Exacerbations in Severe Asthma (Azisast): A  
26 Multicentre Randomised Double-Blind Placebo-Controlled Trial. *Thorax* 68: 322-329.  
27

28  
29 Busse, W.W., Holgate, S., Kerwin, E., Chon, Y., Feng, J., Lin, J. *et al.* (2013) Randomized,  
30 Double-Blind, Placebo-Controlled Study of Brodalumab, a Human Anti-L-17 Receptor  
31 Monoclonal Antibody, in Moderate to Severe Asthma. *Am J Respir Crit Care Med* 188: 1294-  
32 1302.  
33

34  
35 Cameron, E.J., Chaudhuri, R., Mair, F., Mcsharry, C., Greenlaw, N., Weir, C.J. *et al.* (2013)  
36 Randomised Controlled Trial of Azithromycin in Smokers with Asthma. *Eur Respir J* 42: 1412-  
37 1415.  
38

39  
40 Cameron, E.J., Mcsharry, C., Chaudhuri, R., Farrow, S., and Thomson, N.C. (2012) Long-Term  
41 Macrolide Treatment of Chronic Inflammatory Airway Diseases: Risks, Benefits and Future  
42 Developments. *Clin Exp Allergy* 42: 1302-1312.  
43

44  
45 Campbell, L., Maxwell, P., and Waugh, D. (2013) Rationale and Means to Target Pro-  
46 Inflammatory Interleukin-8 (Cxcl8) Signaling in Cancer. *Pharmaceuticals* 6: 929-959.  
47

48  
49 Castro, M., King, T.S., Kunselman, S.J., Hünne Meyer, A., Lahu, G., Templin, S. *et al.* (2014)  
50 Effect of Vitamin D3 on Asthma Treatment Failures in Adults with Symptomatic Asthma and  
51 Lower Vitamin D Levels: The Vida Randomized Clinical Trial. *JAMA* 311(20):2083-91: 2083-  
52 2091.  
53

54  
55 Chalmers, G.W., Macleod, K.J., Little, S.A., Thomson, L.J., Mcsharry, C.P., and Thomson, N.C.  
56 (2002) Influence of Cigarette Smoking on Inhaled Corticosteroid Treatment in Mild Asthma.  
57 *Thorax* 57: 226-230.  
58  
59  
60



- 1  
2  
3 Chapman, R.W., House, A., Richard, J., Prelusky, D., Lamca, J., Wang, P. *et al.* (2010)  
4 Pharmacology of a Potent and Selective Inhibitor of Pde4 for Inhaled Administration. *Eur J*  
5 *Pharmacol* 643: 274-281.  
6  
7  
8 Chapman, R.W., Phillips, J.E., Hipkin, R.W., Curran, A.K., Lundell, D., and Fine, J.S. (2009)  
9 Cxcr2 Antagonists for the Treatment of Pulmonary Disease. *Pharmacol Ther* 121: 55-68.  
10  
11 Chaudhuri, R., Livingston, E., McMahan, A.D., Lafferty, J., Fraser, I., Spears, M. *et al.* (2006)  
12 Effects of Smoking Cessation on Lung Function and Airway Inflammation in Smokers with  
13 Asthma. *Am J Respir Crit Care Med* 174: 127 - 133.  
14  
15  
16 Chaudhuri, R., Norris, V., Kelly, K., Zhu, C.Q., Ambery, C., Lafferty, J. *et al.* (2014) Effects of a  
17 Flap Inhibitor, Gsk2190915, in Asthmatics with High Sputum Neutrophils. *Pulm Pharmacol*  
18 *Ther* 27: 62-69.  
19  
20  
21 Chesné, J., Braza, F., Mahay, G., Brouard, S., Aronica, M., and Magnan, A. (2014) Il-17 in  
22 Severe Asthma. Where Do We Stand? *Am J Respir Crit Care Med* 190: 1094-1101.  
23  
24  
25 Choy, D.F., Hart, K.M., Borthwick, L.A., Shikotra, A., Nagarkar, D.R., Siddiqui, S. *et al.* (2015)  
26 Th2 and Th17 Inflammatory Pathways Are Reciprocally Regulated in Asthma. *Sci Transl Med*  
27 7: 301ra129-301ra129.  
28  
29  
30 Chung, K.F. (2011) P38 Mitogen-Activated Protein Kinase Pathways in Asthma and Copd.  
31 *Chest* 139: 1470-1479.  
32  
33  
34 Cohen, S. and Fleischmann, R. (2010) Kinase Inhibitors: A New Approach to Rheumatoid  
35 Arthritis Treatment. *Curr Opin Rheumatol* 22: 330-335  
36  
37  
38 Corren, J., Lemanske, R.F., Hanania, N.A., Korenblat, P.E., Parsey, M.V., Arron, J.R. *et al.*  
39 (2011) Lebrikizumab Treatment in Adults with Asthma. *N Eng J Med* 365: 1088-1098.  
40  
41  
42 Cowan, D.C., Cowan, J.O., Palmay, R., Williamson, A., and Taylor, D.R. (2010) Effects of  
43 Steroid Therapy on Inflammatory Cell Subtypes in Asthma. *Thorax* 65: 384-390.  
44  
45  
46 Cox, G. (1995) Glucocorticoid Treatment Inhibits Apoptosis in Human Neutrophils.  
47 Separation of Survival and Activation Outcomes. *J Immunol* 154: 4719-4725.  
48  
49  
50 Culic, O., Erakovic, V., and Parnham, M.J. (2001) Anti-Inflammatory Effects of Macrolide  
51 Antibiotics. *Eur J Pharmacol* 429: 209-229.  
52  
53  
54 D'silva, L., Cook, R.J., Allen, C.J., Hargreave, F.E., and Parameswaran, K. (2007) Changing  
55 Pattern of Sputum Cell Counts During Successive Exacerbations of Airway Disease. *Respir*  
56 *Med* 101: 2217-2220.  
57  
58  
59 Dave, S., Brian, R.L., Malcom, B., Marie, A.N., Sara, C., Fabrizia, M. *et al.* (2014) The Effect of  
60 the Inhaled Pde4 Inhibitor Chf6001 on Allergen-Induced Inflammation in Asthmatic Subjects.  
*Am J Resp Crit Care Med*: A4175-A4175.

1  
2  
3  
4 Davis, B.B., Zeki, A.A., Bratt, J.M., Wang, L., Filosto, S., Walby, W.F. *et al.* (2013) Simvastatin  
5 Inhibits Smoke-Induced Airway Epithelial Injury: Implications for Copd Therapy. *Eur Respir J*  
6 42: 350-361.  
7

8  
9 De Groot, J.C., Van Roon, E.N.H., Storm, H., Veeger, N.J.G.M., Zwinderman, A.H., Hiemstra,  
10 P.S. *et al.* (2015) Vitamin D Reduces Eosinophilic Airway Inflammation in Nonatopic Asthma.  
11 *J Allergy Clin Immunol* 135: 670-675.e673.  
12

13  
14 De Savi, C., Cox, R.J., Warner, D.J., Cook, A.R., Dickinson, M.R., Mcdonough, A. *et al.* (2014)  
15 Efficacious Inhaled Pde4 Inhibitors with Low Emetic Potential and Long Duration of Action  
16 for the Treatment of Copd. *J Med Chem* 57: 4661-4676.  
17

18  
19 De Soyza, A., Pavord, I., Elborn, J.S., Smith, D., Wray, H., Puu, M. *et al.* (2015) A Randomised,  
20 Placebo-Controlled Study of the Cxcr2 Antagonist Azd5069 in Bronchiectasis. *Eur Respir J* 46:  
21 1021-1032.  
22

23  
24 Dejager, L., Dendoncker, K., Eggermont, M., Souffriau, J., Van Hauwermeiren, F., Willart, M.  
25 *et al.* (2015 ) Neutralizing Tnf[Alpha] Restores Glucocorticoid Sensitivity in a Mouse Model  
26 of Neutrophilic Airway Inflammation. *Mucosal Immunol* 8: 1212-1225.  
27

28  
29 Denlinger, L.C., King, T.S., Cardet, J.C., Craig, T., Holguin, F., Jackson, D.J. *et al.* (2015 )  
30 Vitamin D Supplementation and the Risk of Colds in Patients with Asthma. *Am J Resp Crit*  
31 *Care Med* Nov 5. [Epub ahead of print]:  
32

33  
34 Desai, D., Newby, C., Symon, F.A., Haldar, P., Shah, S., Gupta, S. *et al.* (2013) Elevated  
35 Sputum Interleukin-5 and Submucosal Eosinophilia in Obese Individuals with Severe Asthma.  
36 *Am J Respir Crit Care Med* 188: 657-663.  
37

38  
39 Dixon, A., Subramanian, M., Desarno, M., Black, K., Lane, L., and Holguin, F. (2015) A Pilot  
40 Randomized Controlled Trial of Pioglitazone for the Treatment of Poorly Controlled Asthma  
41 in Obesity. *Respir Res* 16: 143.  
42

43  
44 Donovan, C., Bailey, S.R., Tran, J., Haitisma, G., Ibrahim, Z.A., Foster, S.R. *et al.* (2015 )  
45 Rosiglitazone Elicits in Vitro Relaxation in Airways and Precision Cut Lung Slices from a  
46 Mouse Model of Chronic Allergic Airways Disease. *Am J Physiol Lung Cell Mol Physiol* 309:  
47 L1219-1228.  
48

49  
50 Dougherty, R.H., Sidhu, S.S., Raman, K., Solon, M., Solberg, O.D., Caughey, G.H. *et al.* (2010)  
51 Accumulation of Intraepithelial Mast Cells with a Unique Protease Phenotype in Th2-High  
52 Asthma. *J Allergy Clin Immunol* 125: 1046-1053.e1048.  
53

54  
55 Doukas, J., Eide, L., Stebbins, K., Racanelli-Layton, A., Dellamary, L., Martin, M. *et al.* (2009)  
56 Aerosolized Phosphoinositide 3-Kinase {Gamma}/{Delta} Inhibitor Tg100-115 [3-[2,4-  
57 Diamino-6-(3-Hydroxyphenyl)Pteridin-7-Yl]Phenol] as a Therapeutic Candidate for Asthma  
58 and Chronic Obstructive Pulmonary Disease. *J Pharmacol Exp Ther* 328: 758-765.  
59  
60

1  
2  
3 Essilfie, A.-T., Horvat, J.C., Kim, R.Y., Mayall, J.R., Pinkerton, J.W., Beckett, E.L. *et al.* (2015)  
4 Macrolide Therapy Suppresses Key Features of Experimental Steroid-Sensitive and Steroid-  
5 Insensitive Asthma. *Thorax* 70: 458-467.  
6

7  
8 Evans, J.F., Ferguson, A.D., Mosley, R.T., and Hutchinson, J.H. (2008) What's All the Flap  
9 About?: 5-Lipoxygenase-Activating Protein Inhibitors for Inflammatory Diseases. *Trends*  
10 *Pharmacol Sc* 29: 72-78.  
11

12  
13 Fahy, J., Kim, K., Liu, J., and Boushey, H. (1995 ) Prominent Neutrophilic Inflammation in  
14 Sputum from Subjects with Asthma Exacerbation. *J Allergy Clin Immunol* 95: 843-852.  
15

16  
17 Franciosi, L.G., Diamant, Z., Banner, K.H., Zuiker, R., Morelli, N., Kamerling, I.M.C. *et al.*  
18 (2013) Efficacy and Safety of Rpl554, a Dual Pde3 and Pde4 Inhibitor, in Healthy Volunteers  
19 and in Patients with Asthma or Chronic Obstructive Pulmonary Disease: Findings from Four  
20 Clinical Trials. *Lancet Respir Med* 1: 714-727.  
21

22  
23 Fu, J.-J., Baines, K.J., Wood, L.G., and Gibson, P.G. (2013) Systemic Inflammation Is  
24 Associated with Differential Gene Expression and Airway Neutrophilia in Asthma. *OMICs* 17:  
25 187-199.  
26

27  
28 Fujitani, Y. and Trifilieff, A. (2003) In Vivo and in Vitro Effects of Sar 943, a Rapamycin  
29 Analogue, on Airway Inflammation and Remodeling. *Am J Respir Crit Care Med* 167: 193-  
30 198.  
31

32  
33 Furukawa, T., Sakagami, T., Koya, T., Hasegawa, T., Kawakami, H., Kimura, Y. *et al.* (2015)  
34 Characteristics of Eosinophilic and Non-Eosinophilic Asthma During Treatment with Inhaled  
35 Corticosteroids. *J Asthma* 52: 417-422.  
36

37  
38 Futosi, K., Fodor, S., and Mócsai, A. (2013) Neutrophil Cell Surface Receptors and Their  
39 Intracellular Signal Transduction Pathways. *Internat Immunopharmacol* 17: 1185-1197.  
40

41  
42 Gaga, M., Brand, P.L.P., and Thomson, N.C. (2015) The Quest for the Grail: Multidimensional  
43 Efforts for Understanding and Targeting Severe Asthma. *Eur Respir J* 46: 1227-1231.  
44

45  
46 Gao, P., Gibson, P.G., Baines, K.J., Yang, I.A., Upham, J.W., Reynolds, P.N. *et al.* (2015) Anti-  
47 Inflammatory Deficiencies in Neutrophilic Asthma: Reduced Galectin-3 and Il-1ra/Il-1 $\beta$ .  
48 *Respir Res* 16: 5.  
49

50  
51 Gauvreau, G., Boulet, L.-P., Schmid-Wirlitsch, C., Cote, J., Duong, M., Killian, K. *et al.* (2011)  
52 Roflumilast Attenuates Allergen-Induced Inflammation in Mild Asthmatic Subjects. *Respir*  
53 *Res* 12: 140.  
54

55  
56 Gibson, P.G., Simpson, J.L., and Saltos, N. (2001) Heterogeneity of Airway Inflammation in  
57 Persistent Asthma : Evidence of Neutrophilic Inflammation and Increased Sputum  
58 Interleukin-8. *Chest* 119: 1329-1336.  
59  
60

- 1  
2  
3 Gielen, V., Johnston, S.L., and Edwards, M.R. (2010) Azithromycin Induces Anti-Viral  
4 Responses in Bronchial Epithelial Cells. *Eur Respir J* 36: 646-654.  
5  
6  
7 Godon, P., Boulet, L.P., Malo, J.L., Cartier, A., and Lemièrè, C. (2002) Assessment and  
8 Evaluation of Symptomatic Steroid-Naive Asthmatics without Sputum Eosinophilia and Their  
9 Response to Inhaled Corticosteroids. *Eur Respir J* 20: 1364-1369.  
10  
11 Green, B.J., Wiriyaichaiorn, S., Grainge, C., Rogers, G.B., Kehagia, V., Lau, L. *et al.* (2014)  
12 Potentially Pathogenic Airway Bacteria and Neutrophilic Inflammation in Treatment  
13 Resistant Severe Asthma. *PLoS ONE* 9: e100645.  
14  
15  
16 Green, R.H., Brightling, C.E., Mckenna, S., Hargadon, B., Parker, D., Bradding, P. *et al.* (2002)  
17 Asthma Exacerbations and Sputum Eosinophil Counts: A Randomised Controlled Trial.  
18 *Lancet* 360: 1715-1721.  
19  
20  
21 Green, R.H., Brightling, C.E., Woltmann, G., Parker, D., Wardlaw, A.J., and Pavord, I.D. (2002)  
22 Analysis of Induced Sputum in Adults with Asthma: Identification of Subgroup with Isolated  
23 Sputum Neutrophilia and Poor Response to Inhaled Corticosteroids. *Thorax* 57: 875-879.  
24  
25  
26 Greenwood, J., Steinman, L., and Zamvil, S.S. (2006) Statin Therapy and Autoimmune  
27 Disease: From Protein Prenylation to Immunomodulation. *Nat Rev Immunol* 6: 358-370.  
28  
29  
30 Guntur, V.P. and Reiner, C.R. (2012) The Potential Use of Tyrosine Kinase Inhibitors in  
31 Severe Asthma. *Curr Opin Allergy Clin Immunol* 12: 68-75.  
32  
33  
34 Haldar, P. and Pavord, I.D. (2007) Noneosinophilic Asthma: A Distinct Clinical and Pathologic  
35 Phenotype. *J Allergy Clin Immunol* 119: 1043-1052.  
36  
37  
38 Haldar, P., Pavord, I.D., Shaw, D.E., Berry, M.A., Thomas, M., Brightling, C.E. *et al.* (2008)  
39 Cluster Analysis and Clinical Asthma Phenotypes. *Am J Resp Crit Car Med* 178: 218-224.  
40  
41  
42 Hammaker, D. and Firestein, G. (2010) "Go Upstream, Young Man": Lessons Learned from  
43 the P38 Saga. *Ann Rheum Dis* 69, Suppl 1:  
44  
45  
46 Hancox, R.J., Cowan, D.C., Aldridge, R.E., Cowan, J.O., Palmay, R., Williamson, A. *et al.* (2012)  
47 Asthma Phenotypes: Consistency of Classification Using Induced Sputum. *Respirology* 17:  
48 461-466.  
49  
50  
51 Hao, M., Lin, J., Shu, J., Zhang, X., Luo, Q., Pan, L. *et al.* (2015) Clarithromycin Might  
52 Attenuate the Airway Inflammation of Smoke-Exposed Asthmatic Mice Via Affecting Hdac2.  
53 *J Thorac Dis* 7: 1189-1197.  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

1  
2  
3 Hastie, A.T., Moore, W.C., Meyers, D.A., Vestal, P.L., Li, H., Peters, S.P. *et al.* (2010) Analyses  
4 of Asthma Severity Phenotypes and Inflammatory Proteins in Subjects Stratified by Sputum  
5 Granulocytes. *J Allergy Clin Immunol* 125: 1028-1036.  
6

7  
8 Heaney, L.G., Djukanovic, R., Woodcock, A., Walker, S., Matthews, J.G., Pavord, I.D. *et al.*  
9 (2015 ) Research in Progress: Medical Research Council United Kingdom Refractory Asthma  
10 Stratification Programme (Rasp-Uk). *Thorax* doi: 10.1136/thoraxjnl-2015-207326. [Epub  
11 ahead of print]:  
12

13  
14 Hernandez, M.L., Mills, K., Almond, M., Todoric, K., Aleman, M.M., Zhang, H. *et al.* (2015) Il-1  
15 Receptor Antagonist Reduces Endotoxin-Induced Airway Inflammation in Healthy  
16 Volunteers. *J Allergy Clin Immunol* 135: 379-385.  
17

18  
19 Holgate, S.T., Noonan, M., Chanez, P., Busse, W., Dupont, L., Pavord, I. *et al.* (2011) Efficacy  
20 and Safety of Etanercept in Moderate-to-Severe Asthma: A Randomised, Controlled Trial.  
21 *Eur Respir J* 37: 1352-1359.  
22

23  
24 Holz, O., Khalilieh, S., Ludwig-Sengpiel, A., Watz, H., Stryszak, P., Soni, P. *et al.* (2010)  
25 Sch527123, a Novel Cxcr2 Antagonist, Inhibits Ozone-Induced Neutrophilia in Healthy  
26 Subjects. *Eur Respir J* 35: 564-570.  
27

28  
29 Hothersall, E., Mcsharry, C., and Thomson, N.C. (2006) Potential Therapeutic Role for Statins  
30 in Respiratory Disease. *Thorax* 61: 729-734.  
31

32  
33 Howarth, P.H., Babu, K.S., Arshad, H.S., Lau, L., Buckley, M., Mcconnell, W. *et al.* (2005)  
34 Tumour Necrosis Factor (Tnf{Alpha}) as a Novel Therapeutic Target in Symptomatic  
35 Corticosteroid Dependent Asthma. *Thorax* 60: 1012-1018.  
36

37  
38 Humbert, M., De Blay, F., Garcia, G., Prud'homme, A., Leroyer, C., Magnan, A. *et al.* (2009)  
39 Masitinib, a C-Kit/Pdgf Receptor Tyrosine Kinase Inhibitor, Improves Disease Control in  
40 Severe Corticosteroid-Dependent Asthmatics. *Allergy* 64: 1194-1201.  
41

42  
43 Ito, K., Caramori, G., and Adcock, I.M. (2007) Therapeutic Potential of Phosphatidylinositol  
44 3-Kinase Inhibitors in Inflammatory Respiratory Disease. *J Pharmacol Exp Ther* 321: 1-8.  
45

46  
47 Jatakanon, A., Lim, S., and Pj, B. (2000) Changes in Sputum Eosinophils Predict Loss of  
48 Asthma Control. *Am J Respir Crit Care Med* 161: 64-72.  
49

50  
51 Jayaram, L., Pizzichini, M.M., Cook, R.J., Boulet, L.-P., Lemiere, C., Pizzichini, E. *et al.* (2006)  
52 Determining Asthma Treatment by Monitoring Sputum Cell Counts: Effect on Exacerbations.  
53 *Eur Respir J* 27: 483-494.  
54

55  
56 Katz, L.E., Gleich, G.J., Hartley, B.F., Yancey, S.W., and Ortega, H.G. (2014) Blood Eosinophil  
57 Count Is a Useful Biomarker to Identify Patients with Severe Eosinophilic Asthma. *Annals Am*  
58 *Thor Soc* 11: 531-536.  
59  
60

1  
2  
3 Kent, S.E., Boyce, M., Diamant, Z., Singh, D., O'connor, B.J., Saggu, P.S. *et al.* (2013) The 5-  
4 Lipoxygenase-Activating Protein Inhibitor, Gsk2190915, Attenuates the Early and Late  
5 Responses to Inhaled Allergen in Mild Asthma. *Clin Exp Allergy* 43: 177-186.  
6

7  
8 Khorasani, N., Baker, J., Johnson, M., Chung, K.F., and Bhavsar, P.K. (2015) Reversal of  
9 Corticosteroid Insensitivity by P38 Mapk Inhibition in Peripheral Blood Mononuclear Cells  
10 from Copd. *Int J Chron Obstruct Pulmon Dis* 10: 283-291.  
11

12 Kim, R.Y., Pinkerton, J.W., Gibson, P.G., Cooper, M.A., Horvat, J.C., and Hansbro, P.M. (2015)  
13 Inflammasomes in Copd and Neutrophilic Asthma. *Thorax* 70: 1199-1201.  
14

15  
16 Kim, S.W., Kim, J.H., Park, C.K., Kim, T.J., Lee, S.Y., Kim, Y.K. *et al.* (2015 ) Effect of Roflumilast  
17 on Airway Remodeling in a Murine Model of Chronic Asthma. *Clin Exp Allergy* doi:  
18 10.1111/cea.12670. [Epub ahead of print]: n/a-n/a.  
19

20  
21 Kirsten, A.M., Förster, K., Radeckzy, E., Linnhoff, A., Balint, B., Watz, H. *et al.* (2015) The  
22 Safety and Tolerability of Oral Azd5069, a Selective Cxcr2 Antagonist, in Patients with  
23 Moderate-to-Severe Copd. *Pulm Pharm Therap* 31: 36-41.  
24

25  
26 Kobayashi, Y., Wada, H., Rossios, C., Takagi, D., Charron, C., Barnes, P.J. *et al.* (2013) A Novel  
27 Macrolide/Fluoroketolide, Solithromycin (Cem-101), Reverses Corticosteroid Insensitivity  
28 Via Phosphoinositide 3-Kinase Pathway Inhibition. *Br J Pharmacol* 169: 1024-1034.  
29

30  
31 Kobayashi, Y., Wada, H., Rossios, C., Takagi, D., Higaki, M., Mikura, S.I. *et al.* (2013) A Novel  
32 Macrolide Solithromycin Exerts Superior Anti-Inflammatory Effect Via Nf-Kb Inhibition. *J*  
33 *Pharmacol Exp Ther* 345: 76-84.  
34

35  
36 Kupczyk, M., Dahlén, B., Sterk, P.J., Nizankowska-Mogilnicka, E., Papi, A., Bel, E.H. *et al.*  
37 (2014) Stability of Phenotypes Defined by Physiological Variables and Biomarkers in Adults  
38 with Asthma. *Allergy* 69: 1198-1204.  
39

40  
41 Kupczyk, M., Ten Brinke, A., Sterk, P.J., Bel, E.H., Papi, A., Chanez, P. *et al.* (2014) Frequent  
42 Exacerbators – a Distinct Phenotype of Severe Asthma. *Clin Exp Allergy* 44: 212-221.  
43

44  
45 Lakshmi, S.P., Reddy, A.T., Zhang, Y., Scirba, F.C., Mallampalli, R.K., Duncan, S.R. *et al.*  
46 (2014) Down-Regulated Peroxisome Proliferator-Activated Receptor  $\gamma$  (Ppar $\gamma$ ) in Lung  
47 Epithelial Cells Promotes a Ppar $\gamma$  Agonist-Reversible Proinflammatory Phenotype in Chronic  
48 Obstructive Pulmonary Disease (COPD). *J Biol Chem* 289: 6383-6393.  
49

50  
51 Lamblin, C., Gosset, P., Tillie-Leblond, I., Saulnier, F., Marquette, C., Wallaert, B. *et al.* (1998)  
52 Bronchial Neutrophilia in Patients with Noninfectious Status Asthmaticus. *Am J Respir Crit*  
53 *Care Med* 157: 394-402.  
54

55  
56 Lazaar, A.L., Sweeney, L.E., Macdonald, A.J., Alexis, N.E., Chen, C., and Tal-Singer, R. (2011)  
57 Sb-656933, a Novel Cxcr2 Selective Antagonist, Inhibits Ex Vivo Neutrophil Activation and  
58 Ozone-Induced Airway Inflammation in Humans. *Br J Clin Pharmacol* 72: 282-293.  
59  
60

1  
2  
3 Lea, S., Plumb, J., Metcalfe, H., Spicer, D., Woodman, P., Fox, J.C. *et al.* (2014) The Effect of  
4 Peroxisome Proliferator-Activated Receptor- $\gamma$  Ligands on in Vitro and in Vivo Models of  
5 Copd. *Eur Respir J* 43: 409-420.  
6

7  
8 Leaker, B., Barnes, P., and O'connor, B. (2013) Inhibition of Lps-Induced Airway Neutrophilic  
9 Inflammation in Healthy Volunteers with an Oral Cxcr2 Antagonist. *Respir Res* 14: 137.  
10

11 Leaker, B.R., Barnes, P.J., O'connor, B.J., Ali, F.Y., Tam, P., Neville, J. *et al.* (2014) The Effects  
12 of the Novel Ship1 Activator Aqx-1125 on Allergen-Induced Responses in Mild-to-Moderate  
13 Asthma. *Clin Exp Allergy* 44: 1146-1153.  
14

15  
16 Lee, J.-H., Lee, D.-S., Kim, E.-K., Choe, K.-H., Oh, Y.-M., Shim, T.-S. *et al.* (2005) Simvastatin  
17 Inhibits Cigarette Smoking-Induced Emphysema and Pulmonary Hypertension in Rat Lungs.  
18 *Am J Respir Crit Care Med* 172: 987-993.  
19

20  
21 Lee, K.S., Jeong, J.S., Kim, S.R., Cho, S.H., Kolliputi, N., Ko, Y.H. *et al.* (2016) Phosphoinositide  
22 3-Kinase- $\Delta$  Regulates Fungus-Induced Allergic Lung Inflammation through Endoplasmic  
23 Reticulum Stress. *Thorax* 71: 52-63.  
24

25  
26 Lemièrè, C., Boulet, L.-P., Chaboillez, S., Forget, A., Chiry, S., Villeneuve, H. *et al.* (2013)  
27 Work-Exacerbated Asthma and Occupational Asthma: Do they Really Differ? *J Allergy Clin*  
28 *Immunol* 131: 704-710.e703.  
29

30  
31 Lemiere, C., Chaboillez, S., Bohadana, A., Blais, L., and Maghni, K. (2014) Noneosinophilic  
32 Responders with Occupational Asthma: A phenotype Associated with a Poor Asthma  
33 Prognosis. *J Allergy Clin Immunol* 133: 883-885.e883.  
34

35  
36 Lemièrè, C., Tremblay, C., Fitzgerald, M., Aaron, S.D., Leigh, R., Boulet, L.-P. *et al.* (2011)  
37 Effects of a Short Course of Inhaled Corticosteroids in Noneosinophilic Asthmatic Subjects.  
38 *Can Respir J* 18: 278-282.  
39

40  
41 Leuppi, J., Salome, C., Jenkins, C., Anderson, S., Xuan, W., Marks, G. *et al.* (2001) Predictive  
42 Markers of Asthma Exacerbation During Stepwise Dose Reduction of Inhaled  
43 Corticosteroids. *Am J Respir Crit Care Med* 163: 406-412.  
44

45  
46 Lipworth, B.J. (2005) Phosphodiesterase-4 Inhibitors for Asthma and Chronic Obstructive  
47 Pulmonary Disease. *Lancet* 365: 167-175.  
48

49  
50 Little, S., Chalmers, G., Macleod, K., Mcsharry, C., and Thomson, N. (2000) Non-Invasive  
51 Markers of Airway Inflammation as Predictors of Oral Steroid Responsiveness in Asthma.  
52 *Thorax* 53: 232-234.  
53

54  
55 Little, S.A., Macleod, K.J., Chalmers, G.W., Love, J.G., Mcsharry, C., and Thomson, N.C. (2002)  
56 Association of Forced Expiratory Volume with Disease Duration and Sputum Neutrophils in  
57 Chronic Asthma. *Am J Med* 112: 446-452.  
58  
59  
60

1  
2  
3 Maghni, K., Lemiere, C., Ghezzi, H., Yuquan, W., and Malo, J.-L. (2004) Airway Inflammation  
4 after Cessation of Exposure to Agents Causing Occupational Asthma. *Am J Respir Crit Care*  
5 *Med* 169: 367-372.  
6

7  
8 Maneechotesuwan, K., Ekjitrakul, W., Kasetsinsombat, K., Wongkajornsilp, A., and Barnes,  
9 P.J. (2010) Statins Enhance the Anti-Inflammatory Effects of Inhaled Corticosteroids in  
10 Asthmatic Patients through Increased Induction of Indoleamine 2, 3-Dioxygenase. *J Allergy*  
11 *Clin Immunol* 126: 754-762.  
12

13  
14 Maneechotesuwan, K., Essilfie-Quaye, S., Kharitonov, S.A., Adcock, I.M., and Barnes, P.J.  
15 (2007) Loss of Control of Asthma Following Inhaled Corticosteroid Withdrawal Is Associated  
16 with Increased Sputum Interleukin-8 and Neutrophils. *Chest* 132: 98-105.  
17

18  
19 Maneechotesuwan, K., Kasetsinsombat, K., Wongkajornsilp, A., and Barnes, P.J. (2013)  
20 Decreased Indoleamine 2,3-Dioxygenase Activity and Il-10/Il-17a Ratio in Patients with  
21 Copd. *Thorax* 68: 330-337.  
22

23  
24 Manni, M.L., Trudeau, J.B., Scheller, E.V., Mandalapu, S., Elloso, M.M., Kolls, J.K. *et al.* (2014)  
25 The Complex Relationship between Inflammation and Lung Function in Severe Asthma.  
26 *Mucosal Immunol* 7: 1186-1198.  
27

28  
29 Marks-Konczalik, J., Costa, M., Robertson, J., Mckie, E., Yang, S., and Pascoe, S. (2015) A  
30 Post-Hoc Subgroup Analysis of Data from a Six Month Clinical Trial Comparing the Efficacy  
31 and Safety of Losmapimod in Moderate-Severe Copd Patients with  $\leq 2\%$  and  $> 2\%$  Blood  
32 Eosinophils. *Respir Med* 109: 860-869.  
33

34  
35 Martineau, A.R., Hanifa, Y., Witt, K.D., Barnes, N.C., Hooper, R.L., Patel, M. *et al.* (2015)  
36 Double-Blind Randomised Controlled Trial of Vitamin D3 Supplementation for the  
37 Prevention of Acute Respiratory Infection in Older Adults and Their Carers (Vidiflu). *Thorax*  
38 70: 953-960.  
39

40  
41 Marwick, J., Caramori, G., Stevenson, C., Casolari, P., Jazrawi, E., Barnes, P. *et al.* (2009)  
42 Inhibition of Pi3kdelta Restores Glucocorticoid Function in Smoking-Induced Airway  
43 Inflammation in Mice. *Am J Respir Crit Care Med* 179: 542-548.  
44

45  
46 Marwick, J.A., Caramori, G., Casolari, P., Mazzoni, F., Kirkham, P.A., Adcock, I.M. *et al.* (2010)  
47 A Role for Phosphoinositol 3-Kinase Delta in the Impairment of Glucocorticoid  
48 Responsiveness in Patients with Chronic Obstructive Pulmonary Disease. *J Allergy Clin*  
49 *Immunol* 125: 1146-1153.  
50

51  
52 Mcgrath, K.W., Icitovic, N., Boushey, H.A., Lazarus, S.C., Sutherland, E.R., Chinchilli, V.M. *et*  
53 *al.* (2012) A Large Subgroup of Mild-to-Moderate Asthma Is Persistently Noneosinophilic.  
54 *Am J Respir Crit Care Med* 185: 612-619.  
55

56  
57 Mckay, A., Leung, B.P., Mcinnes, I.B., Thomson, N.C., and Liew, F.Y. (2004) A Novel Anti-  
58 Inflammatory Role of Simvastatin in a Murine Model of Allergic Asthma. *J Immunol* 172:  
59 2903-2908.  
60



1  
2  
3  
4 Mercado, N., Hakim, A., Kobayashi, Y., Meah, S., Usmani, O.S., Chung, K.F. *et al.* (2012)  
5 Restoration of Corticosteroid Sensitivity by P38 Mitogen Activated Protein Kinase Inhibition  
6 in Peripheral Blood Mononuclear Cells from Severe Asthma. *PLoS ONE* 7: e41582.  
7

8  
9 Miossec, P. and Kolls, J.K. (2012) Targeting Il-17 and Th17 Cells in Chronic Inflammation. *Nat*  
10 *Rev Drug Discov* 11: 763-776.  
11

12 Moore, W.C., Hastie, A.T., Li, X., Li, H., Busse, W.W., Jarjour, N.N. *et al.* (2014) Sputum  
13 Neutrophil Counts Are Associated with More Severe Asthma Phenotypes Using Cluster  
14 Analysis. *J Allergy Clin Immunol* 133: 1557-1563.  
15

16  
17 Moretto, N., Caruso, P., Bosco, R., Marchini, G., Pastore, F., Armani, E. *et al.* (2015) Chf6001,  
18 a Novel Highly Potent and Selective Phosphodiesterase 4 Inhibitor with Robust Anti-  
19 Inflammatory Activity and Suitable for Topical Pulmonary Administration. *J Pharmacol Exp*  
20 *Ther* 352: 559-567.  
21

22  
23 Morissette, M.C., Shen, P., Thayaparan, D., and Stämpfli, M.R. (2015) Impacts of Peroxisome  
24 Proliferator-Activated Receptor- $\gamma$  Activation on Cigarette Smoke-Induced Exacerbated  
25 Response to Bacteria. *Eur Respir J* 45: 191-200.  
26

27  
28 Nair, P., Aziz-Ur-Rehman, A., and Radford, K. (2015) Therapeutic Implications of  
29 'Neutrophilic Asthma'. *Curr Opin Pulm Med* 21: 33-38  
30

31 Nair, P., Gaga, M., Zervas, E., Alagha, K., Hargreave, F.E., O'byrne, P.M. *et al.* (2012) Safety  
32 and Efficacy of a Cxcr2 Antagonist in Patients with Severe Asthma and Sputum Neutrophils:  
33 A Randomized, Placebo-Controlled Clinical Trial. *Clin Exp Allergy* 42: 1097-1103.  
34

35  
36 Nanzer, A.M., Chambers, E.S., Ryanna, K., Richards, D.F., Black, C., Timms, P.M. *et al.* (2013)  
37 Enhanced Production of Il-17a in Patients with Severe Asthma Is Inhibited by  $1\alpha,25-$   
38 Dihydroxyvitamin D3 in a Glucocorticoid-Independent Fashion. *J Allergy Clin Immunol* 132:  
39 297-304.  
40

41  
42 Newby, C., Agbetile, J., Hargadon, B., Monteiro, W., Green, R., Pavord, I. *et al.* (2014) Lung  
43 Function Decline and Variable Airway Inflammatory Pattern: Longitudinal Analysis of Severe  
44 Asthma. *J Allergy Clin Immunol* 134: 287-294.  
45

46  
47 Newcomb, D.C. and Peebles Jr, R.S. (2013) Th17-Mediated Inflammation in Asthma. *Curr*  
48 *Opinion Immunol* 25: 755-760.  
49

50 Nials, A.T., Tralau-Stewart, C.J., Gascoigne, M.H., Ball, D.I., Ranshaw, L.E., and Knowles, R.G.  
51 (2011) In Vivo Characterization of Gsk256066, a High-Affinity Inhaled Phosphodiesterase 4  
52 Inhibitor. *J Pharmacol Exp Ther* 337: 137-144.  
53

54  
55 O'byrne, P., Metev, H., Puu, M., Richter, K., and Keen, C. (2015) Efficacy and Safety of a  
56 Cxcr2 Antagonist, Azd5069, in Severe, Uncontrolled Persistent Asthma. *Am J Resp Crit Care*  
57 *Med* 256: A2503-A2503.  
58  
59  
60

1  
2  
3  
4 Ortega, H.G., Liu, M.C., Pavord, I.D., Brusselle, G.G., Fitzgerald, J.M., Chetta, A. *et al.* (2014)  
5 Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma. *N Eng J Med* 371:  
6 1198-1207.  
7

8  
9 Page, C.P. and Spina, D. (2012) Selective Pde Inhibitors as Novel Treatments for Respiratory  
10 Diseases. *Curr Opin Pharmacol* 12: 275-286.  
11

12 Pavord, I., Brightling, C., Woltmann, G., and Wardlaw, A. (1999) Non-Eosinophilic  
13 Corticosteroid Unresponsive Asthma. *Lancet* 353: 2213-2214.  
14

15  
16 Pavord, I.D., Korn, S., Howarth, P., Bleecker, E.R., Buhl, R., Keene, O.N. *et al.* (2012)  
17 Mepolizumab for Severe Eosinophilic Asthma (Dream): A Multicentre, Double-Blind,  
18 Placebo-Controlled Trial. *Lancet* 380: 651-659.  
19

20  
21 Peters, M.C., Mekonnen, Z.K., Yuan, S., Bhakta, N.R., Woodruff, P.G., and Fahy, J.V. (2014)  
22 Measures of Gene Expression in Sputum Cells Can Identify Th2-High and Th2-Low Subtypes  
23 of Asthma. *J Allergy Clin Immunol* 133: 388-394.  
24

25  
26 Raundhal, M., Morse, C., Khare, A., Oriss, T.B., Milosevic, J., Trudeau, J. *et al.* (2015 ) High  
27 Ifn- $\gamma$  and Low Slpi Mark Severe Asthma in Mice and Humans. *J Clin Invest* 125: 3037-3050.  
28

29 Reiter, J., Demirel, N., Mendy, A., Gasana, J., Vieira, E.R., Colin, A.A. *et al.* (2013) Macrolides  
30 for the Long-Term Management of Asthma – a Meta-Analysis of Randomized Clinical Trials.  
31 *Allergy* 68: 1040-1049.  
32

33  
34 Rennard, S.I., Dale, D.C., Donohue, J.F., Kanniss, F., Magnussen, H., Sutherland, E.R. *et al.*  
35 (2015) Cxcr2 Antagonist Mk-7123—a Phase 2 Proof-of-Concept Trial for Chronic Obstructive  
36 Pulmonary Disease. *Am J Resp Crit Care Med* 191: 1001-1011.  
37

38  
39 Rhee, C.K., Kim, J.W., Park, C.K., Kim, J.S., Kang, J.Y., Kim, S.J. *et al.* (2011) Effect of Imatinib  
40 on Airway Smooth Muscle Thickening in a Murine Model of Chronic Asthma. *Int Arch Allergy*  
41 *Immunol* 155: 243-251.  
42

43  
44 Richards, D.B., Bareille, P., Lindo, E.L., Quinn, D., and Farrow, S.N. (2010) Treatment with a  
45 Peroxisomal Proliferator Activated Receptor Gamma Agonist Has a Modest Effect in the  
46 Allergen Challenge Model in Asthma: A Randomised Controlled Trial. *Respir Med* 104: 668-  
47 674.  
48

49 Saffar, A., Ashdown, H., and Gounni, A. (2011) The Molecular Mechanisms of  
50 Glucocorticoids-Mediated Neutrophil Survival. *Curr Drug Targets* 12: 556-562.  
51

52  
53 Samson, K., Minoguchi, K., Tanaka, A., Oda, N., Yokoe, T., Yamamoto, Y. *et al.* (2006)  
54 Inhibitory Effects of Fluvastatin on Cytokine and Chemokine Production by Peripheral Blood  
55 Mononuclear Cells in Patients with Allergic Asthma. *Clin Exp Allergy* 36: 475-482.  
56  
57  
58  
59  
60

Schleich, F., Manise, M., Sele, J., Henket, M., Seidel, L., and Louis, R. (2013) Distribution of Sputum Cellular Phenotype in a Large Asthma Cohort: Predicting Factors for Eosinophilic Vs Neutrophilic Inflammation. *BMC Pulm Med* 13: 11.

Schleich, F.N., Chevremont, A., Paulus, V., Henket, M., Manise, M., Seidel, L. *et al.* (2014) Importance of Concomitant Local and Systemic Eosinophilia in Uncontrolled Asthma. *Eur Respir J* 44: 97-108.

Schögler, A., Kopf, B.S., Edwards, M.R., Johnston, S.L., Casaulta, C., Kieninger, E. *et al.* (2015) Novel Antiviral Properties of Azithromycin in Cystic Fibrosis Airway Epithelial Cells. *Eur Respir J* 45: 428-439.

Seidel, P., Alkhoury, H., Lalor, D.J., Burgess, J.K., Armour, C.L., and Hughes, J.M. (2012) Thiazolidinediones Inhibit Airway Smooth Muscle Release of the Chemokine Cxcl10: In Vitro Comparison with Current Asthma Therapies. *Respir Res* 13: 90-90.

Shaw, D.E., Berry, M.A., Hargadon, B., Mckenna, S., Shelley, M.J., Green, R.H. *et al.* (2007) Association between Neutrophilic Airway Inflammation and Airflow Limitation in Adults with Asthma. *Chest* 132: 1871-1875.

Shaw, D.E., Sousa, A.R., Fowler, S.J., Fleming, L.J., Roberts, G., Corfield, J. *et al.* (2015) Clinical and Inflammatory Characteristics of the European U-Biopred Adult Severe Asthma Cohort. *Eur Respir J* 46: 1308-1321.

Shen, N., Wang, J., Zhao, M., Pei, F., and He, B. (2011) Anti-Interleukin-17 Antibodies Attenuate Airway Inflammation in Tobacco-Smoke-Exposed Mice. *Inhal Toxicol* 23: 212-218.

Shum, A.K. (2015) T Cell Types That Take Your Breath Away. *Sci Trans Med* 7: 301fs333-301fs333.

Simpson, J., Guest, M., Boggess, M., and Gibson, P. (2015) Occupational Exposures, Smoking and Airway Inflammation in Refractory Asthma. *BMC Pulm Med* 14: 207.

Simpson, J., Scott, R., Boyle, M., and Gibson, P. (2006) Inflammatory Subtypes in Asthma: Assessment and Identification Using Induced Sputum. *Respirol* 11: 54-61.

Simpson, J.L., Gibson, P.G., Yang, I.A., Upham, J., James, A., Reynolds, P.N. *et al.* (2013) Impaired Macrophage Phagocytosis in Non-Eosinophilic Asthma. *Clin Exp Allergy* 43: 29-35.

Simpson, J.L., Gibson, P.G., Yang, I.A., Upham, J., James, A., Reynolds, P.N. *et al.* (2014) Altered Sputum Granzyme B and Granzyme B/Proteinase Inhibitor-9 in Patients with Non-Eosinophilic Asthma. *Respirology* 19: 280-287.

Simpson, J.L., Grissell, T.V., Douwes, J., Scott, R.J., Boyle, M.J., and Gibson, P.G. (2007) Innate Immune Activation in Neutrophilic Asthma and Bronchiectasis. *Thorax* 62: 211-218.

1  
2  
3 Simpson, J.L., Mcelduff, P., and Gibson, P.G. (2010) Assessment and Reproducibility of Non-  
4 Eosinophilic Asthma Using Induced Sputum. *Respiration* 79: 147-151.

5  
6 Simpson, J.L., Phipps, S., Baines, K.J., Oreo, K.M., Gunawardhana, L., and Gibson, P.G. (2014)  
7 Elevated Expression of the Nlrp3 Inflammasome in Neutrophilic Asthma. *Eur Respir J* 43:  
8 1067-1076.

9  
10  
11 Simpson, J.L., Powell, H., Boyle, M.J., Scott, R.J., and Gibson, P.G. (2008) Clarithromycin  
12 Targets Neutrophilic Airway Inflammation in Refractory Asthma. *Am J Respir Crit Care Med*  
13 177: 148-155.

14  
15  
16 Singh, D., Petavy, F., Macdonald, A., Lazaar, A., and O'connor, B. (2010) The Inhaled  
17 Phosphodiesterase 4 Inhibitor Gsk256066 Reduces Allergen Challenge Responses in Asthma.  
18 *Resp Res* 11: 26.

19  
20  
21 Spahn, J., Fost, D., Covar, R., Martin, R., Brown, E., Sj, S. *et al.* (2001) Clarithromycin  
22 Potentiates Glucocorticoid Responsiveness in Patients with Asthma: Results of a Pilot Study.  
23 *Ann Allergy Asthma Immunol* 87: 501-505.

24  
25  
26 Spears, M., Donnelly, I., Jolly, L., Brannigan, M., Ito, K., Mcsharry, C. *et al.* (2009) Effect of  
27 Low-Dose Theophylline Plus Beclometasone on Lung Function in Smokers with Asthma: A  
28 Pilot Study. *Eur Respir J* 33: 1010-1017.

29  
30  
31 Spears, M., Donnelly, I., Jolly, L., Brannigan, M., Ito, K., Mcsharry, C. *et al.* (2009)  
32 Bronchodilatory Effect of the Ppar-[Gamma] Agonist Rosiglitazone in Smokers with Asthma.  
33 *Clin Pharmacol Ther* 86: 49-53.

34  
35  
36 Spears, M., Mcsharry, C., and Thomson, N.C. (2006) Peroxisome Proliferator-Activated  
37 Receptor-Gamma Agonists as Potential Anti-Inflammatory Agents in Asthma and Chronic  
38 Obstructive Pulmonary Disease. *Clin Exp Allergy* 36: 1494-1504.

39  
40  
41 Stephen, J., Delvecchio, C., Spitale, N., Giesler, A., Radford, K., Bilan, P. *et al.* (2013) Ppar  
42 Ligands Decrease Human Airway Smooth Muscle Cell Migration and Extracellular Matrix  
43 Synthesis. *Eur Respir J* 41: 425-432.

44  
45  
46 Suárez-Cuartín, G., Crespo, A., Mateus, E., Torrejón, M., Giner, J., Belda, A. *et al.* (2015)  
47 Variability in Asthma Inflammatory Phenotype in Induced Sputum. Frequency and Causes.  
48 *Arch Bronconeumol* May 4. pii: S0300-2896(15)00110-6. doi: 10.1016/j.arbres.2015.03.007.  
49 [Epub ahead of print]:

50  
51  
52 Sukkar, M.B., Wood, L.G., Tooze, M., Simpson, J.L., McDonald, V.M., Gibson, P.G. *et al.*  
53 (2012) Soluble Rage Is Deficient in Neutrophilic Asthma and Copd. *Eur Respir J* 39: 721-729.

54  
55  
56 Thomson, N.C. (2014) Novel Therapies Targeting Eosinophilic Inflammation in Asthma. *Clin*  
57 *Exp Allergy* 44: 462-468.

1  
2  
3 Thomson, N.C., Charron, C.E., Chaudhuri, R., Spears, M., Ito, K., and Mcsharry, C. (2015 )  
4 Atorvastatin in Combination with Inhaled Beclometasone Modulates Inflammatory Sputum  
5 Mediators in Smokers with Asthma. *Pulm Pharmacol Ther* 31: 1-8.  
6

7  
8 Thomson, N.C., Chaudhuri, R., Heaney, L.G., Bucknall, C., Niven, R.M., Brightling, C.E. *et al.*  
9 (2013) Clinical Outcomes and Inflammatory Biomarkers in Current Smokers and Exsmokers  
10 with Severe Asthma. *J Allergy Clin Immunol* 131: 1008-1016.  
11

12  
13 Thomson, N.C., Chaudhuri, R., Thomson, N.C., and Chaudhuri, R. (2009) Asthma in Smokers:  
14 Challenges and Opportunities. *Curr Opin Pulm Med* 15: 39 - 45.  
15

16  
17 To, Y., Ito, K., Kizawa, Y., Failla, M., Ito, M., Kusama, T. *et al.* (2010) Targeting  
18 Phosphoinositide-3-Kinase-Delta with Theophylline Reverses Corticosteroid Insensitivity in  
19 Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med* 182: 897-904.  
20

21  
22 Trejo Bittar, H.E., Yousem, S.A., and Wenzel, S.E. (2015) Pathobiology of Severe Asthma.  
23 *Annu Rev Pathol* 10: 511-545.  
24

25  
26 Turner, M.O., Hussack, P., Sears, M.R., Dolovich, J., and Hargreave, F.E. (1995) Exacerbations  
27 of Asthma without Sputum Eosinophilia. *Thorax* 50: 1057-1061.  
28

29  
30 Uddin, M., Lau, L.C., Seumois, G.G., Vijayanand, P., Staples, K.J., Bagmane, D. *et al.* (2013)  
31 Egf-Induced Bronchial Epithelial Cells Drive Neutrophil Chemotactic and Anti-Apoptotic  
32 Activity in Asthma. *PLoS ONE* 8: e72502.  
33

34  
35 Uddin, M., Nong, G., Ward, J., Seumois, G.G., Prince, L.R., Wilson, S.J. *et al.* (2010)  
36 Prosurvival Activity for Airway Neutrophils in Severe Asthma. *Thorax* 65:: 684-689.  
37

38  
39 Van Veen, I.H., Ten Brinke, A., Gauw, S.A., Sterk, P.J., Rabe, K.F., and Bel, E.H. (2009)  
40 Consistency of Sputum Eosinophilia in Difficult-to-Treat Asthma: A 5-Year Follow-up Study. *J*  
41 *Allergy Clin Immunol* 124: 615-617.e612.  
42

43  
44 Wagener, A.H., De Nijs, S.B., Lutter, R., Sousa, A.R., Weersink, E.J.M., Bel, E.H. *et al.* (2015)  
45 External Validation of Blood Eosinophils, Feno and Serum Periostin as Surrogates for Sputum  
46 Eosinophils in Asthma. *Thorax* 70: 115-120.  
47

48  
49 Wallace, J., D'silva, L., Brannan, J., Hargreave, F.E., Kanaroglou, P., and Nair, P. (2011)  
50 Association between Proximity to Major Roads and Sputum Cell Counts. *Can Respir J* 18: 13-  
51 18.  
52

53  
54 Wang, F., He, X.Y., Baines, K.J., Gunawardhana, L.P., Simpson, J.L., Li, F. *et al.* (2011)  
55 Different Inflammatory Phenotypes in Adults and Children with Acute Asthma. *Eur Respir J*  
56 38: 567-574.  
57

58  
59 Watz, H., Mistry, S., Lazaar, A., and Investigators., I. (2013) Safety and Tolerability of the  
60 Inhaled Phosphodiesterase 4 Inhibitor Gsk256066 in Moderate Copd. *Pulm Pharmacol Ther*  
26: 588-595.

1  
2  
3  
4 Wenzel, S., Schwartz, L., Langmack, E., and Al, E. (1999) Evidence That Severe Asthma Can  
5 Be Divided Pathologically into Two Inflammatory Subtypes with Distinct Physiologic and  
6 Clinical Characteristics. *Am J Respir Crit Care Med* 160: 1001-1008.  
7

8  
9 Wenzel, S.E., Barnes, P.J., Bleecker, E.R., Bousquet, J., Busse, W., Dahlen, S.-E. *et al.* (2009) A  
10 Randomized, Double-Blind, Placebo-Controlled Study of Tumor Necrosis Factor-Alpha  
11 Blockade in Severe Persistent Asthma. *Am J Respir Crit Care Med* 179: 549-558.  
12

13  
14 Winkler, David g., Faia, Kerrie l., Dinitto, Jonathan p., Ali, Janid a., White, Kerry f., Brophy,  
15 Erin e. *et al.* (2013) Pi3k- $\Delta$  and Pi3k- $\Gamma$  Inhibition by Ipi-145 Abrogates Immune Responses and  
16 Suppresses Activity in Autoimmune and Inflammatory Disease Models. *Chem Biol* 20: 1364-  
17 1374.  
18

19  
20 Wood, L.G., Baines, K.J., Fu, J., Scott, H.A., and Gibson, P.G. (2012) The Neutrophilic  
21 Inflammatory Phenotype Is Associated with Systemic Inflammation in Asthma. *Chest* 142:  
22 86-93.  
23

24  
25 Woodruff, P.G., Modrek, B., Choy, D.F., Jia, G., Abbas, A.R., Ellwanger, A. *et al.* (2009) T-  
26 Helper Type 2-Driven Inflammation Defines Major Subphenotypes of Asthma. *Am J Respir*  
27 *Crit Care Med* 180: 388-395.  
28

29  
30 Wu, Wang, Dong, Liao, and Wen. (2012) Silencing of C-Kit with Small Interference Rna  
31 Attenuates Inflammation in a Murine Model of Allergic Asthma. *Int J Mol Med* 30: 63-68.  
32

33  
34 Wu, W., Chen, H., Li, Y.-M., Wang, S.-Y., Diao, X., and Liu, K.-G. (2014) Intranasal Sirna  
35 Targeting C-Kit Reduces Airway Inflammation in Experimental Allergic Asthma. *Int J Clin Exp*  
36 *Pathol* 7: 5505-5514.  
37

38  
39 Xystrakis, E., Kusumakar, S., Boswell, S., Peek, E., Urry, Z., Richards, D.F. *et al.* (2006)  
40 Reversing the Defective Induction of Il-10-Secreting Regulatory T Cells in Glucocorticoid-  
41 Resistant Asthma Patients. *J Clin Invest* 116: 146-155.  
42

43  
44 Yeganeh, B., Wiechec, E., Ande, S., Sharma, P., Moghadam, A., Post, M. *et al.* (2014)  
45 Targeting the Mevalonate Cascade as a New Therapeutic Approach in Heart Disease, Cancer  
46 and Pulmonary Disease. *Pharmacol Ther* 143: 87-110.  
47

48  
49 Zeki, A.A., Franzi, L., Last, J., and Kenyon, N.J. (2009) Simvastatin Inhibits Airway  
50 Hyperreactivity: Implications for the Mevalonate Pathway and Beyond. *Am J Respir Crit Care*  
51 *Med* 180: 731-740.  
52

53  
54 Zhang, X.Y., Simpson, J.L., Powell, H., Yang, I.A., Upham, J.W., Reynolds, P.N. *et al.* (2014)  
55 Full Blood Count Parameters for the Detection of Asthma Inflammatory Phenotypes. *Clin*  
56 *Exp Allergy* 44: 1137-1145.  
57  
58  
59  
60

Zhang, Y., Leung, D.Y.M., and Goleva, E. (2014) Anti-Inflammatory and Corticosteroid-Enhancing Actions of Vitamin D in Monocytes of Patients with Steroid-Resistant and Those with Steroid-Sensitive Asthma. *J Allergy Clin Immunol* 133: 1744-1752.

Zhao, Y., Huang, Y., He, J., Li, C., Deng, W., Ran, X. *et al.* (2014) Rosiglitazone, a Peroxisome Proliferator-Activated Receptor- $\gamma$  Agonist, Attenuates Airway Inflammation by Inhibiting the Proliferation of Effector T Cells in a Murine Model of Neutrophilic Asthma. *Immunol Lett* 157: 9-15.

## LIST OF ABBREVIATIONS

ACQ: Asthma control questionnaire

ACRN: Asthma Clinical Research Network

AP-1: Activator protein-1

AQLQ: asthma quality of life questionnaire

BAL: Bronchoalveolar lavage

BDP: Beclomethasone dipropionate

BMI: Body mass index

CAMP: Childhood Asthma Management Program

COPD: Chronic obstructive pulmonary disease

*CRHR1*: Corticotrophin-releasing hormone receptor 1 gene

CCL: Chemokine (C-C motif) ligand

CXCL: Chemokine (C-X-C motif) ligand

CXCR: C-X-C chemokine receptor

eNOS: Endothelial nitric oxide synthase

ERK: Extracellular signal-regulated kinase

FCER2: Low-affinity IgE receptor gene

1  
2  
3 FGF: Fibroblast growth factor

4  
5 FLAP: 5-lipoxygenase-activating protein

6  
7 GILZ: Glucocorticoid-inducible leucine zipper 1

8  
9 G-CSF: Granulocyte-colony stimulating factor

10  
11 GLCCI1: Glucocorticoid-induced transcript 1 gene

12  
13 GOAL: Gaining Optimal Asthma Control

14  
15 GR: glucocorticoid receptor

16  
17 GRE: Glucocorticoid-responsive elements

18  
19 HDAC: Histone deacetylase

20  
21 HFA: Hydrofluoroalkane

22  
23 HMG CoA: 3-Hydroxymethyl-3-glutaryl Coenzyme A

24  
25 IDO: Indoleamine 2, 3-dioxygenase

26  
27 IFN: interferon

28  
29 Ig: immunoglobulin

30  
31 IKKs: I $\kappa$ B kinases

32  
33 IL: interleukin

34  
35 JNK: c-Jun N-terminal kinase

36  
37 LABA: Long acting  $\beta_2$ -agonists

38  
39 LPS: lipopolysaccharide

40  
41 LT: leukotriene

42  
43 MAPK: Mitogen-activated protein kinase

44  
45 MKP: Mitogen-activated protein kinase phosphatase 1

46  
47 MMP: Matrix metalloproteinase

48  
49 MPO: Myeloperoxidase



1  
2  
3 NO: nitric oxide

4  
5 NF $\kappa$ B: Nuclear factor  $\kappa$ B

6  
7 PEF: Peak expiratory flow

8  
9 PBMC: Peripheral blood mononuclear cell

10  
11 PDE: Phosphodiesterase

12  
13 PI3K: Phosphoinositide 3-kinase

14  
15 PP2A: Protein phosphatase 2A

16  
17 PPAR $\gamma$ : Peroxisome proliferator-activated receptor- $\gamma$

18  
19 RASP-UK: Refractory Asthma Stratification Programme

20  
21 RBM: Reticular basement membrane thickness

22  
23 sCD40L: Soluble CD40 ligand

24  
25 SHIP1: SH2-containing inositol-50-phosphatase 1

26  
27 SLPI: Secretory leukocyte protease inhibitor expression

28  
29 SNPs: Single-nucleotide polymorphisms

30  
31 STAT: Signal transduction-activated transcription factors

32  
33 SNP: Single nucleotide polymorphisms

34  
35 *TBX21*: T-box expressed in T cells21

36  
37 TGF- $\alpha$ : Transforming growth factor alpha

38  
39 Th<sub>2</sub>: Type 2 helper T-cell (Th<sub>2</sub>)

40  
41 TNF- $\alpha$ : Tumour necrosis factor  $\alpha$

42  
43 TLR: Toll-like receptor

44  
45 U-BOPRED: Unbiased Biomarkers for the Prediction of Respiratory Disease Outcome

**Table 1 Possible factors accounting for neutrophilic airway inflammation in asthma**

- Corticosteroid treatment causing reduced apoptosis of neutrophils and contributing to Th17 mediated neutrophilic inflammation
- Neutrophilia associated with chronic sinopulmonary infection and/or bronchiectasis
- Delay human neutrophil apoptosis in severe asthma due to epithelial growth factor induced release of mediators with neutrophil chemotactic and anti-apoptotic actions from bronchial epithelial cells
- Impaired macrophage phagocytosis of neutrophils
- Neutrophilia associated with altered airway microbiome

1  
2  
3 **Table 2 Clinical phenotypes and factors associated with non-eosinophilic airway**  
4  
5 **inflammation in asthma**  
6  
7

8  
9  
10 Mild to severe asthma in never or ex-smokers (both controlled and uncontrolled)

11  
12 Smokers with asthma

13  
14 High BMI (subgroup)

15  
16 Occupational asthma (subgroup)

17  
18 Factors associated with higher neutrophil counts

- 19  
20  
21  
22 – Older age  
23  
24 – Exposure to environmental pollution  
25  
26  
27 – Respiratory infections  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 3 Treatments targeting non-eosinophilic airway inflammation in asthma****Non-pharmacological interventions**

Avoidance from exposure to environmental and occupational pollutants

Smoking cessation

Dietary supplementation with vitamin D3

**'Off-label' use of licensed drugs**

Macrolides

Statins

Low-dose theophylline

Peroxisome proliferator-activated receptor- $\gamma$  (PPAR $\gamma$ ) agonists

**Novel small molecule drugs*****Drugs targeting neutrophilic inflammation***

C-X-C chemokine receptor (CXCR)2 antagonists

5-lipoxygenase-activating protein (FLAP) inhibitors

***Phosphodiesterase (PDE) inhibitors***

PDE<sub>4</sub> inhibitors

Dual PDE<sub>3</sub> and PDE<sub>4</sub> inhibitors

**Protein kinase inhibitors**

p38 Mitogen-activated protein kinase (MAPK) inhibitors

Narrow spectrum kinase inhibitors

Tyrosine kinase inhibitors

**Phosphoinositide 3 (PI3)-kinase inhibitors**

PI3K- $\delta$  inhibitors

Dual PI3K $\delta/\gamma$  inhibitors

**Biological agents**

Interleukin (IL)-17A receptor blockers

IL-17A blockers

Tumour necrosis factor (TNF)- $\alpha$  receptor blockers

IL-1 $\beta$  monoclonal antibody blockers

Soluble IL-1 receptor monoclonal antibody blockers

IL-6 monoclonal antibody blockers

**FIGURE LEGENDS****Figure 1 Schematic diagram of potential pathways leading to non-eosinophilic inflammation and airway damage in severe asthma**

Several inflammatory pathways could potentially lead to non-eosinophilic inflammation and airway damage in asthma although the exact mechanisms are unclear. Possible pathways are briefly summarized in the schematic diagram. Stimuli such as viruses, cigarette smoke and pollutants could induce the release of chemoattractants including IL-8 to recruit neutrophils to the airways. The release of IL-17A and IL-17F from activated Th17 cells could stimulate the synthesis of neutrophil chemoattractants, such CXCL1 and IL-8 from the airway epithelium. INF- $\gamma$  may also be involved in non-eosinophilic asthma, possibly in part through its release from Th1 cells. Inflammatory mediators released by neutrophils are implicated in causing mucus gland hyperplasia and hypersecretion, airway hyperreactivity and remodelling as well as corticosteroid insensitivity in asthma. Th1 and Th17 cells may induce airway hyperreactivity and/or remodelling independently of neutrophil activation.

*Abbreviations:* CXCL1: chemokine (C-X-C motif) ligand; IFN: interferon; IL: interleukin; LT: leukotriene; MMP: matrix metalloproteinase; MPO: myeloperoxidase; ROC: reactive oxygen species; TNF- $\alpha$ : tumour necrosis factor  $\alpha$

1  
2  
3 **Figure 2 Targets and potential therapies for treating non-eosinophilic airway inflammation**  
4  
5 **in asthma**  
6  
7  
8  
9

10 Non-eosinophilic airway inflammation is found in approximately 50% of patients with asthma.  
11  
12 The proportion of this group with neutrophilic inflammation is less certain because of variable  
13  
14 cut-off points used to define neutrophilia. The higher the cut-off value used to define sputum  
15  
16 neutrophilia the greater the proportion of subjects that are classified as having  
17  
18 paucigranulocytic inflammation. Pathways that may account for poor asthma control in  
19  
20 patients with non-eosinophilic asthma including neutrophilic inflammation, associated  
21  
22 inflammatory phenotypes (Th1-high inflammation, Th17-high inflammation, combination of  
23  
24 Th2 and Th17 inflammation, mast cell induced inflammation, other inflammatory mechanisms)  
25  
26 as well as corticosteroid insensitivity. Non-inflammatory mechanisms such as airway  
27  
28 hyperreactivity and airway remodelling may be important in causing symptoms in some  
29  
30 individuals. Potential treatments targeting specific pathways are listed in the diagram. Novel  
31  
32 small molecules targeting neutrophilic inflammation, such as CXCR2 antagonists reduce  
33  
34 neutrophils, but do not improve clinical outcomes. Smoking cessation in asthmatic smokers and  
35  
36 removal from exposure to occupational agents reduces neutrophilic inflammation. The results  
37  
38 of clinical trials of biological agents targeting mediators associated with non-eosinophilic  
39  
40 inflammation, such as IL-17 and TNF- $\alpha$  are disappointing. Preliminary studies of 'off-label' use  
41  
42 of licensed drugs suggest that macrolides show efficacy in non-smokers with non-eosinophilic  
43  
44 severe asthma and statins, low-dose theophylline and PPAR $\gamma$  agonists may benefit asthmatic  
45  
46 smokers with non-eosinophilic inflammation and associate corticosteroid insensitivity. Inhaled  
47  
48 PDE $_4$  inhibitors, dual PDE $_3$  and PDE $_4$  inhibitors, p38MAPK inhibitors, tyrosine kinase inhibitors  
49  
50 and PI3kinase inhibitors are under development and these compounds may be of benefit in  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 treating non-eosinophilic inflammation and corticosteroid insensitivity. Long-acting  
4  
5 bronchodilators and/or bronchial thermoplasty are possible treatment options for symptomatic  
6  
7 patients with paucigranulocytic inflammation in whom there is no evidence of activated  
8  
9 inflammatory pathways or corticosteroid insensitivity that could be targeted by specific  
10  
11 therapies.  
12  
13

14 *Abbreviations:* CXCR: C-X-C chemokine receptor; FLAP: 5-lipoxygenase-activating protein; IL:  
15  
16 interleukin; PDE: phosphodiesterase; PI3K: phosphoinositide 3-kinase; PPAR $\gamma$ : peroxisome  
17  
18 proliferator-activated receptor- $\gamma$ ;  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## Novel approaches to the management of non-eosinophilic asthma

Neil C Thomson MD, FRCP, FERS

Institute of Infection, Immunity & Inflammation,

University of Glasgow, Glasgow, UK

### Corresponding author

Professor Neil C Thomson, Institute of Infection, Immunity & Inflammation, University of

Glasgow, Glasgow, G12 OYN, UK Telephone: 44-141-211-1673. Fax: 44-141-211-3464

E- mail: [neil.thomson@glasgow.ac.uk](mailto:neil.thomson@glasgow.ac.uk)

**Word count:** 8041 words

**ABSTRACT**

Non-eosinophilic airway inflammation occurs in approximately 50% of patients with asthma. It is subdivided into neutrophilic or paucigranulocytic inflammation, although the proportion of each subtype is uncertain because of variable cut-off points used to define neutrophilia. This article reviews the evidence for non-eosinophilic inflammation being as a target for therapy in asthma and assesses clinical trials of licensed drugs, novel small molecules and biologics agents in non-eosinophilic inflammation. Current symptoms, rate of exacerbations and decline in lung function are generally less in non-eosinophilic asthma than eosinophilic asthma. Non-eosinophilic inflammation is associated with corticosteroid insensitivity. Neutrophil activation in the airways and systemic inflammation is reported in neutrophilic asthma. Neutrophilia in asthma may be due to corticosteroids, associated chronic pulmonary infection, altered airway microbiome and/or delay neutrophil apoptosis. The cause of poorly controlled non-eosinophilic asthma may differ between patients and involve several mechanism including neutrophilic inflammation, Th2-low or other subtypes of airway inflammation and/or corticosteroid insensitivity as well as non-inflammatory pathways such as airway hyperreactivity and remodelling. Smoking cessation in asthmatic smokers and removal from exposure to occupational agents reduces neutrophilic inflammation. Preliminary studies of 'off-label' use of licensed drugs suggest that macrolides show efficacy in non-smokers with non-eosinophilic severe asthma and statins, low-dose theophylline and PPAR $\gamma$  agonists may benefit asthmatic smokers with non-eosinophilic inflammation. Novel small molecules targeting neutrophilic inflammation, such as CXCR2 antagonists reduce neutrophils, but do not improve clinical outcomes in studies to date. Inhaled PDE<sub>4</sub> inhibitors, dual PDE<sub>3</sub> and PDE<sub>4</sub> inhibitors, p38MAPK inhibitors, tyrosine kinase inhibitors and PI3kinase inhibitors are under development and these

1  
2  
3 compounds may be of benefit in non-eosinophilic inflammation. The results of clinical trials of  
4  
5 biological agents targeting mediators associated with non-eosinophilic inflammation, such as IL-  
6  
7 17 and TNF- $\alpha$  are disappointing. Greater understanding of the mechanisms of non-eosinophilic  
8  
9 inflammation in asthma should lead to improved therapies.  
10  
11  
12  
13

14  
15 Word count: 299  
16  
17

18  
19 **Key words:** Airway inflammation; asthma; biological agents; biomarkers; cigarette smoking;  
20  
21 corticosteroid insensitivity; eosinophils; neutrophils; small molecules.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

Personalised medicine in asthma aims ~~is~~ to individualise treatment using non-invasive biomarkers that predict a beneficial response and/or that identify individuals who are at risk of adverse effects [Agustí *et al.*, 2015]. Several airway inflammatory phenotypes are recognised that help identify a therapeutic response to specific treatments in asthma. For example, eosinophilic airway inflammation, which is usually identified on the base ~~sd on the presence~~ of sputum or blood eosinophilia, predicts patients with asthma that are likely to obtain a favourable therapeutic response to corticosteroids [Pavord *et al.*, 1999, Little *et al.*, 2000, Green *et al.*, 2002, Bacci *et al.*, 2006, Berry *et al.*, 2007] and to monoclonal antibodies targeting interleukin (IL)-5 [Pavord *et al.*, 2012, Katz *et al.*, 2014, Thomson, 2014]. Type 2 helper T-cell (Th2)-high subtype of asthma is associated with increased epithelial expression of interleukin IL-4, IL-5 and IL-13 [Woodruff *et al.*, 2009, Arron *et al.*, 2013] and is considered to overlap with eosinophilic airway inflammation [Arron *et al.*, 2013]. Evidence from clinical trials suggests that the presence of Type-2 eosinophilic inflammation predicts a therapeutic response not only to corticosteroids [Woodruff *et al.*, 2009], but to monoclonal antibodies targeting specific cytokines such as IL-5 [Bel *et al.*, 2014, Ortega *et al.*, 2014] and IL-13 [Corren *et al.*, 2011]. Many patients with asthma have non-eosinophilic asthma, sometimes associated with neutrophilic inflammation and/or have a Th2-low type of inflammation. Compared to type-2 eosinophilic inflammation there are relatively few interventions available for non-type 2 inflammatory subgroups. This article aims to discuss the evidence that non-eosinophilic airway inflammation, with or without neutrophic inflammation, is an appropriate target for therapy in asthma and also aims to assess the results of recent clinical trials of licensed drugs, novel small molecules and biologics agents in the treatment of non-eosinophilic asthma.

## IS NON-EOSINOPHILIC AIRWAY INFLAMMATION AN APPROPRIATE TARGET FOR THERAPY IN ASTHMA?

A number of factors need to be considered when attempting to answer the question of whether non-eosinophilic inflammation is an appropriate target for treatment in asthma including the criteria used to define neutrophilic and eosinophilic inflammation, the stability of non-eosinophil inflammation over time, the prevalence of non-eosinophilic inflammation, the strength of evidence for the involvement of non-eosinophilic inflammation in clinical features of asthma and the cause(s) of non-eosinophilic airway inflammation.

### Definition of eosinophilic and neutrophilic airway inflammation

Non-eosinophilic airway inflammation is a term used to describe a subtype of asthma associated with normal numbers of sputum eosinophils. The non-eosinophilic phenotype is subdivided into neutrophilic inflammation, when neutrophil numbers are raised above a defined cut-off level or paucigranulocytic inflammation, when both eosinophil and neutrophil numbers are normal. In addition, some individuals have a mixed type of inflammation, when there is sputum neutrophilia and eosinophilia. Cut-off levels used to define sputum eosinophilia most commonly used are  $\geq 2\%$  [Mcgrath *et al.*, 2012, Hastie *et al.*, 2013],  $> 2\%$  [Peters *et al.*, 2014] or  $\geq 3\%$  [Schleich *et al.*, 2013, Zhang *et al.*, 2014, Wagener *et al.*, 2015]. A  $\geq 3\%$  cut-off is reported to be the most precise value to identify eosinophilic airway inflammation [Simpson *et al.*, 2010]. Sputum eosinophil counts are associated with bronchial tissue eosinophil numbers suggesting that they provide a good indicator of airway eosinophilic pathology [Arron *et al.*, 2014]. The cut-off for a raised sputum neutrophil count is not clearly established with a wide

1  
2  
3 range of values reported in the literature: >40% (Nair, Gaga et al. 2012; Moore, Hastie et al.  
4  
5 2014),  $\geq$ 50% (Chaudhuri, Norris et al. 2014), >61% (Simpson, Milne et al. 2009), >65% (Nair et al  
6  
7 2015) and  $\geq$ 76% (Schleich, Manise et al. 2013). The most appropriate cut-off value that  
8  
9 identifies individuals in whom neutrophils are activated and contributing to the pathogenic  
10  
11 processes in asthma is not certain. In addition, sputum neutrophils do not correlate with  
12  
13 bronchial tissue numbers bringing into doubt their predictive value for identifying neutrophil-  
14  
15 induced airway pathology [Arron *et al.*, 2014]. In addition to the presence of non-eosinophilic  
16  
17 inflammation, Haldar and Pavord [Haldar *et al.*, 2007] proposed that the criteria for a diagnosis  
18  
19 of non-eosinophilic asthma should include objective evidence of airflow obstruction or airway  
20  
21 hyperreactivity, a raised asthma control questionnaire (ACQ) score (>1.5) and the absence of a  
22  
23 significant smoking history, fixed airflow obstruction or associated bronchiectasis-. In the  
24  
25 current article, the criteria for non-eosinophilic asthma include the presence of non-  
26  
27 eosinophilic inflammation as defined above plus objective evidence of asthma, but the review  
28  
29 also includes data from patients with both normal and raised ACQ scores, who have a  
30  
31 significant smoking history or who have fixed airflow obstruction.  
32  
33  
34  
35  
36  
37  
38  
39  
40

#### 41 **Stability of sputum cell counts**

42  
43  
44  
45 Published data on the long term stability of sputum neutrophil and eosinophil counts is  
46  
47 conflicting. Some studies report stable sputum cell counts in patients with mild to severe  
48  
49 asthma follow-up over 6 months [Berry *et al.*, 2007], 12 months [Green *et al.*, 2002], 2 years  
50  
51 [Jayaram *et al.*, 2006] and 5 years [Simpson *et al.*, 2006, Van Veen *et al.*, 2009]. In contrast,  
52  
53 sputum inflammatory cell phenotype changed in 48.6% of patients with severe asthma over  
54  
55 1 year among patients recruited to the BIOmarkers in Severe Chronic AIRway Disease  
56  
57  
58  
59  
60

(BIOAIR) study [Kupczyk *et al.*, 2014]. Similar variability in sputum cell counts has been reported by others [Hancox *et al.*, 2012] and in one study a stable inflammatory phenotype was found in only one third of patients [Al-Samri *et al.*, 2010]. Transient sputum eosinophilia is reported in up to 40% patients with non-eosinophilic inflammation [Bacci *et al.*, 2012, Mcgrath *et al.*, 2012]. The potential for the lack of stability in non-eosinophilic inflammation over time needs to be accounted for in intervention studies targeting sputum inflammatory cell biomarkers.

### Prevalence of non-eosinophilic airway inflammation

The different cut-off values used to define elevated sputum cell counts, particularly sputum neutrophils, may explain the variation in prevalence figures for non-eosinophilic inflammation between studies. Nevertheless, overall up to 50% of adults and adolescents ~~patients~~ with stable mild to severe asthma, and in some studies higher proportions, have non-eosinophilic inflammation [Gibson *et al.*, 2001, Green *et al.*, 2002, Simpson *et al.*, 2006, Wang *et al.*, 2011, Mcgrath *et al.*, 2012, Schleich *et al.*, 2013, Moore *et al.*, 2014, Brooks *et al.*, 2016 ]. For example, a review of sputum cytology data from 995 subjects with mild to moderate asthma enrolled in clinical trials undertaken by the Asthma Clinical Research Network (ACRN) reported that non-eosinophilic inflammation (sputum eosinophils <2%) was present in 64% of patients not taking inhaled corticosteroid and 83% of patients taking inhaled corticosteroids. In a sub-group of patients followed up for 6 months, 47% of the inhaled corticosteroid free patients and 72% of those taking inhaled corticosteroids had persistent non-eosinophilic inflammation [Mcgrath *et al.*, 2012]. In a cluster analysis performed on 423 patients recruited to the Severe Asthma Research Program (SARP)

1  
2  
3 cohort, four asthma inflammatory sub-phenotypes were identified (sputum eosinophilia  
4  
5  $\geq 2\%$ ; sputum neutrophilia  $>40\%$ ) [Moore *et al.*, 2014]. Two groups had mild-to-moderate  
6  
7 allergic asthma with minimal or eosinophil-predominant sputum inflammation whereas the  
8  
9 other two sub-phenotypes had moderate-to-severe asthma with neutrophil-predominant or  
10  
11 mixed granulocytic inflammation [Moore *et al.*, 2014]. A study in a small group of adults  
12  
13 with stable asthma found 51.7% of subjects had a paucigranulocytic phenotype, 27.6%  
14  
15 neutrophilic inflammation and 17.2% eosinophilic inflammation [Wang *et al.*, 2011].  
16  
17  
18  
19  
20  
21

### 22 **Involvement of neutrophilic and non-eosinophilic airway inflammation in asthma**

23  
24  
25  
26 Evidence for the involvement of non-eosinophilic inflammation in asthma is based mainly on  
27  
28 studies examining the association between sputum inflammatory phenotypes and clinical  
29  
30 outcomes in asthma including current symptom control, exacerbations, airflow obstruction and  
31  
32 therapeutic response to corticosteroids. Further evidence is provided by reports of local  
33  
34 activation of neutrophils and systemic inflammation in neutrophilic asthma.  
35  
36  
37  
38  
39

### 40 ***Current symptom control***

41  
42  
43  
44  
45 The severity of current symptoms isare in general similar or slightly lowerbetter in non-  
46  
47 eosinophilic or neutrophilic subgroups of asthma compared d to eosinophilic subgroups [Cowan  
48  
49 *et al.*, 2010, Hastie *et al.*, 2010, Wood *et al.*, 2012, Schleich *et al.*, 2013, Baines *et al.*, 2014,  
50  
51 Newby *et al.*, 2014, Schleich *et al.*, 2014].  
52  
53  
54  
55

### 56 ***Exacerbations***

57  
58  
59  
60



1  
2  
3  
4  
5 Sputum neutrophilia is found in up to 80% of exacerbations in adults with asthma [Turner *et al.*,  
6  
7  
8 1995, Fahy *et al.*, 1995, Lamblin *et al.*, 1998, Green *et al.*, 2002, Jayaram *et al.*, 2006,  
9  
10 Maneechotesuwan *et al.*, 2007, Wang *et al.*, 2011], although the predominant sputum cell type  
11  
12 can alter during successive exacerbations [D'silva *et al.*, 2007]. Sputum eosinophilia is a better  
13  
14 predictor of future exacerbations than sputum neutrophilia [Jatakanon *et al.*, 2000, Leuppi *et*  
15  
16 *al.*, 2001, Kupczyk *et al.*, 2014, Schleich *et al.*, 2014]. For example, a cluster analysis performed  
17  
18 on patients recruited to the BIOAIR study identified two clusters with raised sputum eosinophil  
19  
20 counts that accounted for 83% of subjects who had 2 or more severe exacerbations during  
21  
22 follow-up for 1 year [Kupczyk *et al.*, 2014]. One of these clusters had a mixed inflammatory  
23  
24 profile with raised sputum neutrophils (43% percent of patients). A further cluster had a raised  
25  
26 neutrophil count and a normal eosinophil count (11% of patients) and a non-eosinophilic  
27  
28 paucigranulocytic inflammation was found in only 6% of cases. Patients with severe asthma  
29  
30 associated with eosinophil inflammation have more intubations than non-eosinophilic patients  
31  
32 [Wenzel *et al.*, 1999].  
33  
34  
35  
36  
37  
38  
39  
40

### 41 **Airflow obstruction**

42  
43  
44  
45 Sputum neutrophilia is association with reduced lung function and based on this finding it has  
46  
47 been speculated that airway neutrophils may contribute to the development of persistent  
48  
49 airflow obstruction in asthma [Little *et al.*, 2002, Shaw *et al.*, 2007]. Against this hypothesis, a  
50  
51 recent cluster analysis of lung function decline and sputum eosinophil count performed in 97  
52  
53 patients with severe asthma identified a non-eosinophilic group in whom the decline in FEV<sub>1</sub>  
54  
55 was -14 ml per year compared to an eosinophilic group with highly variable eosinophil counts  
56  
57  
58  
59  
60

1  
2  
3 that had a greater rate of decline in FEV<sub>1</sub> of -41 ml per year [Newby *et al.*, 2014]. These findings  
4  
5 suggest that eosinophilic inflammation, particularly when there is high variability in eosinophil  
6  
7 count, is a greater risk factor for the development of persistent airflow obstruction than non-  
8  
9 eosinophilic inflammation. Bronchodilator reversibility and airway hyperresponsiveness are  
10  
11 similar in eosinophilic and non-eosinophilic asthma [Berry *et al.*, 2007, Mcgrath *et al.*, 2012],  
12  
13 although one study noted greater airway hyperresponsiveness in persistent or intermittent  
14  
15 eosinophilic groups [Mcgrath *et al.*, 2012].  
16  
17  
18  
19  
20  
21

### 22 ***Impaired response to inhaled corticosteroids***

23  
24  
25  
26 Non-eosinophilic inflammation is associated with an impaired therapeutic response to  
27  
28 inhaled corticosteroids [Pavord *et al.*, 1999, Green *et al.*, 2002, Bacci *et al.*, 2006, Berry *et*  
29  
30 *al.*, 2007, Thomson *et al.*, 2009, Mcgrath *et al.*, 2012], although the lack of efficacy may not  
31  
32 be complete. Several clinical studies performed in small numbers of patients with non-  
33  
34 eosinophilic asthma suggest that this group may obtain some benefit from inhaled  
35  
36 corticosteroids although less than that found in eosinophilic patients [Godon *et al.*, 2002,  
37  
38 Cowan *et al.*, 2010, Lemièrre *et al.*, 2011]. Intermittent eosinophilia might be a factor  
39  
40 accounting for corticosteroid sensitivity in some of these patients [Bacci *et al.*, 2012,  
41  
42 Mcgrath *et al.*, 2012, Suárez-Cuartín *et al.*, 2015].  
43  
44  
45  
46  
47  
48  
49

### 50 ***Evidence for neutrophil activation in asthma***

51  
52  
53  
54  
55 There is evidence to suggest that the innate immune system is activated in chronic asthma.  
56  
57 Firstly, sputum IL-8 and neutrophil elastase concentrations and innate immune receptors  
58  
59  
60

1  
2  
3 TLR2, TLR4 and CD14 as well as pro-inflammatory IL-8 and IL1- $\beta$  gene expression levels are  
4  
5 increased in neutrophilic asthma compared to non-neutrophilic asthma [Simpson *et al.*,  
6  
7 2007, Wood *et al.*, 2012]. Secondly, neutrophil activation, as measured by sputum  
8  
9 myeloperoxidase (MPO) levels, is positively associated with sputum neutrophil numbers in  
10  
11 asthma [Little *et al.*, 2002]. Thirdly, specific sputum gene expression signatures are  
12  
13 reported to discriminate eosinophilic asthma from non-eosinophilic asthma as well as to  
14  
15 predict a beneficial response to inhaled corticosteroids [Baines *et al.*, 2014]. In this study,  
16  
17 non-eosinophilic asthma was identified by increased sputum cell expression of IL1 $\beta$  ,  
18  
19 alkaline phosphatase, tissue nonspecific isozyme (ALPL ) and CXCR2, whereas eosinophilic  
20  
21 asthma was characterised by increased expression of Charcot-Leydon crystal protein or  
22  
23 galectin-10 (CLC), carboxypeptidase A3 (CPA3) and deoxyribonuclease I-like 3 (DNASE1L3).  
24  
25 The NLRP3 inflammasome is upregulated in neutrophilic asthma and may increase the  
26  
27 production of IL-1 $\beta$  [Simpson *et al.*, 2014, Kim *et al.*, 2015]. Anti-inflammatory responses  
28  
29 may be impaired in non-eosinophilic asthma based on reduced sputum galectin-3  
30  
31 concentrations, which increases uptake of apoptotic neutrophils and reduced IL-1RA/IL-1 $\beta$   
32  
33 ratio, and which might increase pro-inflammatory actions of IL-1 $\beta$  [Gao *et al.*, 2015]. In  
34  
35 addition, soluble receptor for advanced glycation end-products (RAGE), which is a pattern-  
36  
37 recognition receptor is deficient in BAL samples in neutrophilic asthma [Sukkar *et al.*,  
38  
39 2012]. The T-cell granzyme B pathway, which is thought to mediate apoptosis of epithelial  
40  
41 cells, might be defective in non-eosinophilic asthma, based on the finding of a higher ratio  
42  
43 of the expression of granzyme B to its inhibitor in T cells in this group compared to  
44  
45 eosinophilic asthma [Simpson *et al.*, 2014].  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Systemic inflammation is increased in patients with neutrophilic airway inflammation. The  
4  
5 proportion of patients with elevated CRP, IL-6 and neutrophil elastase concentrations is higher  
6  
7 in neutrophilic asthma compared to a non-neutrophic group [Baines *et al.*, 2011, Wood *et al.*,  
8  
9 2012]. Neutrophilic inflammation is associated with increased  $\alpha$ -defensin and neutrophil  
10  
11 protease gene expression in blood [Baines *et al.*, 2011]. In non-eosinophilic asthma, blood  
12  
13 neutrophils released significantly higher levels of IL-8 at rest [Baines *et al.*, 2010]. In a small  
14  
15 study, gene expression markers of systemic inflammation were associated with higher BMI,  
16  
17 greater history of cigarette smoking, lower FVC% predicted, and increased sputum neutrophils  
18  
19 [Fu *et al.*, 2013].  
20  
21  
22  
23  
24  
25  
26

#### 27 **Potential inflammatory processes leading to non-eosinophilic airway inflammation**

28  
29  
30  
31 Several inflammatory processes could lead to non-inflammation and airway damage in  
32  
33 asthma although the exact immunological mechanisms are unclear (Figure 1) [Trejo Bittar  
34  
35 *et al.*, 2015]. Uncertainty in the clinical relevance of experimental animal models of non-  
36  
37 eosinophilic inflammation has hampered progress in understanding the involvement of  
38  
39 neutrophils and non-eosinophilic inflammation in the pathogenesis of asthma. Stimuli such  
40  
41 as viruses, cigarette smoke and pollutants could induce the release of chemoattractants  
42  
43 including IL-8 to recruit neutrophils to the airways. In experimental asthma models, the  
44  
45 release of IL-17A and IL-17F from activated Th17 cells stimulates the synthesis of  
46  
47 neutrophil chemoattractants including CXCL1 and IL-8 from the airway epithelium.  
48  
49 [Newcomb *et al.*, 2013]. INF- $\gamma$  may also be involved in the pathogenesis of severe asthma  
50  
51 associated with neutrophilic and eosinophilic inflammation, possibly in part through the  
52  
53 release of IFN- $\gamma$  from Th1 cells [Raundhal *et al.*, 2015]. Data from patients with severe  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 asthma and an experimental murine asthma model implicate high INF- $\gamma$  immune  
4 responses and low secretory leukocyte protease inhibitor expression (SLPI) in airway  
5 epithelial cells with airway hyperresponsiveness [Raundhal *et al.*, 2015 ]. Neutrophils are a  
6  
7 potential source of oxygen free radicals and enzymes and their ability to activate other  
8  
9 airway cell types [Futosi *et al.*, 2013]. Neutrophils in asthma are implicated in causing  
10 mucus gland hyperplasia and hypersecretion, airway hyperreactivity and remodelling as  
11 well as corticosteroid insensitivity. Interestingly, Th<sub>1</sub> and Th<sub>17</sub> cells may induce airway  
12 hyperreactivity and/or remodelling independently of neutrophil activation.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23

24 Limited information has been published on the immunopathological characteristics of non-  
25 eosinophilic inflammation in asthma compared with other inflammatory airway phenotypes  
26 including Th<sub>2</sub>-low inflammation, Th<sub>17</sub>-high inflammation or combination of Th<sub>2</sub>/Th<sub>17</sub> profiles.  
27  
28 Bronchial biopsy studies of patients with non-eosinophilic asthma and with Th<sub>2</sub>-low  
29 inflammation report reduced sub-mucosal eosinophil numbers and normal sub-epithelial  
30 basement membrane thickness in both groups [Wenzel *et al.*, 1999, Berry *et al.*, 2007,  
31 Woodruff *et al.*, 2009]. In contrast, bronchial eosinophils numbers and sub-epithelial basement  
32 membrane thickness are both increased in eosinophilic asthma and in Th<sub>2</sub>-high asthma [Wenzel  
33 *et al.*, 1999, Berry *et al.*, 2007, Woodruff *et al.*, 2009]. Mast cell numbers are increased in  
34 eosinophilic asthma [Wenzel *et al.*, 1999] and Th<sub>2</sub>-high asthma [Dougherty *et al.*, 2010],  
35 whereas mast cells numbers are normal in the sub-mucosal of patients with severe non-  
36 eosinophilic asthma [Wenzel *et al.*, 1999] and in the epithelium of non-smoker with Th<sub>2</sub>-low  
37 asthma [Dougherty *et al.*, 2010]. Mast cell numbers in airway smooth muscle are increased in  
38 both non-eosinophilic and eosinophilic asthma [Berry *et al.*, 2007]. Bronchial biopsy neutrophil  
39 numbers are increased to a similar degree in non-eosinophilic severe asthma and eosinophilic  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 severe asthma [Wenzel *et al.*, 1999]. Neutrophil numbers in Th<sub>2</sub>-low asthma have not been  
4  
5 reported. A lower proportion of subjects with non-eosinophilic asthma are atopic compared to  
6  
7 eosinophilic asthma (18% versus 66%) [Berry *et al.*, 2007] and (58% versus 83%) [Gibson *et al.*,  
8  
9 2001]. Severe asthma associated with neutrophilia has significantly higher sputum levels of  
10  
11 Th<sub>17</sub>-related cytokines (CXCL1, CXCL10, CCL2, IL-6, and IL-8) compared with severe asthmatics  
12  
13 with other inflammatory phenotypes [Manni *et al.*, 2014]. The proportion of Th<sub>17</sub> lymphocytes  
14  
15 and the ratio of Th<sub>17</sub> to regulatory T cells (Treg) in the peripheral blood is greater in patients  
16  
17 with non-eosinophilic asthma taking inhaled corticosteroids compared to an eosinophilic  
18  
19 asthma group [Furukawa *et al.*, 2015]. Approximately one third of patients with severe  
20  
21 eosinophilic asthma have a Th17-high signature that is associated with a Th2-low gene  
22  
23 expression profile [Choy *et al.*, 2015]. The number of subjects with non-eosinophilic severe  
24  
25 asthma in this study was not sufficient to determine their Th17 profile [Choy *et al.*, 2015].  
26  
27  
28  
29  
30

31 Taken together, these findings suggest that non-eosinophilic inflammation and Th<sub>2</sub>-low  
32  
33 inflammation in non-smokers with asthma share some similar immunopathological features  
34  
35 including normal eosinophil numbers, submucosal mast cell numbers and sub-epithelial  
36  
37 basement membrane thickness. There is a need for further studies to establish the similarities  
38  
39 and differences in endotypes of non-eosinophilic, Th<sub>2</sub>-low and Th<sub>17</sub> high inflammation to help  
40  
41 identify sub-groups of patients for targeted therapies.  
42  
43  
44  
45  
46  
47

#### 48 Factors accounting for neutrophilic airway inflammation in asthma

49  
50  
51  
52  
53  
54

55 Several factors-mechanisms either alone or in combination could explain raised sputum  
56  
57 neutrophil counts in asthma (Table 1). Firstly, corticosteroids inhibit apoptosis of neutrophils  
58  
59  
60

[Cox, 1995] and their use in asthma may contribute to sputum neutrophilia [Saffar *et al.*, 2011].

In addition, Th2-targeted therapies, including oral corticosteroids may contribute to the development of Th17-high neutrophilic inflammation [Choy *et al.*, 2015, Shum, 2015]. In support of corticosteroids causing neutrophilia in asthma ~~this suggestion~~, inhaled corticosteroid withdrawal from patients with moderate asthma resulted in only one subject with neutrophilic inflammation although the reintroduction of inhaled fluticasone for 4 weeks resulted in a raised neutrophil count in only 5% of subjects [Cowan *et al.*, 2010]. In one study of patients with severe oral corticosteroid dependent asthma associated with increased sputum neutrophil number, markers of neutrophil activation including oxidative burst and surface granular receptor expression were similar to patients with mild asthma [Nair *et al.*, 2015]. In the SARP cohort, however corticosteroid use was not associated with sputum neutrophilia, suggesting that continuous corticosteroid exposure may not be the only influence on sputum neutrophil numbers in severe asthma [Moore *et al.*, 2014]. Secondly, co-morbid conditions such as bronchiectasis or severe airflow obstructions occurring in association with asthma may result in neutrophilic inflammation. Thirdly, delayed human neutrophil apoptosis has been reported in severe asthma [Uddin *et al.*, 2010], possibly due to epithelial growth factor induced release of mediators with neutrophil chemotactic and anti-apoptotic actions from bronchial epithelial cells [Uddin *et al.*, 2010, Uddin *et al.*, 2013]. Fourthly, macrophage efferocytosis is impaired in non-eosinophilic asthma, which may cause airway neutrophilia [Simpson *et al.*, 2013]. Fifthly, altered airway microbiome has been implicated in airway neutrophilia. Airway colonisation determined by terminal restriction fragment length polymorphism (T-RFLP) analysis is associated with more severe airways obstruction and longer duration of disease as well as neutrophilic airway inflammation and raised sputum IL-8 levels [Simpson *et al.*, 2013, Green *et al.*, 2014]. Taken together, these findings suggest that the cause of airway neutrophilia in

1  
2  
3 asthma is likely to be complex, possibly due to corticosteroid treatment inducing impaired  
4  
5 apoptosis of neutrophils and Th17 mediated neutrophilic inflammation, delayed apoptosis of  
6  
7 neutrophils due to epithelial growth factor release and ineffective macrophage efferocytosis of  
8  
9 neutrophils as well as an altered airway microbiome.  
10  
11  
12  
13  
14

### 15 **Clinical phenotypes associated with non-eosinophilic inflammation**

16  
17  
18  
19 Non-eosinophilic inflammation, either paucigranulocytic or neutrophilic occurs in a range of  
20  
21 clinical phenotypes that account for approximately 50% of adults never or ex-smokers with mild  
22  
23 to severe asthma or that have controlled or uncontrolled asthma (Table 2). Non-eosinophilic  
24  
25 inflammation, with or without neutrophilic inflammation is commonly found in smokers with  
26  
27 asthma [Chalmers *et al.*, 2002, Boulet *et al.*, 2006, Thomson *et al.*, 2013]. A high BMI is  
28  
29 associated with non-eosinophilic asthma in some people [Haldar *et al.*, 2008], although others  
30  
31 have submucosal eosinophilia [Desai *et al.*, 2013]. Approximately two thirds of cases of  
32  
33 occupational asthma due to low molecular weight agents have non-eosinophilic inflammation  
34  
35 [Anees *et al.*, 2002], which is associated with a poor asthma prognosis [Lemiere *et al.*, 2014].  
36  
37 Non-occupational-induced asthma that is exacerbated by work exposures is associated with  
38  
39 non-eosinophilic phenotype [Lemière *et al.*, 2013]. Additional factors associated with higher  
40  
41 neutrophil counts include older age [Brooks *et al.*, 2013], exposure to environmental pollution  
42  
43 through living close to car pollution [Wallace *et al.*, 2011], exposure to occupational particulate  
44  
45 matter [Simpson *et al.*, 2015] and respiratory infections.  
46  
47  
48  
49  
50  
51  
52  
53  
54

### 55 **Biomarkers that can identify non-eosinophilic airway inflammation**



1  
2  
3 Are there biomarkers that can identify patients with non-eosinophilic airway inflammation?  
4

5 Blood eosinophil numbers are moderately associated with sputum eosinophils [Schleich *et al.*,  
6  
7 2013, Zhang *et al.*, 2014, Wagener *et al.*, 2015]. Using a cut-off for a blood eosinophil count of  
8  
9  $>0.22 \times 10^9/L$  [Schleich *et al.*, 2013],  $>0.26 \times 10^9/L$  [Zhang *et al.*, 2014] or  $\geq 0.27 \times 10^9/L$   
10  
11 [Wagener *et al.*, 2015] accurately predicts sputum eosinophilia. In contrast, another study  
12  
13 reported that blood eosinophils had a poor predictive value of 47% for sputum eosinophilia  
14  
15 ( $\geq 3\%$  cut-off) although this was better in severe asthma (71%) [Hastie *et al.*, 2013]. In patients  
16  
17 with mild to severe asthma, blood eosinophils were reported to be better than serum periostin  
18  
19 and exhaled nitric oxide in identifying sputum eosinophilia [Wagener *et al.*, 2015]. Blood  
20  
21 neutrophil numbers has a weak relationship with sputum neutrophil count [Schleich *et al.*,  
22  
23 2013, Zhang *et al.*, 2014] and they have a poor predictive value for sputum neutrophilia (64% or  
24  
25 38% for a cut-off of  $\geq 40\%$  or  $\geq 61\%$  cut-off respectively) [Hastie *et al.*, 2013]. In one study  
26  
27 exhaled nitric oxide predicted inhaled corticosteroid response for airway hyperreactivity in non-  
28  
29 eosinophilic asthma (area under the curve 0.81), with an optimum cut-off point of 33 ppb  
30  
31 [Cowan *et al.*, 2010].  
32  
33  
34  
35  
36  
37  
38  
39  
40

#### 41 **Which inflammatory phenotype to target?**

42  
43  
44  
45 In summary, non-eosinophilic airway inflammation is found in approximately 50% of patients  
46  
47 with mild to severe asthma. The proportion of this group with neutrophilic inflammation is less  
48  
49 certain because of variable cut-off points used in different studies to define neutrophilia.  
50  
51

52  
53 Current symptoms, rate of exacerbations and rate of decline in lung function are generally less  
54  
55 severe in non-eosinophilic asthma compared to eosinophilic asthma. Non-eosinophilic  
56  
57 inflammation is associated with an impaired response to inhaled corticosteroids. There is some  
58  
59  
60

1  
2  
3 evidence that neutrophils are activated in the airways of patients with neutrophilic asthma and  
4  
5 that biomarkers of systemic inflammation is increased in this group. Neutrophilia in asthma  
6  
7 may be due to corticosteroids, associated chronic pulmonary infection, altered airway  
8  
9 microbiome and/or delay neutrophil apoptosis, particularly in severe disease. Non-eosinophilic  
10  
11 asthma and Th2-low asthma may share some common immunopathological features, but  
12  
13 further investigation is required. Due to the lack of effective specific therapies targeting non-  
14  
15 eosinophilic inflammation including neutrophilic inflammation there is currently no definitive  
16  
17 evidence for the involvement of these inflammatory phenotypes in chronic asthma. Additional  
18  
19 pathways may account for poor asthma control in patients with non-eosinophilic asthma  
20  
21 including Th1 inflammation, Th17 inflammation, or a combination of Th2 and Th17  
22  
23 inflammation as well as corticosteroid insensitivity (Figure 1). [Recent work suggests a](#)  
24  
25 [reciprocal relationship between Th2 and Th17 pathways in severe disease and that](#)  
26  
27 [corticosteroid treatment may contribute to the emergence of a Th17-high profile](#) [Choy *et al.*,  
28  
29 2015]. Non-inflammatory mechanisms may also be important in some individuals including  
30  
31 airway hyperreactivity and airway remodelling.  
32  
33  
34  
35  
36  
37  
38  
39

#### 40 TREATMENTS TARGETING NON-EOSINOPHILIC AIRWAY INFLAMMATION

41  
42  
43  
44  
45 Many patients with asthma continue to have poorly controlled disease despite treatment with  
46  
47 currently available therapies. There is an unmet need for novel treatments that will impact  
48  
49 favourably on clinical outcomes in patients with non-eosinophilic inflammation. Non-  
50  
51 pharmacological interventions, 'off-label' use of licensed drugs, novel small molecules and  
52  
53 biologics agents are being investigated as possible treatments of non-eosinophilic inflammation  
54  
55 in asthma (Table 3 and [Figure 2](#)):-  
56  
57  
58  
59  
60

## Non-pharmacological interventions

Avoidance from exposure to environmental and occupational pollutants may reduce neutrophilic inflammation in asthma. In a study of smokers with asthma of whom a subgroup quit smoking for 6 weeks the proportion of sputum neutrophils reduced, corticosteroid sensitivity improved and the FEV<sub>1</sub> increased compared to those who continued to smoke [Chaudhuri *et al.*, 2006]. After cessation of exposure to occupational agents, neutrophilic inflammation reduced in people in whom their asthma was cured or improved compared to those in whom there was no improvement [Maghni *et al.*, 2004].

Several clinical trials have examined the effect of dietary supplement of vitamin D in asthma, based on the anti-inflammatory and corticosteroid-enhancing actions of vitamin D [Nanzer *et al.*, 2013, Zhang *et al.*, 2014] [Xystrakis *et al.*, 2006]. Two large randomized clinical trials of vitamin D3 supplementation in patients with asthma and vitamin D insufficiency [VIDA and ViDiAs trials], although not selected for specific airway inflammatory cell profiles or corticosteroid insensitivity, reported no improvements in clinical outcomes [Castro *et al.*, 2014, Martineau *et al.*, 2015, Denlinger *et al.*, 2015]. Interestingly, vitamin D supplementation reduces eosinophilic inflammation in patients with non-atopic asthma, suggesting that certain inflammatory phenotypes might benefit from vitamin D3 supplementation [De Groot *et al.*, 2015].

## 'Off-label' use of licensed drugs

Several drugs licensed for the treatment of medical conditions other than asthma have been investigated for their efficacy in asthma, including patients with non-eosinophilic inflammation.

1  
2  
3 Candidate drugs have been chosen usually because of pre-clinical evidence of anti-  
4  
5 inflammatory effects that might be relevant to treatment of asthma. Some examples are  
6  
7 reviewed below.  
8  
9

### 10 11 12 **Macrolides** 13

14  
15  
16  
17 Macrolides may be of benefit in the treatment of chronic asthma [Reiter *et al.*, 2013], including  
18  
19 non-eosinophilic asthma [Simpson *et al.*, 2008], although prescribing macrolides as a long-term  
20  
21 treatment increases the risk of adverse drug effects and the development of microbial  
22  
23 resistance [Cameron *et al.*, 2012]. The mechanism(s) of action of macrolides in the treatment of  
24  
25 airway diseases is not known, but could be due to antibacterial and/or anti-inflammatory  
26  
27 actions, which include inhibition of NF- $\kappa$ B and other transcription factors as well as reduction in  
28  
29 neutrophil migration and/or function [Culic *et al.*, 2001, Fujitani *et al.*, 2003, Simpson *et al.*,  
30  
31 2008, Cameron *et al.*, 2012, Kobayashi *et al.*, 2013]. Macrolides have additional potentially  
32  
33 beneficial properties including anti-viral actions [Gielen *et al.*, 2010, Schögler *et al.*, 2015] and  
34  
35 an ability to restore corticosteroid sensitivity by inhibiting the phosphoinositide 3-kinase (PI3K)  
36  
37 pathway and restoring histone deacetylase (HDAC)2 activity [Spahn *et al.*, 2001, Charron *et al.*,  
38  
39 2007, Kobayashi *et al.*, 2013, Hao *et al.*, 2015] and by attenuating TNF $\alpha$  and IL-17 immune  
40  
41 responses [Essilfie *et al.*, 2015]. Two recent exploratory clinical trials have investigated the  
42  
43 effects of macrolides in non-eosinophilic asthma. In one trial, smokers with mild to moderate  
44  
45 asthma associated with non-eosinophilic inflammation were randomized to azithromycin 250  
46  
47 mg per day or placebo [Cameron *et al.*, 2013]. After 12 weeks, treatment with azithromycin  
48  
49 was not associated with improvements in morning PEF, ACQ score, AQLQ score and  
50  
51 methacholine PC<sub>20</sub> compared to placebo and did not alter induced sputum differential counts,  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 bacterial load, *C. pneumonia*, *M. pneumoniae* seropositivity or upper airways respiratory virus  
4  
5 prevalence. In an other randomized controlled trial patients with exacerbation-prone severe  
6  
7 asthma received low-dose azithromycin or placebo as add-on treatment to combination  
8  
9 therapy of inhaled corticosteroids and long-acting  $\beta_2$  agonists for 6 months [Brusselle *et al.*,  
10  
11 2013]. The rate of severe exacerbations and lower respiratory tract infections requiring  
12  
13 treatment with antibiotics was not reduced by azithromycin. In a predefined subgroup with  
14  
15 non-eosinophilic severe asthma (blood eosinophilia  $\leq 200/\mu\text{l}$ ) there was a reduction in the rate  
16  
17 of primary endpoints in azithromycin-treated patients [Brusselle *et al.*, 2013]. Azithromycin  
18  
19 improved AQLQ scores, but did change ACQ scores or lung function. Based on these findings,  
20  
21 further clinical trials of macrolides in non-eosinophilic severe asthma are indicated. Novel  
22  
23 analogues of macrolides have been developed that have enhanced anti-inflammatory  
24  
25 properties than current macrolides, such as solithromycin (CEM-101) [Kobayashi *et al.*, 2013,  
26  
27 Kobayashi *et al.*, 2013] or that lack anti-bacterial properties, such as the non-antibiotic  
28  
29 azithromycin derivative CSY0073 [Balloy *et al.*, 2014].  
30  
31  
32  
33  
34  
35  
36  
37

### 38 **Statins**

39  
40  
41  
42  
43 Statins have pleiotropic immunomodulatory actions [Greenwood *et al.*, 2006] that may of  
44  
45 value in the treatment of chronic inflammatory diseases [Greenwood *et al.*, 2006, Hothersall  
46  
47 *et al.*, 2006, Yeganeh *et al.*, 2014]. In experimental models of allergic asthma [Mckay *et al.*,  
48  
49 2004, Zeki *et al.*, 2009] and tobacco-smoke-induced lung inflammation [Lee *et al.*, 2005,  
50  
51 Davis *et al.*, 2013] statins reduce inflammatory pathways potentially relevant to the  
52  
53 pathogenesis of asthma and smoke-induced airway diseases. Statins might also restore  
54  
55 corticosteroid sensitivity in asthma [Samson *et al.*, 2006, Maneechotesuwan *et al.*, 2010].  
56  
57  
58  
59  
60

1  
2  
3 Taken together, these findings suggest that statin treatment may have anti-inflammatory  
4 effects in people with asthma including smokers with asthma. A randomized double-blind  
5 parallel group trial undertaken in seventy one smokers with mild to moderate asthma  
6 associated with non-eosinophilic inflammation compared treatment with atorvastatin 40 mg  
7 per day with placebo. After 4 weeks treatment inhaled beclometasone 400 µg per day was  
8 added to both treatment arms for a further 4 weeks [Braganza *et al.*, 2011]. At 4 weeks,  
9 there was an improvement in ACQ and AQLQ scores with atorvastatin, but not in lung  
10 function. There was no significant improvement with atorvastatin and inhaled  
11 beclometasone compared to inhaled beclometasone alone in clinical outcome measures at  
12 8 weeks. In a follow-up study the effects of atorvastatin alone and in combination with  
13 inhaled corticosteroid was investigated on their ability to suppress the concentration of a  
14 range of cytokines, chemokines and growth factors in sputum samples collected during the  
15 previous clinical trial [Braganza *et al.*, 2011, Thomson *et al.*, 2015 ]. Sputum mediator  
16 concentrations were not reduced by inhaled beclometasone alone. Atorvastatin significantly  
17 reduced sputum concentrations of CCL7, IL-12p70, sCD40L, FGF-2, CCL4, TGF-α and MMP-8  
18 compared with placebo and, when combined with inhaled beclometasone, reduced sputum  
19 concentrations of MMP-8, IL-1β, IL-10, MMP-9, sCD40L, FGF-2, IL-7, G-CSF and CCL7  
20 compared to ICS alone. Improvements in ACQ and/or AQLQ scores with atorvastatin and  
21 inhaled beclometasone were associated with decreases in G-CSF, IL-7, CCL2 and CXCL8.  
22 Interestingly, simvastatin suppresses airway IL-17 and upregulated IL-10 in patients with  
23 stable COPD [Maneechotesuwan *et al.*, 2013]. Taken together, these findings suggest that  
24 short-term treatment with atorvastatin alone or in combination with inhaled  
25 beclometasone reduces several sputum cytokines, chemokines and growth factors  
26 concentrations unresponsive to inhaled corticosteroids alone in asthmatic smokers with  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 non-eosinophilic inflammation. There is a need for long-term clinical studies examining  
4  
5 effect of statins on exacerbations and airway remodelling in chronic non-eosinophilic  
6  
7 asthma.  
8  
9

### 10 11 **Low-dose theophylline** 12 13

14  
15  
16 Low dose theophylline has been shown to restore corticosteroid sensitivity *in-vitro* possibly  
17  
18 by increasing HDAC-2 activity, which is suppressed in severe asthma and in smokers with  
19  
20 asthma and a similar clinical effect might occur in people with severe disease or who are  
21  
22 smokers [Barnes, 2009, To *et al.*, 2010]. Theophylline inhibits oxidative stress dependent  
23  
24 PI3K- $\delta$  activation and restores corticosteroid sensitivity in PBMCs from patients with COPD  
25  
26 [To *et al.*, 2010]. An exploratory clinical trial examined the effects of low dose theophylline  
27  
28 added to inhaled beclometasone compared to inhaled beclometasone alone in smokers  
29  
30 with asthma associated with non-eosinophilic inflammation [Spears *et al.*, 2009]. The  
31  
32 addition of low dose theophylline to inhaled beclometasone, at a dose titrated to provide a  
33  
34 'sub-therapeutic' concentration, resulted in increased efficacy as measured by lung function  
35  
36 and suggested the restoration of corticosteroid sensitivity in those treated with the  
37  
38 combination. Clinical trials to date have not investigated the therapeutic effects of adding  
39  
40 low dose theophylline to patients with severe asthma. A fixed combination of ultra-low dose  
41  
42 of theophylline with fluticasone, SKP-2075 (Skepharma), in a dry powder inhaler is under  
43  
44 development for the treatment COPD. This combination would potentially be of benefit in  
45  
46 the treatment of severe asthma and smokers with asthma, possibly in those people with  
47  
48 non-eosinophilic inflammation.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### **PPAR $\gamma$ agonist**

In pre-clinical studies peroxisome proliferator-activated receptor- $\gamma$  (PPAR $\gamma$ ) agonists exert anti-inflammatory effects potentially relevant to the treatment of inflammatory airway diseases including asthma and COPD [Spears *et al.*, 2006, Belvisi *et al.*, 2008, Seidel *et al.*, 2012, Stephen *et al.*, 2013, Bourke *et al.*, 2014, Lakshmi *et al.*, 2014, Lea *et al.*, 2014, Donovan *et al.*, 2015 ].

For example, PPAR $\gamma$  agonists reduce eosinophilic and neutrophilic lung infiltration in experimental animal models exposed to allergen or tobacco smoke [Bauer *et al.*, 2010, Lea *et al.*, 2014, Zhao *et al.*, 2014, Morissette *et al.*, 2015]. The oral PPAR $\gamma$  agonist rosiglitazone had a modest effect in attenuating the allergen-induced late asthmatic response [Richards *et al.*, 2010]. A further proof of concept study reported that rosiglitazone compared with inhaled beclometasone dipropionate resulted in improvement in lung function and a borderline reduction in sputum IL-8 concentration in smokers with mild to moderate asthma that was associated with non-eosinophilic inflammation [Spears *et al.*, 2009]. The oral PPAR $\gamma$  agonist pioglitazone is not effective in obese asthmatics [Dixon *et al.*, 2015]. Inhaled PPAR $\gamma$  agonist analogues, such as AD3277 (Pulmagen) are under development for the treatment of chronic inflammatory airway diseases and potentially might be of benefit in non-eosinophilic asthma.

### **Novel small molecule drugs**

Novel small molecule inhibitors have been developed for treating neutrophilic/non-eosinophilic asthma including CXCR2 antagonists, FLAP inhibitors, PDE<sub>4</sub> inhibitors, dual PDE<sub>3</sub> and PDE<sub>4</sub> inhibitor and various protein kinase inhibitors.



**CXCR2 antagonist**

CXCR2 receptors are expressed on neutrophils as well as on airway goblet cells, fibroblasts and airway smooth muscle [Chapman *et al.*, 2009]. Ligands for the CXCR2 receptor include the chemokines CXCL8 (IL-8), growth-related protein (Gro)- $\alpha$ , - $\beta$ , and - $\gamma$  (CXCL1–3), epithelial-derived neutrophil attractant-78 (ENA-78; CXCL5), granulocyte chemotactic protein-2 (GCP-2; CXCL6) and neutrophil-activating peptide-2 (NAP-2; CXCL7) [Chapman *et al.*, 2009, Campbell *et al.*, 2013]. Activation of CXCR2 receptors result in neutrophil chemotaxis, proteases production, airway goblet cell hyperplasia, pulmonary blood vessel angiogenesis, collagen deposition and airway smooth muscle contraction and migration [Chapman *et al.*, 2009]. The effects of CXCR2 antagonists have been studied on airway challenges that induce sputum neutrophilia. The CXCR2 antagonist, AZD8309 inhibits LPS-induced airway neutrophilic inflammation in healthy volunteers [Leaker *et al.*, 2013] and the CXCR2 antagonist, SB656933 inhibited *ex vivo* neutrophil activation and ozone-induced airway inflammation in humans [Lazaar *et al.*, 2011]. The CXCR2 antagonist, SCH527123 inhibits ozone-induced neutrophilia in healthy subjects [Holz *et al.*, 2010]. A randomized, placebo-controlled clinical trial of the CXCR2 antagonist SCH527123 administered for 4 weeks to patients with severe asthma and sputum neutrophils > 40% resulted in a reduction of 36.3% in sputum neutrophil percentage, fewer mild exacerbations and a trend towards improvement in ACQ score [Nair *et al.*, 2012]. A clinical trial of the efficacy and safety of a CXCR2 antagonist AZD5069 in severe, uncontrolled persistent asthma reported that the addition of AZD5069 to combination ICS/LABA treatment did not improve clinical outcomes despite a dose-dependent reduction in blood neutrophil counts [O'byrne *et al.*, 2015]. A lack

1  
2  
3 of improvement in clinical outcome despite a reduction in sputum neutrophil counts was  
4 reported with the CXCR2 antagonist AZD5069 in bronchiectasis [De Soyza *et al.*, 2015]. A  
5 recent trial of the CXCR2 antagonist Navarixin (SCH527123) in COPD led to significant  
6 improvements in FEV<sub>1</sub> and reduction in sputum neutrophil count, particularly in current  
7 smokers with COPD [Rennard *et al.*, 2015]. The CXCR2 antagonist AZD8309 administered  
8 for 4 weeks to patients with moderate to severe COPD was well tolerated with no increase  
9 in the rate of infections [Kirsten *et al.*, 2015]. A small-molecule oral CXCR2 antagonists  
10 Danirixin (GSK1325756) is undergoing a clinical trial in patients with COPD at risk of  
11 exacerbations (ClinicalTrials.gov Identifier: NCT02130193). Oral CXCR2 antagonists could  
12 potentially cause neutropenia, and the therapeutic index of these compounds requires  
13 careful assessment.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

### 31 **FLAP inhibitors**

32  
33  
34  
35 Pro-inflammatory cysteinyl leukotrienes (LTs) are synthesised from arachidonic acid in  
36 inflammatory cells by 5-lipoxygenase (LO) and 5-lipoxygenase activating protein (FLAP).  
37 FLAP inhibitors such as GSK-2190915 [Evans *et al.*, 2008] prevent the formation of LTB<sub>4</sub>,  
38 which may be of value in the treatment of neutrophilic asthma. GSK2190915 markedly  
39 inhibited *ex vivo* calcium ionophore stimulated blood LTB<sub>4</sub> formation and urinary  
40 leukotriene E<sub>4</sub> (LTE<sub>4</sub>) formation [Bain *et al.*, 2013]. Pre-treatment with GSK2190915 reduces  
41 the early and late phase response to allergen challenge and results in a significant reduction  
42 of sputum LTB<sub>4</sub> levels [Kent *et al.*, 2013]. Despite suppressing the target mediator LTB<sub>4</sub>, the  
43 FLAP inhibitor GSK2190915 has no short-term effect on sputum cell counts or clinical  
44 endpoints in smokers and non-smokers with asthma associated with neutrophilic  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 inflammation (sputum neutrophilia  $\geq 50\%$  for one sample and  $>45\%$  for the other),  
4  
5 suggesting that LTB<sub>4</sub> suppression alone is inadequate in controlling airway neutrophils in  
6  
7 asthma [Chaudhuri *et al.*, 2014]. No active clinical trials of FLAP inhibitors in asthma are  
8  
9 currently registered on ClinicalTrials.gov.  
10  
11

### 12 13 14 **PDE<sub>4</sub> inhibitors and dual PDE<sub>3</sub> and PDE<sub>4</sub> inhibitors**

15  
16  
17  
18  
19 Phosphodiesterase (PDE)<sub>4</sub> inhibitors have immunomodulatory effects on inflammatory cells  
20  
21 potentially relevant to the treatment of asthma [Lipworth, 2005, Page *et al.*, 2012, Kim *et*  
22  
23 *al.*, 2015 ]. In an allergen challenge study the oral PDE<sub>4</sub> inhibitor roflumilast attenuated the  
24  
25 rise in sputum eosinophils and neutrophils numbers after the late asthmatic response  
26  
27 [Gauvreau *et al.*, 2011]. High doses of PDE<sub>4</sub> inhibitors may be necessary to treat severe  
28  
29 asthma, and gastro-intestinal side effects limit their use [Lipworth, 2005, Bateman *et al.*,  
30  
31 2006, Bousquet *et al.*, 2006]. The inhaled administration of PDE<sub>4</sub> inhibitors may improve the  
32  
33 therapeutic index of PDE<sub>4</sub> inhibitors [Chapman *et al.*, 2010, Singh *et al.*, 2010, Nials *et al.*,  
34  
35 2011, De Savi *et al.*, 2014, Moretto *et al.*, 2015]. Inhaled PDE<sub>4</sub> inhibitors GSK256066 and  
36  
37 CHF6001 both inhibit allergen-induced late asthmatic responses [Singh *et al.*, 2010, Dave *et*  
38  
39 *al.*, 2014] and in patients with moderate COPD inhaled GSK256066 for 4 weeks was well  
40  
41 tolerated although there was no inhibitory effect on sputum and blood inflammatory  
42  
43 biomarkers [Watz *et al.*, 2013]. The inhaled dual PDE<sub>3</sub> and PDE<sub>4</sub> inhibitor RPL554 (Verona  
44  
45 Pharma) has bronchodilator effects and is well tolerated in patients with asthma and COPD  
46  
47 [Franciosi *et al.*, 2013]. In healthy subjects inhaled RPL554 attenuates the neutrophilic  
48  
49 response to LPS challenge [Franciosi *et al.*, 2013]. RPL554 is under development for the  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 treatment of asthma and COPD (ClinicalTrials.gov Identifier: NCT02427165 and  
4  
5 NCT02542254 respectively).  
6  
7  
8  
9

### 10 **Protein kinase inhibitors**

11  
12  
13  
14  
15 Protein kinases are involved in cellular signalling of pro-inflammatory cytokines in asthma  
16  
17 and the inhibition of these kinases may have a role in the treatment of severe asthma  
18  
19 associated with non-eosinophilic asthma [Bhavsar *et al.*, 2010, Cohen *et al.*, 2010,  
20  
21 Hammaker *et al.*, 2010, Chung, 2011, Guntur *et al.*, 2012]. Several p38MAPK inhibitors  
22  
23 restore corticosteroid sensitivity in PBMCs from patients with severe asthma [Bhavsar *et al.*,  
24  
25 2010, Mercado *et al.*, 2012] and COPD [Khorasani *et al.*, 2015]. Clinical trials of p38MAPK  
26  
27 inhibitors oral losmapimod (GW856553) and inhaled AZD7624 are register for the treatment  
28  
29 COPD (ClinicalTrials.gov Identifier: NCT02299375 and NCT02238483 respectively), although  
30  
31 neither are registered for the treatment of asthma. Interestingly, a *post-hoc* analysis of a 6  
32  
33 month clinical trial of oral losmapimod (GW856553) in COPD reported a reduction in  
34  
35 exacerbations in a sub-group of patients with a blood eosinophil count  $\leq 2\%$  [Marks-  
36  
37 Konczalik *et al.*, 2015], which may suggest a preferentially beneficial effect of p38MAPK  
38  
39 inhibitors in non-eosinophilic inflammation. A imatinib, a specific ckit tyrosine kinase  
40  
41 inhibitor that attenuates airway hyperresponsiveness, inflammation and remodelling in  
42  
43 murine model of asthma [Berlin *et al.*, 2005, Rhee *et al.*, 2011] is under development for  
44  
45 patients with severe refractory asthma (ClinicalTrials.gov Identifier: NCT01097694). A  
46  
47 tyrosine kinase inhibitor masitinib targets c-kit and platelet-derived growth factor (PDGF)  
48  
49 receptor improved asthma control in patients with severe corticosteroid-dependent asthma  
50  
51 [Humbert *et al.*, 2009] and a further clinical trial underway in patients with severe asthma  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 treated with oral corticosteroids (ClinicalTrials.gov Identifier: NCT01449162). An alternative  
4  
5 therapeutic strategy to silencing c-kit with small interference RNA has been shown to  
6  
7 attenuate inflammation in a murine model of allergic asthma [Wu *et al.*, 2012, Wu *et al.*,  
8  
9 2014]. Clinical trials of protein kinase inhibitors have not been studied in patients with  
10  
11 sputum inflammatory subtypes such as non-eosinophilic asthma.  
12  
13

### 14 15 16 17 **PI3kinase inhibitors** 18

19  
20  
21 Low dose theophylline is thought to act, at least in part, through the inhibition of PI3K [Ito *et*  
22  
23 *al.*, 2007, To *et al.*, 2010]. Pre-clinical studies suggest that PI3K- $\delta$  inhibitors could potentially  
24  
25 reverse corticosteroid insensitivity by increasing HDAC2 activity [Marwick *et al.*, 2009, Marwick  
26  
27 *et al.*, 2010] and by reversing fungal-induced steroid resistant airway inflammation through  
28  
29 modulation of endoplasmic reticulum stress [Lee *et al.*, 2016]. Selective PI3K inhibitors are  
30  
31 being developed as novel therapies for the treatment of chronic inflammatory airway diseases.  
32  
33 An inhaled PI3K $\delta$  inhibitor GSK2269557 is undergoing several clinical trials in asthma and COPD.  
34  
35 PI3K  $\delta$  and  $\gamma$  isoforms are involved in inflammatory cell recruitment and activation and dual  
36  
37 PI3K $\delta/\gamma$  inhibitors, such as TG100-115 and IPI-145 reduces airway inflammation induced by  
38  
39 allergen or cigarette smoke in murine models [Doukas *et al.*, 2009, Winkler *et al.*, 2013] and  
40  
41 restored corticosteroid sensitivity in the smoke model [Doukas *et al.*, 2009]. RV1729, a PI3K $\delta/\gamma$   
42  
43 Inhibitor has undergone early stage clinical evaluation in asthma and COPD. SH2-containing  
44  
45 inositol-50-phosphatase 1 (SHIP1) is an endogenous inhibitor of the PI3K pathway. A SHIP1  
46  
47 activator AQX-1125 reduced the allergen-induced late asthmatic response with a non-  
48  
49 significant trend for a reduction in sputum eosinophils and neutrophils [Leaker *et al.*, 2014].  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Further development of AQX-1125 is underway for the treatment of COPD (ClinicalTrials.gov  
4  
5 Identifier: NCT01954628).  
6  
7  
8  
9

## 10 **Biological agents**

11  
12  
13  
14  
15 Monoclonal antibody blockers of inflammatory cytokines such as IL-17 and TNF- $\alpha$  that activate  
16  
17 receptors on the surface of neutrophils have been investigated as treatments for asthma.  
18  
19

### 20 ***IL-17 blockers***

21  
22  
23  
24  
25  
26 In pre-clinical studies Th<sub>17</sub> cells and IL-17 are implicated in causing neutrophilic inflammation  
27  
28 and corticosteroid insensitivity [Shen *et al.*, 2011, Newcomb *et al.*, 2013, Chesné *et al.*,  
29  
30 2014]. IL-17 concentrations and expression are increased in BAL, sputum and bronchial  
31  
32 biopsy samples in severe patients asthma that correlate with sputum neutrophils.  
33  
34

35  
36 Monoclonal inhibitors of IL-17 are in clinical development [Miossec *et al.*, 2012].  
37

38  
39 Brodalumab is a human monoclonal antibody that binds with high affinity to human IL-  
40  
41 17RA, blocking the biologic activity of IL-17A, -17F, -17A/F heterodimer, and IL-25. A  
42  
43 randomized clinical trial of brodalumab in adults with inadequately controlled moderate to  
44  
45 severe asthma receiving regular inhaled corticosteroids, but not selected for neutrophilic  
46  
47 inflammation, reported no improvement in the primary outcome ACQ score or in lung  
48  
49 function and symptom-free days [Busse *et al.*, 2013]. A subgroup with high bronchodilator  
50  
51 reversibility demonstrated a borderline improvement an ACQ score. A further clinical trial of  
52  
53 brodalumab in inadequately controlled asthma subjects with high bronchodilator  
54  
55 reversibility was recently terminated due to a lack of observed efficacy in a pre-specified  
56  
57  
58  
59  
60

interim analysis (ClinicalTrials.gov Identifier: NCT01902290). The results of a preliminary proof of efficacy study of the IL-17A monoclonal antibody blocker secukinumab (AIN457) in patients with uncontrolled asthma was also recently terminated. The investigators report that further investigations would require changes in study design, the use of different endpoints, a different IL-17 antibody or a different patient population (ClinicalTrials.gov Identifier: NCT01478360).

### ***TNF- $\alpha$ blockers***

Neutralizing TNF $\alpha$  restores corticosteroid sensitivity in a mouse model of neutrophilic airway inflammation [Dejager *et al.*, 2015]. Several small clinical studies in severe asthma of the soluble TNF- $\alpha$  receptor blocker etanercept reported beneficial effects on clinical outcomes [Howarth *et al.*, 2005, Berry *et al.*, 2006], whereas larger studies with etanercept [Holgate *et al.*, 2011] and the TNF- $\alpha$  receptor blocker golimumab [Wenzel *et al.*, 2009] did not confirm a consistent beneficial clinical effect. When combined with concerns over increased risk of severe infections and malignancies with TNF- $\alpha$  receptor blocker treatment [Wenzel *et al.*, 2009] it is unlikely that this target will be developed further for the treatment of asthma.

### ***Other monoclonal antibodies***

Monoclonal antibodies that block IL-1 $\beta$ , for example, canakinumab or block the soluble IL-1 receptor, for example, anakinra [Hernandez *et al.*, 2015] might be of benefit in neutrophilic asthma, although no clinical studies are currently registered. An IL-6 monoclonal antibody blocker tocilizumab is licensed for the treatment of rheumatoid arthritis. Tocilizumab could

1  
2  
3 potentially be of benefit in neutrophilic asthma although no clinical studies are registered in  
4  
5 asthma.  
6  
7  
8  
9

## 10 **Conclusions and future developments**

11  
12  
13  
14  
15 Non-eosinophilic airway inflammation is a term used to describe a subtype of asthma  
16  
17 associated with normal numbers of sputum eosinophils. Up to 50% of patients with stable mild  
18  
19 to severe never or ex-smokers with asthma have non-eosinophilic inflammation and this  
20  
21 inflammatory phenotype is also found in smokers with asthma, some patient with a high BMI or  
22  
23 occupational asthma. The non-eosinophilic phenotype is subdivided into neutrophilic  
24  
25 inflammation, when neutrophil numbers are raised above a defined cut-off level or  
26  
27 paucigranulocytic inflammation, when both eosinophil and neutrophil numbers are normal. The  
28  
29 relative proportions of each subtype is uncertain because of variable cut-off points used to  
30  
31 define neutrophilia. The most appropriate value that indicates that neutrophils are activated  
32  
33 and contributing to the pathogenic processes in asthma is not certain. The severity of current  
34  
35 symptoms are in general similar or slightly better in non-eosinophilic or neutrophilic subgroups  
36  
37 of asthma compare to eosinophilic subgroups. Sputum eosinophilia is a better predictor of  
38  
39 future exacerbations and a greater risk factor for more rapid decline in lung function than  
40  
41 sputum neutrophilia. Non-eosinophilic inflammation is associated with an impaired therapeutic  
42  
43 response to inhaled corticosteroids. Neutrophilic inflammation is associated with activation of  
44  
45 the innate immune system in asthma and systemic inflammation. Several mechanisms either  
46  
47 alone or in combination could explain raised sputum neutrophil counts in asthma including  
48  
49 corticosteroids, associated chronic sinopulmonary infection, delay human neutrophil apoptosis  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 due to epithelial growth factor, impaired macrophage phagocytosis and altered airway  
4  
5 microbiome. Limited information has been published on the immunopathological  
6  
7 characteristics of non-eosinophilic inflammation compared with other inflammatory airway  
8  
9 phenotypes including Th2-low inflammation, Th17-high inflammation or combination of  
10  
11 Th2/Th17 profiles in asthma. Taken together, the finding suggest that non-eosinophilic  
12  
13 inflammation and Th2-low inflammation in non-smokers with asthma share some similar  
14  
15 immunopathological features including normal eosinophil numbers, submucosal mast cell  
16  
17 numbers and sub-epithelial basement membrane thickness. ~~Blood neutrophil numbers are a~~  
18  
19 ~~poor predictive for sputum neutrophilia~~. Due to the lack of effective specific therapies targeting  
20  
21 non-eosinophilic inflammation including neutrophilic inflammation there is currently no  
22  
23 definitive evidence for the involvement of these inflammatory phenotypes in chronic asthma.  
24  
25 Additional pathways may account for poor asthma control in patients with non-eosinophilic  
26  
27 asthma including Th1 inflammation, Th17 inflammation, or a combination of Th2 and Th17  
28  
29 inflammation as well as corticosteroid insensitivity (Figure 2). The role of corticosteroid  
30  
31 treatment in causing neutrophilic and Th17 inflammation in severe asthma requires further  
32  
33 investigation. Non-inflammatory mechanisms may also be important in some individuals  
34  
35 including airway hyperreactivity and airway remodelling.  
36  
37  
38  
39  
40  
41  
42  
43  
44

45  
46 There is an unmet need for novel treatments that will impact favourably on clinical outcomes in  
47  
48 patients with non-eosinophilic inflammation. Non-pharmacological interventions, 'off-label'  
49  
50 use of licensed drugs, novel small molecules and biologics agents are being investigated as  
51  
52 possible treatments of non-eosinophilic inflammation in asthma. Smoking cessation in smokers  
53  
54 with asthma and cessation of exposure to occupational agents are associated with a reduction  
55  
56 in neutrophilic inflammation. Preliminary data of studies of 'off-label' use of licensed drugs  
57  
58  
59  
60

1  
2  
3 suggest that macrolides show efficacy in non-smokers with non-eosinophilic asthma and  
4  
5  
6 statins, low-dose theophylline and PPAR $\gamma$  agonist may be beneficial in asthmatic smokers with  
7  
8 non-eosinophilic inflammation and corticosteroid insensitivity. Further clinical studies are  
9  
10 indicated to confirm these findings and to determine the role of these therapies in the  
11  
12 management of severe asthma. Novel small molecules targeting neutrophilic inflammation in  
13  
14 asthma such as CXCR2 antagonists reduce neutrophil counts, but do not improve clinical  
15  
16 outcomes. A FLAP inhibitor did not reduce neutrophils or improve symptoms. Inhaled PDE4  
17  
18 inhibitors and dual PDE3 and PDE4 inhibitors are potential therapies for neutrophilic asthma  
19  
20 and a dual PDE3 and PDE4 inhibitors is under development for the treatment of asthma and  
21  
22 COPD. Additional small molecule drugs including p38MAPK inhibitors, tyrosine kinase inhibitors  
23  
24 and PI3kinase inhibitors are under development for asthma. The development of biological  
25  
26 agents to target non-eosinophilic inflammation in asthma has been disappointing to date with  
27  
28 the termination of clinical programmes of monoclonal antibodies targeting IL-17 and TNF- $\alpha$ . In  
29  
30 the future, the selection of patients with severe asthma and evidence of Th17-high  
31  
32 inflammation may be more likely to identify a subpopulation that respond ~~to~~ to IL-17 blockers.  
33  
34  
35  
36  
37  
38 Long-acting bronchodilators and/or bronchial thermoplasty are possible treatment options for  
39  
40 symptomatic patients with paucigranulocytic inflammation in whom there is no evidence of  
41  
42 activated inflammatory pathways or corticosteroid insensitivity that could be targeted by  
43  
44 specific therapies.  
45  
46  
47  
48  
49

50  
51 Greater understanding of the mechanisms of non-eosinophilic inflammation in asthma should  
52  
53 lead to improved therapies. International collaborative programmes of research investigating  
54  
55 pathogenic mechanism of severe asthma have focused mainly on type 2 eosinophilic  
56  
57 inflammation. The Unbiased Biomarkers for the Prediction of Respiratory Disease Outcome (U-  
58  
59  
60

1  
2  
3 BOPRED) study [Shaw *et al.*, 2015 ] and the UK Refractory Asthma Stratification Programme  
4  
5 (RASP-UK) [Heaney *et al.*, 2015 ] are designed to identify new phenotypes/endotypes and  
6  
7 treatment targets and will hopefully identify new approaches to the treatment of patients with  
8  
9 non-eosinophilic asthma.  
10  
11

#### 12 13 14 **Declaration of Conflicting Interests**

15  
16  
17  
18 In the last three years Professor Thomson has participated in advisory boards and/or  
19  
20 received consultancy/lecture fees from Boston Scientific, Genentech, GlaxoSmithKline,  
21  
22 Novartis, Respivert, Roche and Takeda and industry-sponsored grant funding to the  
23  
24 University of Glasgow from Boston Scientific, Glaxo SmithKline and Novartis for participating  
25  
26 in clinical trials.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

Agustí, A., Antó, J.M., Auffray, C., Barbé, F., Barreiro, E., Dorca, J. *et al.* (2015) Personalized Respiratory Medicine: Exploring the Horizon, Addressing the Issues. Summary of a Brn-Ajrccm Workshop Held in Barcelona on June 12, 2014. *Am J Resp Crit Care Med* 191: 391-401.

Al-Samri, M.T., Benedetti, A., Préfontaine, D., Olivenstein, R., Lemièrre, C., Nair, P. *et al.* (2010) Variability of Sputum Inflammatory Cells in Asthmatic Patients Receiving Corticosteroid Therapy: A Prospective Study Using Multiple Samples. *J Allergy Clin Immunol* 125: 1161-1163.e1164.

Anees, W., Huggins, V., Pavord, I.D., Robertson, A.S., and Burge, P.S. (2002) Occupational Asthma Due to Low Molecular Weight Agents: Eosinophilic and Non-Eosinophilic Variants. *Thorax* 57: 231-236.

Arron, J.R., Choy, D.F., Laviolette, M., Kelsen, S.G., Hatab, A., Leigh, R. *et al.* (2014) Disconnect between Sputum Neutrophils and Other Measures of Airway Inflammation in Asthma. *Eur Respir J* 43: 627-629.

Arron, J.R., Scheerens, H., Matthews, J.G., and David, R.W. (2013) Redefining Approaches to Asthma: Developing Targeted Biologic Therapies. In: Editors: Webb, D., Enna, S., and Lecount, L., (eds), *Adv Pharmacol - Immunopharmacol*, Vol. Volume 66. Academic Press: Amsterdam.

Bacci, E., Cianchetti, S., Bartoli, M., Dente, F.L., Di Franco, A., Vagaggini, B. *et al.* (2006) Low Sputum Eosinophils Predict the Lack of Response to Beclomethasone in Symptomatic Asthmatic Patients. *Chest* 129: 565-572.

Bacci, E., Latorre, M., Cianchetti, S., Bartoli, M., Costa, F., Di Franco, A. *et al.* (2012) Transient Sputum Eosinophilia May Occur over Time in Non-Eosinophilic Asthma and This Is Not Prevented by Salmeterol. *Respirology* 17: 1199-1206.

Bain, G., King, C.D., Schaab, K., Rewolinski, M., Norris, V., Ambery, C. *et al.* (2013) Pharmacodynamics, Pharmacokinetics and Safety of Gsk2190915, a Novel Oral Anti-Inflammatory 5-Lipoxygenase-Activating Protein Inhibitor. *Br J Clin Pharmacol* 75: 779-790.

Baines, K.J., Simpson, J.L., Bowden, N.A., Scott, R.J., and Gibson, P.G. (2010) Differential Gene Expression and Cytokine Production from Neutrophils in Asthma Phenotypes. *Eur Respir J* 35: 522-531.

Baines, K.J., Simpson, J.L., Wood, L.G., Scott, R.J., Fibbens, N.L., Powell, H. *et al.* (2014) Sputum Gene Expression Signature of 6 Biomarkers Discriminates Asthma Inflammatory Phenotypes. *J Allergy Clin Immunol* 133: 997-1007.

- 1  
2  
3 Baines, K.J., Simpson, J.L., Wood, L.G., Scott, R.J., and Gibson, P.G. (2011) Systemic  
4 Upregulation of Neutrophil Alpha--Defensins and Serine Proteases in Neutrophilic Asthma.  
5 *Thorax* 66: 942-947.  
6  
7  
8 Balloy, V., Deveaux, A., Lebeaux, D., Tabary, O., Le Rouzic, P., Ghigo, J.M. *et al.* (2014)  
9 Azithromycin Analogue Csy0073 Attenuates Lung Inflammation Induced by Lps Challenge. *Br*  
10 *J Pharmacol* 171: 1783-1794.  
11  
12 Barnes, P.J. (2009) Role of Hdac2 in the Pathophysiology of Copd. *Annu Rev Physiol* 71: 451-  
13 464.  
14  
15  
16 Bateman, E., D., Izquierdo, J., L., Harnest, U., Hofbauer, P., Magyar, P., Schmid-Wirlitsch, C.  
17 *et al.* (2006) Efficacy and Safety of Roflumilast in the Treatment of Asthma. *Ann Allergy*  
18 *Asthma & Immunol* 96: 679-686.  
19  
20  
21 Bauer, C.M.T., Zavitz, C.C.J., Botelho, F.M., Lambert, K.N., Brown, E.G., Mossman, K.L. *et al.*  
22 (2010) Treating Viral Exacerbations of Chronic Obstructive Pulmonary Disease: Insights from  
23 a Mouse Model of Cigarette Smoke and H1n1 Influenza Infection. *PLoS ONE* 5: e13251.  
24  
25  
26 Bel, E.H., Wenzel, S.E., Thompson, P.J., Prazma, C.M., Keene, O.N., Yancey, S.W. *et al.* (2014)  
27 Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma. *N Eng J Med* 371:  
28 1189-1197.  
29  
30  
31 Belvisi, M.G. and Hele, D.J. (2008) Peroxisome Proliferator-Activated Receptors as Novel  
32 Targets in Lung Disease. *Chest* 134: 152-157.  
33  
34  
35 Berlin, A.A. and Lukacs, N.W. (2005) Treatment of Cockroach Allergen Asthma Model with  
36 Imatinib Attenuates Airway Responses. *Am J Respir Crit Care Med* 171: 35-39.  
37  
38  
39 Berry, M., Hargadon, B., Shelley, M., Parker, D., Shaw, D., Green, R. *et al.* (2006) Inhibition of  
40 Tumor Necrosis Factor A for Refractory Asthma. *N Eng J Med* 354: 754-758.  
41  
42  
43 Berry, M., Morgan, A., Shaw, D.E., Parker, D., Green, R., Brightling, C. *et al.* (2007)  
44 Pathological Features and Inhaled Corticosteroid Response of Eosinophilic and Non-  
45 Eosinophilic Asthma. *Thorax* 62: 1043-1049.  
46  
47  
48 Bhavsar, P., Khorasani, N., Hew, M., Johnson, M., and Chung, K.F. (2010) Effect of P38 Mapk  
49 Inhibition on Corticosteroid Suppression of Cytokine Release in Severe Asthma. *Eur Respir J*  
50 35: 750-756.  
51  
52  
53 Boulet, L.-P., Lemiere, C., Archambault, F., Carrier, G., Descary, M.C., and Deschesnes, F.  
54 (2006) Smoking and Asthma: Clinical and Radiologic Features, Lung Function, and Airway  
55 Inflammation. *Chest* 129: 661-668.  
56  
57  
58 Bourke, J.E., Bai, Y., Donovan, C., Esposito, J.G., Tan, X., and Sanderson, M.J. (2014) Novel  
59 Small Airway Bronchodilator Responses to Rosiglitazone in Mouse Lung Slices. *Am J Respir*  
60 *Cell Mol Biol* 50: 748-756.

1  
2  
3  
4 Bousquet, J., Aubier, M., Sastre, J., Izquierdo, J.L., Adler, L.M., Hofbauer, P. *et al.* (2006)  
5 Comparison of Roflumilast, an Oral Anti-Inflammatory, with Beclomethasone Dipropionate  
6 in the Treatment of Persistent Asthma. *Allergy* 61: 72-78.  
7

8  
9 Braganza, G., Chaudhuri, R., Mcsharry, C., Weir, C.J., Donnelly, I., Jolly, L. *et al.* (2011) Effects  
10 of Short-Term Treatment with Atorvastatin in Smokers with Asthma - a Randomized  
11 Controlled Trial. *BMC Pulm Med* 11: 16  
12

13  
14 Brooks, C.R., Gibson, P.G., Douwes, J., Van Dalen, C.J., and Simpson, J.L. (2013) Relationship  
15 between Airway Neutrophilia and Ageing in Asthmatics and Non-Asthmatics. *Respirology* 18:  
16 857-865.  
17

18  
19 Brooks, C.R., Van Dalen, C.J., Zacharasiewicz, A., Simpson, J.L., Harper, J.L., Le Gros, G. *et al.*  
20 (2016 ) Absence of Airway Inflammation in a Large Proportion of Adolescents with Asthma.  
21 *Respirology* Dec 22. doi: 10.1111/resp.12701. [Epub ahead of print]: n/a-n/a.  
22

23  
24 Brusselle, G.G., Vanderstichele, C., Jordens, P., Deman, R., Slabbynck, H., Ringoet, V. *et al.*  
25 (2013) Azithromycin for Prevention of Exacerbations in Severe Asthma (Azisast): A  
26 Multicentre Randomised Double-Blind Placebo-Controlled Trial. *Thorax* 68: 322-329.  
27

28  
29 Busse, W.W., Holgate, S., Kerwin, E., Chon, Y., Feng, J., Lin, J. *et al.* (2013) Randomized,  
30 Double-Blind, Placebo-Controlled Study of Brodalumab, a Human Anti-L-17 Receptor  
31 Monoclonal Antibody, in Moderate to Severe Asthma. *Am J Respir Crit Care Med* 188: 1294-  
32 1302.  
33

34  
35 Cameron, E.J., Chaudhuri, R., Mair, F., Mcsharry, C., Greenlaw, N., Weir, C.J. *et al.* (2013)  
36 Randomised Controlled Trial of Azithromycin in Smokers with Asthma. *Eur Respir J* 42: 1412-  
37 1415.  
38

39  
40 Cameron, E.J., Mcsharry, C., Chaudhuri, R., Farrow, S., and Thomson, N.C. (2012) Long-Term  
41 Macrolide Treatment of Chronic Inflammatory Airway Diseases: Risks, Benefits and Future  
42 Developments. *Clin Exp Allergy* 42: 1302-1312.  
43

44  
45 Campbell, L., Maxwell, P., and Waugh, D. (2013) Rationale and Means to Target Pro-  
46 Inflammatory Interleukin-8 (Cxcl8) Signaling in Cancer. *Pharmaceuticals* 6: 929-959.  
47

48  
49 Castro, M., King, T.S., Kunselman, S.J., Hünemeyer, A., Lahu, G., Templin, S. *et al.* (2014)  
50 Effect of Vitamin D3 on Asthma Treatment Failures in Adults with Symptomatic Asthma and  
51 Lower Vitamin D Levels: The Vida Randomized Clinical Trial. *JAMA* 311(20):2083-91: 2083-  
52 2091.  
53

54  
55 Chalmers, G.W., Macleod, K.J., Little, S.A., Thomson, L.J., Mcsharry, C.P., and Thomson, N.C.  
56 (2002) Influence of Cigarette Smoking on Inhaled Corticosteroid Treatment in Mild Asthma.  
57 *Thorax* 57: 226-230.  
58  
59  
60

- 1  
2  
3 Chapman, R.W., House, A., Richard, J., Prelusky, D., Lamca, J., Wang, P. *et al.* (2010)  
4 Pharmacology of a Potent and Selective Inhibitor of Pde4 for Inhaled Administration. *Eur J*  
5 *Pharmacol* 643: 274-281.  
6  
7  
8 Chapman, R.W., Phillips, J.E., Hipkin, R.W., Curran, A.K., Lundell, D., and Fine, J.S. (2009)  
9 Cxcr2 Antagonists for the Treatment of Pulmonary Disease. *Pharmacol Ther* 121: 55-68.  
10  
11 Charron, C., Sunazuka, T., Oomura, S., and Ito, K. (2007) Em-703, a Non-Antibacterial  
12 Erythromycin Derivative, Restores Hdac2 Promoter Activation Diminished under Hypoxia  
13 and Oxidative Stress, American Thoracic Society International Meeting.  
14  
15  
16 Chaudhuri, R., Livingston, E., McMahon, A.D., Lafferty, J., Fraser, I., Spears, M. *et al.* (2006)  
17 Effects of Smoking Cessation on Lung Function and Airway Inflammation in Smokers with  
18 Asthma. *Am J Respir Crit Care Med* 174: 127 - 133.  
19  
20  
21 Chaudhuri, R., Norris, V., Kelly, K., Zhu, C.Q., Ambery, C., Lafferty, J. *et al.* (2014) Effects of a  
22 Flap Inhibitor, Gsk2190915, in Asthmatics with High Sputum Neutrophils. *Pulm Pharmacol*  
23 *Ther* 27: 62-69.  
24  
25  
26 Chesné, J., Braza, F., Mahay, G., Brouard, S., Aronica, M., and Magnan, A. (2014) Il-17 in  
27 Severe Asthma. Where Do We Stand? *Am J Respir Crit Care Med* 190: 1094-1101.  
28  
29  
30 Choy, D.F., Hart, K.M., Borthwick, L.A., Shikotra, A., Nagarkar, D.R., Siddiqui, S. *et al.* (2015)  
31 Th2 and Th17 Inflammatory Pathways Are Reciprocally Regulated in Asthma. *Sci Transl Med*  
32 7: 301ra129-301ra129.  
33  
34  
35 Chung, K.F. (2011) P38 Mitogen-Activated Protein Kinase Pathways in Asthma and Copd.  
36 *Chest* 139: 1470-1479.  
37  
38  
39 Cohen, S. and Fleischmann, R. (2010) Kinase Inhibitors: A New Approach to Rheumatoid  
40 Arthritis Treatment. *Curr Opin Rheumatol* 22: 330-335  
41  
42  
43 Corren, J., Lemanske, R.F., Hanania, N.A., Korenblat, P.E., Parsey, M.V., Arron, J.R. *et al.*  
44 (2011) Lebrikizumab Treatment in Adults with Asthma. *N Eng J Med* 365: 1088-1098.  
45  
46  
47 Cowan, D.C., Cowan, J.O., Palmay, R., Williamson, A., and Taylor, D.R. (2010) Effects of  
48 Steroid Therapy on Inflammatory Cell Subtypes in Asthma. *Thorax* 65: 384-390.  
49  
50  
51 Cox, G. (1995) Glucocorticoid Treatment Inhibits Apoptosis in Human Neutrophils.  
52 Separation of Survival and Activation Outcomes. *J Immunol* 154: 4719-4725.  
53  
54  
55 Culic, O., Erakovic, V., and Parnham, M.J. (2001) Anti-Inflammatory Effects of Macrolide  
56 Antibiotics. *Eur J Pharmacol* 429: 209-229.  
57  
58  
59  
60 D'silva, L., Cook, R.J., Allen, C.J., Hargreave, F.E., and Parameswaran, K. (2007) Changing  
Pattern of Sputum Cell Counts During Successive Exacerbations of Airway Disease. *Respir*  
*Med* 101: 2217-2220.

1  
2  
3  
4 Dave, S., Brian, R.L., Malcom, B., Marie, A.N., Sara, C., Fabrizia, M. *et al.* (2014) The Effect of  
5 the Inhaled Pde4 Inhibitor Chf6001 on Allergen-Induced Inflammation in Asthmatic Subjects.  
6 *Am J Resp Crit Care Med*: A4175-A4175.  
7

8  
9 Davis, B.B., Zeki, A.A., Bratt, J.M., Wang, L., Filosto, S., Walby, W.F. *et al.* (2013) Simvastatin  
10 Inhibits Smoke-Induced Airway Epithelial Injury: Implications for Copd Therapy. *Eur Respir J*  
11 42: 350-361.  
12

13  
14 De Groot, J.C., Van Roon, E.N.H., Storm, H., Veeger, N.J.G.M., Zwinderman, A.H., Hiemstra,  
15 P.S. *et al.* (2015) Vitamin D Reduces Eosinophilic Airway Inflammation in Nonatopic Asthma.  
16 *J Allergy Clin Immunol* 135: 670-675.e673.  
17

18  
19 De Savi, C., Cox, R.J., Warner, D.J., Cook, A.R., Dickinson, M.R., Mcdonough, A. *et al.* (2014)  
20 Efficacious Inhaled Pde4 Inhibitors with Low Emetic Potential and Long Duration of Action  
21 for the Treatment of Copd. *J Med Chem* 57: 4661-4676.  
22

23  
24 De Soyza, A., Pavord, I., Elborn, J.S., Smith, D., Wray, H., Puu, M. *et al.* (2015) A Randomised,  
25 Placebo-Controlled Study of the Cxcr2 Antagonist Azd5069 in Bronchiectasis. *Eur Respir J* 46:  
26 1021-1032.  
27

28  
29 Dejager, L., Dendoncker, K., Eggermont, M., Souffriau, J., Van Hauwermeiren, F., Willart, M.  
30 *et al.* (2015 ) Neutralizing Tnf[Alpha] Restores Glucocorticoid Sensitivity in a Mouse Model  
31 of Neutrophilic Airway Inflammation. *Mucosal Immunol* 8: 1212-1225.  
32

33  
34 Denlinger, L.C., King, T.S., Cardet, J.C., Craig, T., Holguin, F., Jackson, D.J. *et al.* (2015 )  
35 Vitamin D Supplementation and the Risk of Colds in Patients with Asthma. *Am J Resp Crit*  
36 *Care Med* Nov 5. [Epub ahead of print]:  
37

38  
39 Desai, D., Newby, C., Symon, F.A., Haldar, P., Shah, S., Gupta, S. *et al.* (2013) Elevated  
40 Sputum Interleukin-5 and Submucosal Eosinophilia in Obese Individuals with Severe Asthma.  
41 *Am J Respir Crit Care Med* 188: 657-663.  
42

43  
44 Dixon, A., Subramanian, M., Desarno, M., Black, K., Lane, L., and Holguin, F. (2015) A Pilot  
45 Randomized Controlled Trial of Pioglitazone for the Treatment of Poorly Controlled Asthma  
46 in Obesity. *Respir Res* 16: 143.  
47

48  
49 Donovan, C., Bailey, S.R., Tran, J., Haitsma, G., Ibrahim, Z.A., Foster, S.R. *et al.* (2015 )  
50 Rosiglitazone Elicits in Vitro Relaxation in Airways and Precision Cut Lung Slices from a  
51 Mouse Model of Chronic Allergic Airways Disease. *Am J Physiol Lung Cell Mol Physiol* 309:  
52 L1219-1228.  
53

54  
55 Dougherty, R.H., Sidhu, S.S., Raman, K., Solon, M., Solberg, O.D., Caughey, G.H. *et al.* (2010)  
56 Accumulation of Intraepithelial Mast Cells with a Unique Protease Phenotype in Th2-High  
57 Asthma. *J Allergy Clin Immunol* 125: 1046-1053.e1048.  
58  
59  
60



1  
2  
3 Doukas, J., Eide, L., Stebbins, K., Racanelli-Layton, A., Dellamary, L., Martin, M. *et al.* (2009)  
4 Aerosolized Phosphoinositide 3-Kinase  $\{\text{Gamma}\}/\{\text{Delta}\}$  Inhibitor Tg100-115 [3-[2,4-  
5 Diamino-6-(3-Hydroxyphenyl)Pteridin-7-yl]Phenol] as a Therapeutic Candidate for Asthma  
6 and Chronic Obstructive Pulmonary Disease. *J Pharmacol Exp Ther* 328: 758-765.  
7

8  
9 Essilfie, A.-T., Horvat, J.C., Kim, R.Y., Mayall, J.R., Pinkerton, J.W., Beckett, E.L. *et al.* (2015)  
10 Macrolide Therapy Suppresses Key Features of Experimental Steroid-Sensitive and Steroid-  
11 Insensitive Asthma. *Thorax* 70: 458-467.  
12

13  
14 Evans, J.F., Ferguson, A.D., Mosley, R.T., and Hutchinson, J.H. (2008) What's All the Flap  
15 About?: 5-Lipoxygenase-Activating Protein Inhibitors for Inflammatory Diseases. *Trends*  
16 *Pharmacol Sc* 29: 72-78.  
17

18  
19 Fahy, J., Kim, K., Liu, J., and Boushey, H. (1995 ) Prominent Neutrophilic Inflammation in  
20 Sputum from Subjects with Asthma Exacerbation. *J Allergy Clin Immunol* 95: 843-852.  
21

22  
23 Franciosi, L.G., Diamant, Z., Banner, K.H., Zuiker, R., Morelli, N., Kamerling, I.M.C. *et al.*  
24 (2013) Efficacy and Safety of Rpl554, a Dual Pde3 and Pde4 Inhibitor, in Healthy Volunteers  
25 and in Patients with Asthma or Chronic Obstructive Pulmonary Disease: Findings from Four  
26 Clinical Trials. *Lancet Respir Med* 1: 714-727.  
27

28  
29 Fu, J.-J., Baines, K.J., Wood, L.G., and Gibson, P.G. (2013) Systemic Inflammation Is  
30 Associated with Differential Gene Expression and Airway Neutrophilia in Asthma. *OMICS* 17:  
31 187-199.  
32

33  
34 Fujitani, Y. and Trifilieff, A. (2003) In Vivo and in Vitro Effects of Sar 943, a Rapamycin  
35 Analogue, on Airway Inflammation and Remodeling. *Am J Respir Crit Care Med* 167: 193-  
36 198.  
37

38  
39 Furukawa, T., Sakagami, T., Koya, T., Hasegawa, T., Kawakami, H., Kimura, Y. *et al.* (2015)  
40 Characteristics of Eosinophilic and Non-Eosinophilic Asthma During Treatment with Inhaled  
41 Corticosteroids. *J Asthma* 52: 417-422.  
42

43  
44 Futosi, K., Fodor, S., and Mócsai, A. (2013) Neutrophil Cell Surface Receptors and Their  
45 Intracellular Signal Transduction Pathways. *Internat Immunopharmacol* 17: 1185-1197.  
46

47  
48 Gao, P., Gibson, P.G., Baines, K.J., Yang, I.A., Upham, J.W., Reynolds, P.N. *et al.* (2015) Anti-  
49 Inflammatory Deficiencies in Neutrophilic Asthma: Reduced Galectin-3 and Il-1ra/Il-1 $\beta$ .  
50 *Respir Res* 16: 5.  
51

52  
53 Gauvreau, G., Boulet, L.-P., Schmid-Wirlitsch, C., Cote, J., Duong, M., Killian, K. *et al.* (2011)  
54 Roflumilast Attenuates Allergen-Induced Inflammation in Mild Asthmatic Subjects. *Respir*  
55 *Res* 12: 140.  
56

57  
58 Gibson, P.G., Simpson, J.L., and Saltos, N. (2001) Heterogeneity of Airway Inflammation in  
59 Persistent Asthma : Evidence of Neutrophilic Inflammation and Increased Sputum  
60 Interleukin-8. *Chest* 119: 1329-1336.

- 1  
2  
3  
4 Gielen, V., Johnston, S.L., and Edwards, M.R. (2010) Azithromycin Induces Anti-Viral  
5 Responses in Bronchial Epithelial Cells. *Eur Respir J* 36: 646-654.  
6  
7  
8 Godon, P., Boulet, L.P., Malo, J.L., Cartier, A., and Lemièrè, C. (2002) Assessment and  
9 Evaluation of Symptomatic Steroid-Naive Asthmatics without Sputum Eosinophilia and Their  
10 Response to Inhaled Corticosteroids. *Eur Respir J* 20: 1364-1369.  
11  
12 Green, B.J., Wiriyaichaiorn, S., Grainge, C., Rogers, G.B., Kehagia, V., Lau, L. *et al.* (2014)  
13 Potentially Pathogenic Airway Bacteria and Neutrophilic Inflammation in Treatment  
14 Resistant Severe Asthma. *PLoS ONE* 9: e100645.  
15  
16  
17 Green, R.H., Brightling, C.E., Mckenna, S., Hargadon, B., Parker, D., Bradding, P. *et al.* (2002)  
18 Asthma Exacerbations and Sputum Eosinophil Counts: A Randomised Controlled Trial.  
19 *Lancet* 360: 1715-1721.  
20  
21  
22 Green, R.H., Brightling, C.E., Woltmann, G., Parker, D., Wardlaw, A.J., and Pavord, I.D. (2002)  
23 Analysis of Induced Sputum in Adults with Asthma: Identification of Subgroup with Isolated  
24 Sputum Neutrophilia and Poor Response to Inhaled Corticosteroids. *Thorax* 57: 875-879.  
25  
26  
27 Greenwood, J., Steinman, L., and Zamvil, S.S. (2006) Statin Therapy and Autoimmune  
28 Disease: From Protein Prenylation to Immunomodulation. *Nat Rev Immunol* 6: 358-370.  
29  
30  
31 Guntur, V.P. and Reiner, C.R. (2012) The Potential Use of Tyrosine Kinase Inhibitors in  
32 Severe Asthma. *Curr Opin Allergy Clin Immunol* 12: 68-75.  
33  
34  
35 Haldar, P. and Pavord, I.D. (2007) Noneosinophilic Asthma: A Distinct Clinical and Pathologic  
36 Phenotype. *J Allergy Clin Immunol* 119: 1043-1052.  
37  
38  
39 Haldar, P., Pavord, I.D., Shaw, D.E., Berry, M.A., Thomas, M., Brightling, C.E. *et al.* (2008)  
40 Cluster Analysis and Clinical Asthma Phenotypes. *Am J Resp Crit Car Med* 178: 218-224.  
41  
42  
43 Hammaker, D. and Firestein, G. (2010) "Go Upstream, Young Man": Lessons Learned from  
44 the P38 Saga. *Ann Rheum Dis* 69, Suppl 1:  
45  
46  
47 Hancox, R.J., Cowan, D.C., Aldridge, R.E., Cowan, J.O., Palmay, R., Williamson, A. *et al.* (2012)  
48 Asthma Phenotypes: Consistency of Classification Using Induced Sputum. *Respirology* 17:  
49 461-466.  
50  
51  
52 Hao, M., Lin, J., Shu, J., Zhang, X., Luo, Q., Pan, L. *et al.* (2015) Clarithromycin Might  
53 Attenuate the Airway Inflammation of Smoke-Exposed Asthmatic Mice Via Affecting Hdac2.  
54 *J Thorac Dis* 7: 1189-1197.  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

1  
2  
3 Hastie, A.T., Moore, W.C., Meyers, D.A., Vestal, P.L., Li, H., Peters, S.P. *et al.* (2010) Analyses  
4 of Asthma Severity Phenotypes and Inflammatory Proteins in Subjects Stratified by Sputum  
5 Granulocytes. *J Allergy Clin Immunol* 125: 1028-1036.  
6

7  
8 Heaney, L.G., Djukanovic, R., Woodcock, A., Walker, S., Matthews, J.G., Pavord, I.D. *et al.*  
9 (2015 ) Research in Progress: Medical Research Council United Kingdom Refractory Asthma  
10 Stratification Programme (Rasp-Uk). *Thorax* doi: 10.1136/thoraxjnl-2015-207326. [Epub  
11 ahead of print]:  
12

13  
14 Hernandez, M.L., Mills, K., Almond, M., Todoric, K., Aleman, M.M., Zhang, H. *et al.* (2015) Il-1  
15 Receptor Antagonist Reduces Endotoxin-Induced Airway Inflammation in Healthy  
16 Volunteers. *J Allergy Clin Immunol* 135: 379-385.  
17

18  
19 Holgate, S.T., Noonan, M., Chanez, P., Busse, W., Dupont, L., Pavord, I. *et al.* (2011) Efficacy  
20 and Safety of Etanercept in Moderate-to-Severe Asthma: A Randomised, Controlled Trial.  
21 *Eur Respir J* 37: 1352-1359.  
22

23  
24 Holz, O., Khalilieh, S., Ludwig-Sengpiel, A., Watz, H., Stryszak, P., Soni, P. *et al.* (2010)  
25 Sch527123, a Novel Cxcr2 Antagonist, Inhibits Ozone-Induced Neutrophilia in Healthy  
26 Subjects. *Eur Respir J* 35: 564-570.  
27

28  
29 Hothersall, E., Mcsharry, C., and Thomson, N.C. (2006) Potential Therapeutic Role for Statins  
30 in Respiratory Disease. *Thorax* 61: 729-734.  
31

32  
33 Howarth, P.H., Babu, K.S., Arshad, H.S., Lau, L., Buckley, M., Mcconnell, W. *et al.* (2005)  
34 Tumour Necrosis Factor (Tnf{Alpha}) as a Novel Therapeutic Target in Symptomatic  
35 Corticosteroid Dependent Asthma. *Thorax* 60: 1012-1018.  
36

37  
38 Humbert, M., De Blay, F., Garcia, G., Prud'homme, A., Leroyer, C., Magnan, A. *et al.* (2009)  
39 Masitinib, a C-Kit/Pdgf Receptor Tyrosine Kinase Inhibitor, Improves Disease Control in  
40 Severe Corticosteroid-Dependent Asthmatics. *Allergy* 64: 1194-1201.  
41

42  
43 Ito, K., Caramori, G., and Adcock, I.M. (2007) Therapeutic Potential of Phosphatidylinositol  
44 3-Kinase Inhibitors in Inflammatory Respiratory Disease. *J Pharmacol Exp Ther* 321: 1-8.  
45

46  
47 Jatakanon, A., Lim, S., and Pj, B. (2000) Changes in Sputum Eosinophils Predict Loss of  
48 Asthma Control. *Am J Respir Crit Care Med* 161: 64-72.  
49

50  
51 Jayaram, L., Pizzichini, M.M., Cook, R.J., Boulet, L.-P., Lemiere, C., Pizzichini, E. *et al.* (2006)  
52 Determining Asthma Treatment by Monitoring Sputum Cell Counts: Effect on Exacerbations.  
53 *Eur Respir J* 27: 483-494.  
54

55  
56 Katz, L.E., Gleich, G.J., Hartley, B.F., Yancey, S.W., and Ortega, H.G. (2014) Blood Eosinophil  
57 Count Is a Useful Biomarker to Identify Patients with Severe Eosinophilic Asthma. *Annals Am*  
58 *Thor Soc* 11: 531-536.  
59  
60

1  
2  
3 Kent, S.E., Boyce, M., Diamant, Z., Singh, D., O'connor, B.J., Saggu, P.S. *et al.* (2013) The 5-  
4 Lipoxygenase-Activating Protein Inhibitor, Gsk2190915, Attenuates the Early and Late  
5 Responses to Inhaled Allergen in Mild Asthma. *Clin Exp Allergy* 43: 177-186.  
6

7  
8 Khorasani, N., Baker, J., Johnson, M., Chung, K.F., and Bhavsar, P.K. (2015) Reversal of  
9 Corticosteroid Insensitivity by P38 Mapk Inhibition in Peripheral Blood Mononuclear Cells  
10 from Copd. *Int J Chron Obstruct Pulmon Dis* 10: 283-291.  
11

12 Kim, R.Y., Pinkerton, J.W., Gibson, P.G., Cooper, M.A., Horvat, J.C., and Hansbro, P.M. (2015)  
13 Inflammasomes in Copd and Neutrophilic Asthma. *Thorax* 70: 1199-1201.  
14

15  
16 Kim, S.W., Kim, J.H., Park, C.K., Kim, T.J., Lee, S.Y., Kim, Y.K. *et al.* (2015 ) Effect of Roflumilast  
17 on Airway Remodeling in a Murine Model of Chronic Asthma. *Clin Exp Allergy* doi:  
18 10.1111/cea.12670. [Epub ahead of print]: n/a-n/a.  
19

20  
21 Kirsten, A.M., Förster, K., Radeckzy, E., Linnhoff, A., Balint, B., Watz, H. *et al.* (2015) The  
22 Safety and Tolerability of Oral Azd5069, a Selective Cxcr2 Antagonist, in Patients with  
23 Moderate-to-Severe Copd. *Pulm Pharm Therap* 31: 36-41.  
24

25  
26 Kobayashi, Y., Wada, H., Rossios, C., Takagi, D., Charron, C., Barnes, P.J. *et al.* (2013) A Novel  
27 Macrolide/Fluoroketolide, Solithromycin (Cem-101), Reverses Corticosteroid Insensitivity  
28 Via Phosphoinositide 3-Kinase Pathway Inhibition. *Br J Pharmacol* 169: 1024-1034.  
29

30  
31 Kobayashi, Y., Wada, H., Rossios, C., Takagi, D., Higaki, M., Mikura, S.I. *et al.* (2013) A Novel  
32 Macrolide Solithromycin Exerts Superior Anti-Inflammatory Effect Via Nf-Kb Inhibition. *J*  
33 *Pharmacol Exp Ther* 345: 76-84.  
34

35  
36 Kupczyk, M., Dahlén, B., Sterk, P.J., Nizankowska-Mogilnicka, E., Papi, A., Bel, E.H. *et al.*  
37 (2014) Stability of Phenotypes Defined by Physiological Variables and Biomarkers in Adults  
38 with Asthma. *Allergy* 69: 1198-1204.  
39

40  
41 Kupczyk, M., Ten Brinke, A., Sterk, P.J., Bel, E.H., Papi, A., Chanez, P. *et al.* (2014) Frequent  
42 Exacerbators – a Distinct Phenotype of Severe Asthma. *Clin Exp Allergy* 44: 212-221.  
43

44  
45 Lakshmi, S.P., Reddy, A.T., Zhang, Y., Scirba, F.C., Mallampalli, R.K., Duncan, S.R. *et al.*  
46 (2014) Down-Regulated Peroxisome Proliferator-Activated Receptor  $\Gamma$  (Ppar $\gamma$ ) in Lung  
47 Epithelial Cells Promotes a Ppar $\gamma$  Agonist-Reversible Proinflammatory Phenotype in Chronic  
48 Obstructive Pulmonary Disease (COPD). *J Biol Chem* 289: 6383-6393.  
49

50  
51 Lamblin, C., Gosset, P., Tillie-Leblond, I., Saulnier, F., Marquette, C., Wallaert, B. *et al.* (1998)  
52 Bronchial Neutrophilia in Patients with Noninfectious Status Asthmaticus. *Am J Respir Crit*  
53 *Care Med* 157: 394-402.  
54

55  
56 Lazaar, A.L., Sweeney, L.E., Macdonald, A.J., Alexis, N.E., Chen, C., and Tal-Singer, R. (2011)  
57 Sb-656933, a Novel Cxcr2 Selective Antagonist, Inhibits Ex Vivo Neutrophil Activation and  
58 Ozone-Induced Airway Inflammation in Humans. *Br J Clin Pharmacol* 72: 282-293.  
59  
60

1  
2  
3 Lea, S., Plumb, J., Metcalfe, H., Spicer, D., Woodman, P., Fox, J.C. *et al.* (2014) The Effect of  
4 Peroxisome Proliferator-Activated Receptor- $\gamma$  Ligands on in Vitro and in Vivo Models of  
5 Copd. *Eur Respir J* 43: 409-420.  
6

7  
8 Leaker, B., Barnes, P., and O'connor, B. (2013) Inhibition of Lps-Induced Airway Neutrophilic  
9 Inflammation in Healthy Volunteers with an Oral Cxcr2 Antagonist. *Respir Res* 14: 137.  
10

11 Leaker, B.R., Barnes, P.J., O'connor, B.J., Ali, F.Y., Tam, P., Neville, J. *et al.* (2014) The Effects  
12 of the Novel Ship1 Activator Aqx-1125 on Allergen-Induced Responses in Mild-to-Moderate  
13 Asthma. *Clin Exp Allergy* 44: 1146-1153.  
14

15  
16 Lee, J.-H., Lee, D.-S., Kim, E.-K., Choe, K.-H., Oh, Y.-M., Shim, T.-S. *et al.* (2005) Simvastatin  
17 Inhibits Cigarette Smoking-Induced Emphysema and Pulmonary Hypertension in Rat Lungs.  
18 *Am J Respir Crit Care Med* 172: 987-993.  
19

20  
21 Lee, K.S., Jeong, J.S., Kim, S.R., Cho, S.H., Kolliputi, N., Ko, Y.H. *et al.* (2016) Phosphoinositide  
22 3-Kinase- $\Delta$  Regulates Fungus-Induced Allergic Lung Inflammation through Endoplasmic  
23 Reticulum Stress. *Thorax* 71: 52-63.  
24

25  
26 Lemière, C., Boulet, L.-P., Chaboillez, S., Forget, A., Chiry, S., Villeneuve, H. *et al.* (2013)  
27 Work-Exacerbated Asthma and Occupational Asthma: Do they Really Differ? *J Allergy Clin*  
28 *Immunol* 131: 704-710.e703.  
29

30  
31 Lemiere, C., Chaboillez, S., Bohadana, A., Blais, L., and Maghni, K. (2014) Noneosinophilic  
32 Responders with Occupational Asthma: A phenotype Associated with a Poor Asthma  
33 Prognosis. *J Allergy Clin Immunol* 133: 883-885.e883.  
34

35  
36 Lemière, C., Tremblay, C., Fitzgerald, M., Aaron, S.D., Leigh, R., Boulet, L.-P. *et al.* (2011)  
37 Effects of a Short Course of Inhaled Corticosteroids in Noneosinophilic Asthmatic Subjects.  
38 *Can Respir J* 18: 278-282.  
39

40  
41 Leuppi, J., Salome, C., Jenkins, C., Anderson, S., Xuan, W., Marks, G. *et al.* (2001) Predictive  
42 Markers of Asthma Exacerbation During Stepwise Dose Reduction of Inhaled  
43 Corticosteroids. *Am J Respir Crit Care Med* 163: 406-412.  
44

45  
46 Lipworth, B.J. (2005) Phosphodiesterase-4 Inhibitors for Asthma and Chronic Obstructive  
47 Pulmonary Disease. *Lancet* 365: 167-175.  
48

49  
50 Little, S., Chalmers, G., Macleod, K., Mcsharry, C., and Thomson, N. (2000) Non-Invasive  
51 Markers of Airway Inflammation as Predictors of Oral Steroid Responsiveness in Asthma.  
52 *Thorax* 53: 232-234.  
53

54  
55 Little, S.A., Macleod, K.J., Chalmers, G.W., Love, J.G., Mcsharry, C., and Thomson, N.C. (2002)  
56 Association of Forced Expiratory Volume with Disease Duration and Sputum Neutrophils in  
57 Chronic Asthma. *Am J Med* 112: 446-452.  
58  
59  
60

1  
2  
3 Maghni, K., Lemiere, C., Ghezzi, H., Yuquan, W., and Malo, J.-L. (2004) Airway Inflammation  
4 after Cessation of Exposure to Agents Causing Occupational Asthma. *Am J Respir Crit Care*  
5 *Med* 169: 367-372.  
6

7  
8 Maneechotesuwan, K., Ekjitrakul, W., Kasetsinsombat, K., Wongkajornsilp, A., and Barnes,  
9 P.J. (2010) Statins Enhance the Anti-Inflammatory Effects of Inhaled Corticosteroids in  
10 Asthmatic Patients through Increased Induction of Indoleamine 2, 3-Dioxygenase. *J Allergy*  
11 *Clin Immunol* 126: 754-762.  
12

13  
14 Maneechotesuwan, K., Essilfie-Quaye, S., Kharitonov, S.A., Adcock, I.M., and Barnes, P.J.  
15 (2007) Loss of Control of Asthma Following Inhaled Corticosteroid Withdrawal Is Associated  
16 with Increased Sputum Interleukin-8 and Neutrophils. *Chest* 132: 98-105.  
17

18  
19 Maneechotesuwan, K., Kasetsinsombat, K., Wongkajornsilp, A., and Barnes, P.J. (2013)  
20 Decreased Indoleamine 2,3-Dioxygenase Activity and Il-10/Il-17a Ratio in Patients with  
21 Copd. *Thorax* 68: 330-337.  
22

23  
24 Manni, M.L., Trudeau, J.B., Scheller, E.V., Mandalapu, S., Elloso, M.M., Kolls, J.K. *et al.* (2014)  
25 The Complex Relationship between Inflammation and Lung Function in Severe Asthma.  
26 *Mucosal Immunol* 7: 1186-1198.  
27

28  
29 Marks-Konczalik, J., Costa, M., Robertson, J., Mckie, E., Yang, S., and Pascoe, S. (2015) A  
30 Post-Hoc Subgroup Analysis of Data from a Six Month Clinical Trial Comparing the Efficacy  
31 and Safety of Losmapimod in Moderate-Severe Copd Patients with  $\leq 2\%$  and  $> 2\%$  Blood  
32 Eosinophils. *Respir Med* 109: 860-869.  
33

34  
35 Martineau, A.R., Hanifa, Y., Witt, K.D., Barnes, N.C., Hooper, R.L., Patel, M. *et al.* (2015)  
36 Double-Blind Randomised Controlled Trial of Vitamin D3 Supplementation for the  
37 Prevention of Acute Respiratory Infection in Older Adults and Their Carers (Vidiflu). *Thorax*  
38 70: 953-960.  
39

40  
41 Marwick, J., Caramori, G., Stevenson, C., Casolari, P., Jazrawi, E., Barnes, P. *et al.* (2009)  
42 Inhibition of Pi3kdelta Restores Glucocorticoid Function in Smoking-Induced Airway  
43 Inflammation in Mice. *Am J Respir Crit Care Med* 179: 542-548.  
44

45  
46 Marwick, J.A., Caramori, G., Casolari, P., Mazzoni, F., Kirkham, P.A., Adcock, I.M. *et al.* (2010)  
47 A Role for Phosphoinositol 3-Kinase Delta in the Impairment of Glucocorticoid  
48 Responsiveness in Patients with Chronic Obstructive Pulmonary Disease. *J Allergy Clin*  
49 *Immunol* 125: 1146-1153.  
50

51  
52 Mcgrath, K.W., Icitovic, N., Boushey, H.A., Lazarus, S.C., Sutherland, E.R., Chinchilli, V.M. *et*  
53 *al.* (2012) A Large Subgroup of Mild-to-Moderate Asthma Is Persistently Noneosinophilic.  
54 *Am J Respir Crit Care Med* 185: 612-619.  
55

56  
57 Mckay, A., Leung, B.P., Mcinnes, I.B., Thomson, N.C., and Liew, F.Y. (2004) A Novel Anti-  
58 Inflammatory Role of Simvastatin in a Murine Model of Allergic Asthma. *J Immunol* 172:  
59 2903-2908.  
60

- 1  
2  
3  
4 Mercado, N., Hakim, A., Kobayashi, Y., Meah, S., Usmani, O.S., Chung, K.F. *et al.* (2012)  
5 Restoration of Corticosteroid Sensitivity by P38 Mitogen Activated Protein Kinase Inhibition  
6 in Peripheral Blood Mononuclear Cells from Severe Asthma. *PLoS ONE* 7: e41582.  
7  
8  
9 Miossec, P. and Kolls, J.K. (2012) Targeting Il-17 and Th17 Cells in Chronic Inflammation. *Nat*  
10 *Rev Drug Discov* 11: 763-776.  
11  
12 Moore, W.C., Hastie, A.T., Li, X., Li, H., Busse, W.W., Jarjour, N.N. *et al.* (2014) Sputum  
13 Neutrophil Counts Are Associated with More Severe Asthma Phenotypes Using Cluster  
14 Analysis. *J Allergy Clin Immunol* 133: 1557-1563.  
15  
16  
17 Moretto, N., Caruso, P., Bosco, R., Marchini, G., Pastore, F., Armani, E. *et al.* (2015) Chf6001,  
18 a Novel Highly Potent and Selective Phosphodiesterase 4 Inhibitor with Robust Anti-  
19 Inflammatory Activity and Suitable for Topical Pulmonary Administration. *J Pharmacol Exp*  
20 *Ther* 352: 559-567.  
21  
22  
23 Morissette, M.C., Shen, P., Thayaparan, D., and Stämpfli, M.R. (2015) Impacts of Peroxisome  
24 Proliferator-Activated Receptor- $\gamma$  Activation on Cigarette Smoke-Induced Exacerbated  
25 Response to Bacteria. *Eur Respir J* 45: 191-200.  
26  
27  
28 Nair, P., Aziz-Ur-Rehman, A., and Radford, K. (2015) Therapeutic Implications of  
29 'Neutrophilic Asthma'. *Curr Opin Pulm Med* 21: 33-38  
30  
31 Nair, P., Gaga, M., Zervas, E., Alagha, K., Hargreave, F.E., O'byrne, P.M. *et al.* (2012) Safety  
32 and Efficacy of a Cxcr2 Antagonist in Patients with Severe Asthma and Sputum Neutrophils:  
33 A Randomized, Placebo-Controlled Clinical Trial. *Clin Exp Allergy* 42: 1097-1103.  
34  
35  
36 Nanzer, A.M., Chambers, E.S., Ryanna, K., Richards, D.F., Black, C., Timms, P.M. *et al.* (2013)  
37 Enhanced Production of Il-17a in Patients with Severe Asthma Is Inhibited by  $1\alpha,25-$   
38 Dihydroxyvitamin D3 in a Glucocorticoid-Independent Fashion. *J Allergy Clin Immunol* 132:  
39 297-304.  
40  
41  
42 Newby, C., Agbetile, J., Hargadon, B., Monteiro, W., Green, R., Pavord, I. *et al.* (2014) Lung  
43 Function Decline and Variable Airway Inflammatory Pattern: Longitudinal Analysis of Severe  
44 Asthma. *J Allergy Clin Immunol* 134: 287-294.  
45  
46  
47 Newcomb, D.C. and Peebles Jr, R.S. (2013) Th17-Mediated Inflammation in Asthma. *Curr*  
48 *Opinion Immunol* 25: 755-760.  
49  
50 Nials, A.T., Tralau-Stewart, C.J., Gascoigne, M.H., Ball, D.I., Ranshaw, L.E., and Knowles, R.G.  
51 (2011) In Vivo Characterization of Gsk256066, a High-Affinity Inhaled Phosphodiesterase 4  
52 Inhibitor. *J Pharmacol Exp Ther* 337: 137-144.  
53  
54  
55 O'byrne, P., Metev, H., Puu, M., Richter, K., and Keen, C. (2015) Efficacy and Safety of a  
56 Cxcr2 Antagonist, Azd5069, in Severe, Uncontrolled Persistent Asthma. *Am J Resp Crit Care*  
57 *Med* 256: A2503-A2503.  
58  
59  
60

1  
2  
3  
4 Ortega, H.G., Liu, M.C., Pavord, I.D., Brusselle, G.G., Fitzgerald, J.M., Chetta, A. *et al.* (2014)  
5 Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma. *N Eng J Med* 371:  
6 1198-1207.  
7

8  
9 Page, C.P. and Spina, D. (2012) Selective Pde Inhibitors as Novel Treatments for Respiratory  
10 Diseases. *Curr Opin Pharmacol* 12: 275-286.  
11

12 Pavord, I., Brightling, C., Woltmann, G., and Wardlaw, A. (1999) Non-Eosinophilic  
13 Corticosteroid Unresponsive Asthma. *Lancet* 353: 2213-2214.  
14

15  
16 Pavord, I.D., Korn, S., Howarth, P., Bleecker, E.R., Buhl, R., Keene, O.N. *et al.* (2012)  
17 Mepolizumab for Severe Eosinophilic Asthma (Dream): A Multicentre, Double-Blind,  
18 Placebo-Controlled Trial. *Lancet* 380: 651-659.  
19

20  
21 Peters, M.C., Mekonnen, Z.K., Yuan, S., Bhakta, N.R., Woodruff, P.G., and Fahy, J.V. (2014)  
22 Measures of Gene Expression in Sputum Cells Can Identify Th2-High and Th2-Low Subtypes  
23 of Asthma. *J Allergy Clin Immunol* 133: 388-394.  
24

25  
26 Raundhal, M., Morse, C., Khare, A., Oriss, T.B., Milosevic, J., Trudeau, J. *et al.* (2015 ) High  
27 Ifn- $\gamma$  and Low Slpi Mark Severe Asthma in Mice and Humans. *J Clin Invest* 125: 3037-3050.  
28

29 Reiter, J., Demirel, N., Mendy, A., Gasana, J., Vieira, E.R., Colin, A.A. *et al.* (2013) Macrolides  
30 for the Long-Term Management of Asthma – a Meta-Analysis of Randomized Clinical Trials.  
31 *Allergy* 68: 1040-1049.  
32

33  
34 Rennard, S.I., Dale, D.C., Donohue, J.F., Kanniss, F., Magnussen, H., Sutherland, E.R. *et al.*  
35 (2015) Cxcr2 Antagonist Mk-7123—a Phase 2 Proof-of-Concept Trial for Chronic Obstructive  
36 Pulmonary Disease. *Am J Resp Crit Care Med* 191: 1001-1011.  
37

38  
39 Rhee, C.K., Kim, J.W., Park, C.K., Kim, J.S., Kang, J.Y., Kim, S.J. *et al.* (2011) Effect of Imatinib  
40 on Airway Smooth Muscle Thickening in a Murine Model of Chronic Asthma. *Int Arch Allergy*  
41 *Immunol* 155: 243-251.  
42

43  
44 Richards, D.B., Bareille, P., Lindo, E.L., Quinn, D., and Farrow, S.N. (2010) Treatment with a  
45 Peroxisomal Proliferator Activated Receptor Gamma Agonist Has a Modest Effect in the  
46 Allergen Challenge Model in Asthma: A Randomised Controlled Trial. *Respir Med* 104: 668-  
47 674.  
48

49 Saffar, A., Ashdown, H., and Gounni, A. (2011) The Molecular Mechanisms of  
50 Glucocorticoids-Mediated Neutrophil Survival. *Curr Drug Targets* 12: 556-562.  
51

52  
53 Samson, K., Minoguchi, K., Tanaka, A., Oda, N., Yokoe, T., Yamamoto, Y. *et al.* (2006)  
54 Inhibitory Effects of Fluvastatin on Cytokine and Chemokine Production by Peripheral Blood  
55 Mononuclear Cells in Patients with Allergic Asthma. *Clin Exp Allergy* 36: 475-482.  
56  
57  
58  
59  
60



Schleich, F., Manise, M., Sele, J., Henket, M., Seidel, L., and Louis, R. (2013) Distribution of Sputum Cellular Phenotype in a Large Asthma Cohort: Predicting Factors for Eosinophilic Vs Neutrophilic Inflammation. *BMC Pulm Med* 13: 11.

Schleich, F.N., Chevremont, A., Paulus, V., Henket, M., Manise, M., Seidel, L. *et al.* (2014) Importance of Concomitant Local and Systemic Eosinophilia in Uncontrolled Asthma. *Eur Respir J* 44: 97-108.

Schögler, A., Kopf, B.S., Edwards, M.R., Johnston, S.L., Casaulta, C., Kieninger, E. *et al.* (2015) Novel Antiviral Properties of Azithromycin in Cystic Fibrosis Airway Epithelial Cells. *Eur Respir J* 45: 428-439.

Seidel, P., Alkhouri, H., Lalor, D.J., Burgess, J.K., Armour, C.L., and Hughes, J.M. (2012) Thiazolidinediones Inhibit Airway Smooth Muscle Release of the Chemokine Cxcl10: In Vitro Comparison with Current Asthma Therapies. *Respir Res* 13: 90-90.

Shaw, D.E., Berry, M.A., Hargadon, B., Mckenna, S., Shelley, M.J., Green, R.H. *et al.* (2007) Association between Neutrophilic Airway Inflammation and Airflow Limitation in Adults with Asthma. *Chest* 132: 1871-1875.

Shaw, D.E., Sousa, A.R., Fowler, S.J., Fleming, L.J., Roberts, G., Corfield, J. *et al.* (2015 ) Clinical and Inflammatory Characteristics of the European U-Biopred Adult Severe Asthma Cohort. *Eur Respir J*:

Shen, N., Wang, J., Zhao, M., Pei, F., and He, B. (2011) Anti-Interleukin-17 Antibodies Attenuate Airway Inflammation in Tobacco-Smoke-Exposed Mice. *Inhal Toxicol* 23: 212-218.

Shum, A.K. (2015) T Cell Types That Take Your Breath Away. *Sci Trans Med* 7: 301fs333-301fs333.

Simpson, J., Guest, M., Boggess, M., and Gibson, P. (2015) Occupational Exposures, Smoking and Airway Inflammation in Refractory Asthma. *BMC Pulm Med* 14: 207.

Simpson, J., Scott, R., Boyle, M., and Gibson, P. (2006) Inflammatory Subtypes in Asthma: Assessment and Identification Using Induced Sputum. *Respirol* 11: 54-61.

Simpson, J.L., Gibson, P.G., Yang, I.A., Upham, J., James, A., Reynolds, P.N. *et al.* (2013) Impaired Macrophage Phagocytosis in Non-Eosinophilic Asthma. *Clin Exp Allergy* 43: 29-35.

Simpson, J.L., Gibson, P.G., Yang, I.A., Upham, J., James, A., Reynolds, P.N. *et al.* (2014) Altered Sputum Granzyme B and Granzyme B/Proteinase Inhibitor-9 in Patients with Non-Eosinophilic Asthma. *Respirology* 19: 280-287.

Simpson, J.L., Grissell, T.V., Douwes, J., Scott, R.J., Boyle, M.J., and Gibson, P.G. (2007) Innate Immune Activation in Neutrophilic Asthma and Bronchiectasis. *Thorax* 62: 211-218.

- 1  
2  
3 Simpson, J.L., Mcelduff, P., and Gibson, P.G. (2010) Assessment and Reproducibility of Non-  
4 Eosinophilic Asthma Using Induced Sputum. *Respiration* 79: 147-151.  
5  
6  
7 Simpson, J.L., Phipps, S., Baines, K.J., Oreo, K.M., Gunawardhana, L., and Gibson, P.G. (2014)  
8 Elevated Expression of the Nlrp3 Inflammasome in Neutrophilic Asthma. *Eur Respir J* 43:  
9 1067-1076.  
10  
11 Simpson, J.L., Powell, H., Boyle, M.J., Scott, R.J., and Gibson, P.G. (2008) Clarithromycin  
12 Targets Neutrophilic Airway Inflammation in Refractory Asthma. *Am J Respir Crit Care Med*  
13 177: 148-155.  
14  
15  
16 Singh, D., Petavy, F., Macdonald, A., Lazaar, A., and O'connor, B. (2010) The Inhaled  
17 Phosphodiesterase 4 Inhibitor Gsk256066 Reduces Allergen Challenge Responses in Asthma.  
18 *Resp Res* 11: 26.  
19  
20  
21 Spahn, J., Fost, D., Covar, R., Martin, R., Brown, E., Sj, S. *et al.* (2001) Clarithromycin  
22 Potentiates Glucocorticoid Responsiveness in Patients with Asthma: Results of a Pilot Study.  
23 *Ann Allergy Asthma Immunol* 87: 501-505.  
24  
25  
26 Spears, M., Donnelly, I., Jolly, L., Brannigan, M., Ito, K., Mcsharry, C. *et al.* (2009) Effect of  
27 Low-Dose Theophylline Plus Beclometasone on Lung Function in Smokers with Asthma: A  
28 Pilot Study. *Eur Respir J* 33: 1010-1017.  
29  
30  
31 Spears, M., Donnelly, I., Jolly, L., Brannigan, M., Ito, K., Mcsharry, C. *et al.* (2009)  
32 Bronchodilatory Effect of the Ppar-[Gamma] Agonist Rosiglitazone in Smokers with Asthma.  
33 *Clin Pharmacol Ther* 86: 49-53.  
34  
35  
36 Spears, M., Mcsharry, C., and Thomson, N.C. (2006) Peroxisome Proliferator-Activated  
37 Receptor-Gamma Agonists as Potential Anti-Inflammatory Agents in Asthma and Chronic  
38 Obstructive Pulmonary Disease. *Clin Exp Allergy* 36: 1494-1504.  
39  
40  
41 Stephen, J., Delvecchio, C., Spitale, N., Giesler, A., Radford, K., Bilan, P. *et al.* (2013) Ppar  
42 Ligands Decrease Human Airway Smooth Muscle Cell Migration and Extracellular Matrix  
43 Synthesis. *Eur Respir J* 41: 425-432.  
44  
45  
46 Suárez-Cuartín, G., Crespo, A., Mateus, E., Torrejón, M., Giner, J., Belda, A. *et al.* (2015)  
47 Variability in Asthma Inflammatory Phenotype in Induced Sputum. Frequency and Causes.  
48 *Arch Bronconeumol* May 4. pii: S0300-2896(15)00110-6. doi: 10.1016/j.arbres.2015.03.007.  
49 [Epub ahead of print]:  
50  
51  
52 Sukkar, M.B., Wood, L.G., Tooze, M., Simpson, J.L., Mcdonald, V.M., Gibson, P.G. *et al.*  
53 (2012) Soluble Rage Is Deficient in Neutrophilic Asthma and Copd. *Eur Respir J* 39: 721-729.  
54  
55  
56 Thomson, N.C. (2014) Novel Therapies Targeting Eosinophilic Inflammation in Asthma. *Clin*  
57 *Exp Allergy* 44: 462-468.  
58  
59  
60

1  
2  
3 Thomson, N.C., Charron, C.E., Chaudhuri, R., Spears, M., Ito, K., and Mcsharry, C. (2015 )  
4 Atorvastatin in Combination with Inhaled Beclometasone Modulates Inflammatory Sputum  
5 Mediators in Smokers with Asthma. *Pulm Pharmacol Ther* 31: 1-8.  
6

7  
8 Thomson, N.C., Chaudhuri, R., Heaney, L.G., Bucknall, C., Niven, R.M., Brightling, C.E. *et al.*  
9 (2013) Clinical Outcomes and Inflammatory Biomarkers in Current Smokers and Exsmokers  
10 with Severe Asthma. *J Allergy Clin Immunol* 131: 1008-1016.  
11

12  
13 Thomson, N.C., Chaudhuri, R., Thomson, N.C., and Chaudhuri, R. (2009) Asthma in Smokers:  
14 Challenges and Opportunities. *Curr Opin Pulm Med* 15: 39 - 45.  
15

16  
17 To, Y., Ito, K., Kizawa, Y., Failla, M., Ito, M., Kusama, T. *et al.* (2010) Targeting  
18 Phosphoinositide-3-Kinase-Delta with Theophylline Reverses Corticosteroid Insensitivity in  
19 Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med* 182: 897-904.  
20

21  
22 Trejo Bittar, H.E., Yousem, S.A., and Wenzel, S.E. (2015) Pathobiology of Severe Asthma.  
23 *Annu Rev Pathol* 10: 511-545.  
24

25  
26 Turner, M.O., Hussack, P., Sears, M.R., Dolovich, J., and Hargreave, F.E. (1995) Exacerbations  
27 of Asthma without Sputum Eosinophilia. *Thorax* 50: 1057-1061.  
28

29  
30 Uddin, M., Lau, L.C., Seumois, G.G., Vijayanand, P., Staples, K.J., Bagmane, D. *et al.* (2013)  
31 Egf-Induced Bronchial Epithelial Cells Drive Neutrophil Chemotactic and Anti-Apoptotic  
32 Activity in Asthma. *PLoS ONE* 8: e72502.  
33

34  
35 Uddin, M., Nong, G., Ward, J., Seumois, G.G., Prince, L.R., Wilson, S.J. *et al.* (2010)  
36 Prosurvival Activity for Airway Neutrophils in Severe Asthma. *Thorax* 65:: 684-689.  
37

38  
39 Van Veen, I.H., Ten Brinke, A., Gauw, S.A., Sterk, P.J., Rabe, K.F., and Bel, E.H. (2009)  
40 Consistency of Sputum Eosinophilia in Difficult-to-Treat Asthma: A 5-Year Follow-up Study. *J*  
41 *Allergy Clin Immunol* 124: 615-617.e612.  
42

43  
44 Wagener, A.H., De Nijs, S.B., Lutter, R., Sousa, A.R., Weersink, E.J.M., Bel, E.H. *et al.* (2015)  
45 External Validation of Blood Eosinophils, Feno and Serum Periostin as Surrogates for Sputum  
46 Eosinophils in Asthma. *Thorax* 70: 115-120.  
47

48  
49 Wallace, J., D'silva, L., Brannan, J., Hargreave, F.E., Kanaroglou, P., and Nair, P. (2011)  
50 Association between Proximity to Major Roads and Sputum Cell Counts. *Can Respir J* 18: 13-  
51 18.  
52

53  
54 Wang, F., He, X.Y., Baines, K.J., Gunawardhana, L.P., Simpson, J.L., Li, F. *et al.* (2011)  
55 Different Inflammatory Phenotypes in Adults and Children with Acute Asthma. *Eur Respir J*  
56 38: 567-574.  
57

58  
59 Watz, H., Mistry, S., Lazaar, A., and Investigators., I. (2013) Safety and Tolerability of the  
60 Inhaled Phosphodiesterase 4 Inhibitor Gsk256066 in Moderate Copd. *Pulm Pharmacol Ther*  
26: 588-595.

1  
2  
3  
4 Wenzel, S., Schwartz, L., Langmack, E., and Al, E. (1999) Evidence That Severe Asthma Can  
5 Be Divided Pathologically into Two Inflammatory Subtypes with Distinct Physiologic and  
6 Clinical Characteristics. *Am J Respir Crit Care Med* 160: 1001-1008.  
7

8  
9 Wenzel, S.E., Barnes, P.J., Bleecker, E.R., Bousquet, J., Busse, W., Dahlen, S.-E. *et al.* (2009) A  
10 Randomized, Double-Blind, Placebo-Controlled Study of Tumor Necrosis Factor-Alpha  
11 Blockade in Severe Persistent Asthma. *Am J Respir Crit Care Med* 179: 549-558.  
12

13  
14 Winkler, David g., Faia, Kerrie l., Dinitto, Jonathan p., Ali, Janid a., White, Kerry f., Brophy,  
15 Erin e. *et al.* (2013) Pi3k- $\Delta$  and Pi3k- $\Gamma$  Inhibition by Ipi-145 Abrogates Immune Responses and  
16 Suppresses Activity in Autoimmune and Inflammatory Disease Models. *Chem Biol* 20: 1364-  
17 1374.  
18

19  
20 Wood, L.G., Baines, K.J., Fu, J., Scott, H.A., and Gibson, P.G. (2012) The Neutrophilic  
21 Inflammatory Phenotype Is Associated with Systemic Inflammation in Asthma. *Chest* 142:  
22 86-93.  
23

24  
25 Woodruff, P.G., Modrek, B., Choy, D.F., Jia, G., Abbas, A.R., Ellwanger, A. *et al.* (2009) T-  
26 Helper Type 2-Driven Inflammation Defines Major Subphenotypes of Asthma. *Am J Respir*  
27 *Crit Care Med* 180: 388-395.  
28

29  
30 Wu, Wang, Dong, Liao, and Wen. (2012) Silencing of C-Kit with Small Interference Rna  
31 Attenuates Inflammation in a Murine Model of Allergic Asthma. *Int J Mol Med* 30: 63-68.  
32

33  
34 Wu, W., Chen, H., Li, Y.-M., Wang, S.-Y., Diao, X., and Liu, K.-G. (2014) Intranasal Sirna  
35 Targeting C-Kit Reduces Airway Inflammation in Experimental Allergic Asthma. *Int J Clin Exp*  
36 *Pathol* 7: 5505-5514.  
37

38  
39 Xystrakis, E., Kusumakar, S., Boswell, S., Peek, E., Urry, Z., Richards, D.F. *et al.* (2006)  
40 Reversing the Defective Induction of Il-10-Secreting Regulatory T Cells in Glucocorticoid-  
41 Resistant Asthma Patients. *J Clin Invest* 116: 146-155.  
42

43  
44 Yeganeh, B., Wiechec, E., Ande, S., Sharma, P., Moghadam, A., Post, M. *et al.* (2014)  
45 Targeting the Mevalonate Cascade as a New Therapeutic Approach in Heart Disease, Cancer  
46 and Pulmonary Disease. *Pharmacol Ther* 143: 87-110.  
47

48  
49 Zeki, A.A., Franzi, L., Last, J., and Kenyon, N.J. (2009) Simvastatin Inhibits Airway  
50 Hyperreactivity: Implications for the Mevalonate Pathway and Beyond. *Am J Respir Crit Care*  
51 *Med* 180: 731-740.  
52

53  
54 Zhang, X.Y., Simpson, J.L., Powell, H., Yang, I.A., Upham, J.W., Reynolds, P.N. *et al.* (2014)  
55 Full Blood Count Parameters for the Detection of Asthma Inflammatory Phenotypes. *Clin*  
56 *Exp Allergy* 44: 1137-1145.  
57  
58  
59  
60

Zhang, Y., Leung, D.Y.M., and Goleva, E. (2014) Anti-Inflammatory and Corticosteroid-Enhancing Actions of Vitamin D in Monocytes of Patients with Steroid-Resistant and Those with Steroid-Sensitive Asthma. *J Allergy Clin Immunol* 133: 1744-1752.

Zhao, Y., Huang, Y., He, J., Li, C., Deng, W., Ran, X. *et al.* (2014) Rosiglitazone, a Peroxisome Proliferator-Activated Receptor- $\gamma$  Agonist, Attenuates Airway Inflammation by Inhibiting the Proliferation of Effector T Cells in a Murine Model of Neutrophilic Asthma. *Immunol Lett* 157: 9-15.

## LIST OF ABBREVIATIONS

ACQ: Asthma control questionnaire

ACRN: Asthma Clinical Research Network

AP-1: Activator protein-1

AQLQ: asthma quality of life questionnaire

BAL: Bronchoalveolar lavage

BDP: Beclomethasone dipropionate

BMI: Body mass index

CAMP: Childhood Asthma Management Program

COPD: Chronic obstructive pulmonary disease

*CRHR1*: Corticotrophin-releasing hormone receptor 1 gene

CCL: Chemokine (C-C motif) ligand

CXCL: Chemokine (C-X-C motif) ligand

CXCR: C-X-C chemokine receptor

eNOS: Endothelial nitric oxide synthase

ERK: Extracellular signal-regulated kinase

FCER2: Low-affinity IgE receptor gene

1  
2  
3 FGF: Fibroblast growth factor

4  
5 FLAP: 5-lipoxygenase-activating protein

6  
7 GILZ: Glucocorticoid-inducible leucine zipper 1

8  
9 G-CSF: Granulocyte-colony stimulating factor

10  
11 GLCCI1: Glucocorticoid-induced transcript 1 gene

12  
13 GOAL: Gaining Optimal Asthma Control

14  
15 GR: glucocorticoid receptor

16  
17 GRE: Glucocorticoid-responsive elements

18  
19 HDAC: Histone deacetylase

20  
21 HFA: Hydrofluoroalkane

22  
23 HMG CoA: 3-Hydroxymethyl-3-glutaryl Coenzyme A

24  
25 IDO: Indoleamine 2, 3-dioxygenase

26  
27 IFN: interferon

28  
29 Ig: immunoglobulin

30  
31 IKKs: I $\kappa$ B kinases

32  
33 IL: interleukin

34  
35 JNK: c-Jun N-terminal kinase

36  
37 LABA: Long acting  $\beta_2$ -agonists

38  
39 LPS: lipopolysaccharide

40  
41 LT: leukotriene

42  
43 MAPK: Mitogen-activated protein kinase

44  
45 MKP: Mitogen-activated protein kinase phosphatase 1

46  
47 MMP: Matrix metalloproteinase

48  
49 MPO: Myeloperoxidase

1  
2  
3 NO: nitric oxide

4  
5 NF $\kappa$ B: Nuclear factor  $\kappa$ B

6  
7 PEF: Peak expiratory flow

8  
9 PBMC: Peripheral blood mononuclear cell

10  
11 PDE: Phosphodiesterase

12  
13 PI3K: Phosphoinositide 3-kinase

14  
15 PP2A: Protein phosphatase 2A

16  
17 PPAR $\gamma$ : Peroxisome proliferator-activated receptor- $\gamma$

18  
19 RASP-UK: Refractory Asthma Stratification Programme

20  
21 RBM: Reticular basement membrane thickness

22  
23 sCD40L: Soluble CD40 ligand

24  
25 SHIP1: SH2-containing inositol-50-phosphatase 1

26  
27 SLPI: Secretory leukocyte protease inhibitor expression

28  
29 SNPs: Single-nucleotide polymorphisms

30  
31 STAT: Signal transduction-activated transcription factors

32  
33 SNP: Single nucleotide polymorphisms

34  
35 *TBX21*: T-box expressed in T cells21

36  
37 TGF- $\alpha$ : Transforming growth factor alpha

38  
39 Th<sub>2</sub>: Type 2 helper T-cell (Th<sub>2</sub>)

40  
41 TNF- $\alpha$ : ~~T~~umour necrosis factor  $\alpha$

42  
43 TLR: Toll-like receptor

44  
45 U-BOPRED: Unbiased Biomarkers for the Prediction of Respiratory Disease Outcome

1  
2  
3 Table 1 Possible factors accounting for cause(s) of neutrophilic airway inflammation in  
4  
5 asthma  
6  
7  
8  
9

- 10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- Corticosteroid treatment causing reduced apoptosis of neutrophils and contributing to Th17 mediated neutrophilic inflammation
  - Neutrophilia associated with chronic sinopulmonary infection and/or bronchiectasis
  - Delay human neutrophil apoptosis in severe asthma due to epithelial growth factor induced release of mediators with neutrophil chemotactic and anti-apoptotic actions from bronchial epithelial cells
  - Impaired macrophage phagocytosis of neutrophils
  - Neutrophilia associated with altered airway microbiome



1  
2  
3 **Table 2 Clinical phenotypes and factors associated with non-eosinophilic airway**  
4  
5 **inflammation in asthma**  
6  
7

8  
9  
10 Mild to severe asthma in never or ex-smokers (both controlled and uncontrolled)

11  
12 Smokers with asthma

13  
14 High BMI (subgroup)

15  
16 Occupational asthma (subgroup)

17  
18 Factors associated with higher neutrophil counts

- 19  
20  
21 – Older age  
22  
23 – Exposure to environmental pollution  
24  
25  
26 – Respiratory infections  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 3 Treatments targeting non-eosinophilic airway inflammation in asthma****Non-pharmacological interventions**

Avoidance from exposure to environmental and occupational pollutants

Smoking cessation

Dietary supplementation with vitamin D3

**'Off-label' use of licensed drugs**

Macrolides

Statins

Low-dose theophylline

Peroxisome proliferator-activated receptor- $\gamma$  (PPAR $\gamma$ ) agonists

**Novel small molecule drugs*****Drugs targeting neutrophilic inflammation***

C-X-C chemokine receptor (CXCR)2 antagonists

5-lipoxygenase-activating protein (FLAP) inhibitors

***Phosphodiesterase (PDE) inhibitors***

PDE<sub>4</sub> inhibitors

Dual PDE<sub>3</sub> and PDE<sub>4</sub> inhibitors

**Protein kinase inhibitors**

p38 Mitogen-activated protein kinase (MAPK) inhibitors

Narrow spectrum kinase inhibitors

Tyrosine kinase inhibitors

**Phosphoinositide 3 (PI3)-kinase inhibitors**

PI3K- $\delta$  inhibitors

Dual PI3K $\delta$ / $\gamma$  inhibitors

**Biological agents**

Interleukin (IL)-17A receptor blockers

IL-17A blockers

Tumour necrosis factor (TNF)- $\alpha$  receptor blockers

IL-1 $\beta$  monoclonal antibody blockers

Soluble IL-1 receptor monoclonal antibody blockers

IL-6 monoclonal antibody blockers

## FIGURE LEGENDS

**Figure 1 Schematic diagram of potential pathways leading to non-eosinophilic inflammation and airway damage in severe asthma**

Several inflammatory pathways could potentially lead to non-eosinophilic inflammation and airway damage in asthma although the exact mechanisms are unclear. Possible pathways are briefly summarized in the schematic diagram. Stimuli such as viruses, cigarette smoke and pollutants could induce the release of chemoattractants including IL-8 to recruit neutrophils to the airways. The release of IL-17A and IL-17F from activated Th17 cells could stimulate the synthesis of neutrophil chemoattractants, such CXCL1 and IL-8 from the airway epithelium. INF- $\gamma$  may also be involved in non-eosinophilic asthma, possibly in part through its release from Th1 cells. Inflammatory mediators released by neutrophils are implicated in causing mucus gland hyperplasia and hypersecretion, airway hyperreactivity and remodelling as well as corticosteroid insensitivity in asthma. Th1 and Th17 cells may induce airway hyperreactivity and/or remodelling independently of neutrophil activation.

Abbreviations: CXCL1: chemokine (C-X-C motif) ligand; IFN: interferon; IL: interleukin; LT: leukotriene; MMP: matrix metalloproteinase; MPO: myeloperoxidase; ROC: reactive oxygen species; TNF- $\alpha$ : tumour necrosis factor  $\alpha$

1  
2  
3  
4  
5  
6  
7  
8 **Figure 24 Targets and potential therapies for treating non-eosinophilic airway**  
9 **inflammation in asthma**  
10  
11  
12  
13  
14

15 Non-eosinophilic airway inflammation is found in approximately 50% of patients with asthma.  
16 The proportion of this group with neutrophilic inflammation is less certain because of variable  
17 cut-off points used to define neutrophilia. The higher the cut-off value used to define sputum  
18 neutrophilia the greater the proportion of subjects that are classified as having  
19 paucigranulocytic inflammation. Pathways that may account for poor asthma control in  
20 patients with non-eosinophilic asthma including neutrophilic inflammation, associated  
21 inflammatory phenotypes (Th1-high inflammation, Th17-high inflammation, combination of  
22 Th2 and Th17 inflammation, mast cell induced inflammation, other inflammatory mechanisms)  
23 as well as corticosteroid insensitivity. Non-inflammatory mechanisms such as airway  
24 hyperreactivity and airway remodelling may be important in causing symptoms in some  
25 individuals.  
26  
27 Potential treatments targeting specific pathways are listed in the diagram. Novel small  
28 molecules targeting neutrophilic inflammation, such as CXCR2 antagonists reduce neutrophils,  
29 but do not improve clinical outcomes. Smoking cessation in asthmatic smokers and removal  
30 from exposure to occupational agents reduces neutrophilic inflammation. The results of clinical  
31 trials of biological agents targeting mediators associated with non-eosinophilic inflammation,  
32 such as IL-17 and TNF- $\alpha$  are disappointing. Preliminary studies of 'off-label' use of licensed  
33 drugs suggest that macrolides show efficacy in non-smokers with non-eosinophilic severe  
34 asthma and statins, low-dose theophylline and PPAR $\gamma$  agonists may benefit asthmatic smokers  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 with non-eosinophilic inflammation and associate corticosteroid insensitivity. Inhaled PDE<sub>4</sub>  
4 inhibitors, dual PDE<sub>3</sub> and PDE<sub>4</sub> inhibitors, p38MAPK inhibitors, tyrosine kinase inhibitors and  
5 PI3kinase inhibitors are under development and these compounds may be of benefit in treating  
6 non-eosinophilic inflammation and corticosteroid insensitivity. Long-acting bronchodilators  
7 and/or bronchial thermoplasty are possible treatment options for symptomatic patients with  
8 paucigranulocytic inflammation in whom there is no evidence of activated inflammatory  
9 pathways or corticosteroid insensitivity that could be targeted by specific therapies.  
10  
11 Abbreviations: CXCR: C-X-C chemokine receptor; FLAP: 5-lipoxygenase-activating protein; IL:  
12 interleukin; PDE: phosphodiesterase; PI3K: phosphoinositide 3-kinase; PPAR $\gamma$ : peroxisome  
13 proliferator-activated receptor- $\gamma$ ;  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1 Schematic diagram of potential pathways leading to non-eosinophilic inflammation and airway damage in severe asthma

Several inflammatory pathways could potentially lead to non-eosinophilic inflammation and airway damage in asthma although the exact mechanisms are unclear. Possible pathways are briefly summarized in the schematic diagram. Stimuli such as viruses, cigarette smoke and pollutants could induce the release of chemoattractants including IL-8 to recruit neutrophils to the airways. The release of IL-17A and IL-17F from activated Th17 cells could stimulate the synthesis of neutrophil chemoattractants, such CXCL1 and IL-8 from the airway epithelium.  $INF\gamma$  may also be involved in non-eosinophilic asthma, possibly in part through its release from Th1 cells. Inflammatory mediators released by neutrophils are implicated in causing mucus gland hyperplasia and hypersecretion, airway hyperreactivity and remodelling as well as corticosteroid insensitivity in asthma. Th1 and Th17 cells may induce airway hyperreactivity and/or remodelling independently of neutrophil activation.

Abbreviations: CXCL1: chemokine (C-X-C motif) ligand;  $INF\gamma$ : interferon; IL: interleukin; LT: leukotriene; MMP: matrix metalloproteinase; MPO: myeloperoxidase; ROC: reactive oxygen species;  $TNF\alpha$ : tumour necrosis factor  $\alpha$

338x190mm (230 x 230 DPI)




Figure 2 Targets and potential therapies for treating non-eosinophilic airway inflammation in asthma

Non-eosinophilic airway inflammation is found in approximately 50% of patients with asthma. The proportion of this group with neutrophilic inflammation is less certain because of variable cut-off points used to define neutrophilia. The higher the cut-off value used to define sputum neutrophilia the greater the proportion of subjects that are classified as having paucigranulocytic inflammation. Pathways that may account for poor asthma control in patients with non-eosinophilic asthma including neutrophilic inflammation, associated inflammatory phenotypes (Th1-high inflammation, Th17-high inflammation, combination of Th2 and Th17 inflammation, mast cell induced inflammation, other inflammatory mechanisms) as well as corticosteroid insensitivity. Non-inflammatory mechanisms such as airway hyperreactivity and airway remodelling may be important in causing symptoms in some individuals. Potential treatments targeting specific pathways are listed in the diagram. Novel small molecules targeting neutrophilic inflammation, such as CXCR2 antagonists reduce neutrophils, but do not improve clinical outcomes. Smoking cessation in asthmatic smokers and removal from exposure to occupational agents reduces neutrophilic inflammation. The results of clinical trials of biological agents targeting mediators associated with non-eosinophilic inflammation, such as IL-17 and TNF- $\alpha$  are disappointing. Preliminary studies of 'off-label' use of licensed drugs suggest that macrolides show efficacy in non-smokers with non-eosinophilic severe asthma and statins, low-dose theophylline and PPAR $\gamma$  agonists may benefit asthmatic smokers with non-eosinophilic inflammation and associate corticosteroid insensitivity. Inhaled PDE4 inhibitors, dual PDE3 and PDE4 inhibitors, p38MAPK inhibitors, tyrosine kinase inhibitors and PI3kinase inhibitors are under development and these compounds may be of benefit in treating non-eosinophilic inflammation and corticosteroid insensitivity. Long-acting bronchodilators and/or bronchial thermoplasty are possible treatment options for symptomatic patients with paucigranulocytic inflammation in whom there is no evidence of activated inflammatory pathways or corticosteroid insensitivity that could be targeted by specific therapies.

Abbreviations: CXCR: C-X-C chemokine receptor; FLAP: 5-lipoxygenase-activating protein; IL: interleukin; PDE: phosphodiesterase; PI3K: phosphoinositide 3-kinase; PPAR $\gamma$ : peroxisome proliferator-activated receptor- $\gamma$ ;

338x190mm (230 x 230 DPI)